Principles of Molecular Oncology
Principles of Molecular Oncology Third Edition
Edited by Miguel H. Bronchud, MD, Ph...
156 downloads
2917 Views
22MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Principles of Molecular Oncology
Principles of Molecular Oncology Third Edition
Edited by Miguel H. Bronchud, MD, PhD Hospital General of Granollers, Barcelona, Spain
MaryAnn Foote, PhD MA Foote Associates, Westlake Village, CA
Giuseppe Giaccone, MD, PhD National Cancer Institute, Bethesda, Maryland
Olufunmilayo Olopade, MD University of Chicago Medical Center, Chicago, IL
Paul Workman, PhD CRC Center for Cancer Therapeutics, Surrey, United Kingdom
Foreword by Karen Antman, MD Clinical Dean and Provost, Boston University School of Medicine Boston, MA
© 2008 Humana Press Inc. 999 Riverview Drive, Suite 208 Totowa, New Jersey 07512 humanapress.com
All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by anymeans, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher. All articles, comments, opinions, conclusions, or recommendations are those of the author(s), and do not necessarily reflect the views of the publisher. Due diligence has been taken by the publishers, editors, and authors of this book to assure the accuracy of the information published and to describe generally accepted practices. The contributors herein have carefully checked to ensure that the drug selections and dosages set forth in this text are accurate and in accord with the standards accepted at the time of publication. Notwithstanding, as new research, changes in government regulations, and knowledge from clinical experience relating to drug therapy and drug reactions constantly occurs, the reader is advised to check the product information provided by the manufacturer of each drug for any change in dosages or for additional warnings and contraindications. This is of utmost importance when the recommended drug herein is a new or infrequently used drug. It is the responsibility of the treating physician to determine dosages and treatment strategies for individual patients. Further it is the responsibility of the health care provider to ascertain the Food and Drug Administration status of each drug or device used in their clinical practice. The publisher, editors, and authors are not responsible for errors or omissions or for any consequences from the application of the information presented in this book and make no warranty, express or implied, with respect to the contents in this publication. Cover design by Nancy K. Fallatt For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel.: 973-256-1699; Fax: 973-256-8341; or visit our website at www.humanapress.com The opinions expressed herein are the views of the authors and may not necessarily reflect the official policy of the National Institute on Drug Abuse or any other parts of the US Department of Health and Human Services. The US Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company names appearing in this publication are used only because they are considered essential in the context of the studies reported herein. This publication is printed on acid-free paper. ∞ ANSI Z39.48-1984 (American National Standards Institute) Permanence of Paper for Printed Library Materials. Photocopy Authorization Policy: Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted byHumana Press Inc., provided that the base fee of US $30.00 per copy, plus US $.30 per page, is paid directly to the CopyrightClearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Humana Press Inc. The fee code for users of the Transactional Reporting Service is: [978-1-934115-25-1/08 $30.00]. Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1
eISBN 978-1-59745-470-4 Library of Congress Control Number: 2007930945
Foreword
The global shared vision for oncology is prediction and prevention of cancer rather than the paradigm of the past, diagnosis and treatment. Examples available today include vaccines for hepatitis and human papilloma virus to prevent hepatoma and cervical cancer respectively, avoidance of cervical cancer by removal of premalignant lesions found on Pap smear or colonoscopy and polypectomy for prevention of colon cancer. In the future, the use of genome wide scans to determine risks, followed by interventions to prevent or at least delay the emergence of disease provides a model not only for cancer but also for other life-threatening diseases. Many new molecularly targeted diagnostics and therapeutics described in this text, developed based on the rapid growth in our understanding of the molecular basis of cancer, already substantially improve survival of patients with previously lethal malignancies, and also improve quality of life because of fewer toxicities. Clearly research in academia and in the pharmaceutical industry is likely to continue to identify “drugable” targets and construct new diagnostics and therapeutics. Balancing this optimistic vision for the future control of cancer is the complexity of the cancer problem—both the cancer itself at the molecular level, but also globally at the social and political level. The public perceives cancer as a single disease and desires “a cure for cancer.” Actually, hundreds of malignancies have been identified by traditional diagnostic methods. Even within common cancer categories such as breast or colon cancer, however, subclassifications (and now molecular subclassifications) exist. Whether each patient’s cancer will ultimately prove to be unique, or whether cancers will fall into a reasonable number of groups for which treatment can be targeted based on affected molecular pathways is as yet unknown.
Past as Prologue Enthusiasts have compared current “targeted” therapies with “empiric” therapies of the past. Certainly the relative value of hypothesis generated research versus observations and empiricism has been debated. Each has provided major advances.
(Data mining of genome-wide scans is a current example of the value of observational studies compared to hypothesis driven research.) Observations of breast cancer responses to oophorectomy (Beatson, Lancet. 1896;2:104–107) and of responses of prostate cancer to estrogens (Huggins and Hodges, Cancer Res. 1941;1, 203) established systemic hormonal therapies of today. The use of alkylating agents in lymphoma derived from observations of lymphopenia in soldiers after accidental exposure to sulfur mustards stockpiled for use in World War II. Nevertheless, the characteristic of the cancer research of the past as exclusively “empiric” is inaccurate. The development of systemic treatment for cancer over the second half of the 20th century is a tribute to the creativity of cancer investigators and their application of the science of their time. Once the antitumor effect of nitrogen mustard was recognized, medicinal chemists constructed cyclophosphamide as a prodrug intended to be metabolized within tumor cells and created l phenylalanine mustard to target the production of melanin in melanoma cells. Both drugs proved effective in cancer despite metabolism and mechanisms in vitro that turned out to be different from those planned. Molecularly targeted drugs similarly do not always perform as planned. The quintessential example of targeted therapy, imatinib (Gleevec) was developed to target the PDGF (Platelet-derived Growth Factor) receptor tyrosine kinase but clinically proved most useful in CML (Chronic Myeloid Leukemia) (with translocations involving c-abl) and gastrointestinal stromal tumors (GIST, with mutated c-kit). Natural products, the class of drugs that were developed empirically based on screening have, in fact, proved effective in the treatment of many common malignancies. Both targeted hypothesis-driven drug development and empiric observations are likely to provide important leads in the future.
Essential Collaborators Despite progress in our understanding of carcinogenesis and the targets for its treatment, cancer remains a major public health problem globally in developed and developing nations. Patients v
vi
present with lesions comprising more than 1010 tumors cells. Sections of the tumor or metastases do not necessarily have identical molecular signatures. Clearly the wish for the simplicity of a single magic bullet targeting a single pathway seems unrealistic today based on our emerging knowledge of the regulatory intranet of the cell and the need for disruption of multiple pathways for a cancer to emerge. Combinations of systemic agents can target multiple components of the regulatory system of the cancer cell but also decrease the chance of emergence of resistant tumor clones. Avoiding the emergence of resistance provides the rational for combinations for both cancers and of infectious diseases such as TB or AIDS. To date combinations are generally required for the cure of malignancies.
Foreword
Solving the cancer problem will require collaborations of scientists both in academia and industry, individuals in government (research dollars, health policy and regulatory risk reduction), and public health as well as clinical oncologists. New effective anticancer agents will have to be affordable for both developed and developing countries. Cancer incidence and mortality are falling in many developed countries but rising in developing countries. Progress has been significant but considerable challenges remain. Karen Antman, MD Clinical Dean and Provost Boston University School of Medicine
Foreword to the Second Edition
The second edition of Principles of Molecular Oncology is published 200 years after the exposition of Dalton’s atomic theory of matter and 50 years after Watson and Crick described the basic structure of DNA. This edition comes less than four years after the first and is a consequence of the pace of discovery in such an exciting field of research. In the first edition it was anticipated that the publication of the sequenced human genome would appear in the middle of the first decade of the 21st century. It was published in 2001 and already sequenced genomes for several viruses, bacteria, plants, and animals are available. In 1844 Darwin wrote to a friend, “at last gleams of light have come and I am almost convinced (quite contrary to the opinion I started with) that species are not (it is like confessing a murder) immutable”. His The Origin of Species issued in 1859 provided evidence for the evolutionary theory of life and represented one of the most important discoveries in biology. The controversy surrounding Darwin’s theory resulted in the famous debate between Bishop Wilberforce and Thomas Huxley. When Wilberforce finished his long tirade against the theory, Huxley replied tersely “I have come here in the cause of science only” and went on to demolish the Bishop’s argument. The two men had very different backgrounds in education. Scientific method has continued to be the cornerstone in the study of life and human disease. The discovery of the structure and chemistry of DNA and the subsequent genetic research by many scientists have led to a much better understanding of the mechanisms of human biology and evolution and of the function of genes. The last 50 years has been a golden era in this important field with enormous consequences for applied medicine. Darwin of course knew nothing of genes; the processes he described were those of trial and error taking place over a vast time scale. Recent discoveries in human genetics have not been without controversy, but clinical research has benefited from the move away from trial and error to a more rational approach in the development of new patient management techniques for many medical conditions. The techniques involved are being applied in the study of human cancer and the molecu-
lar discoveries relating to the diagnosis, prevention, early detection, and new treatments are the subject of this book. Progress in the field of molecular oncology has been much faster than previously imagined because of the abundance of innovative technology. High throughput technology for gene sequencing and expression, including comparative genomic hybridization, proteomics, and proteoglycan research, has already allowed the study of biologic function using sequenced DNA, RNA, protein, and oligosaccharide molecules. We are already awash with data and the new subject of bioinformatics has been developed to bring some order to the problem. Poincaré, the famous French mathematician, knew from the work of Newton that the behavior of 2 bodies acting in a gravitational field could be explained with reasonable accuracy using simple mathematics but the behavior of 3 bodies was much more difficult to describe. He spent an important part of his working life on this problem and his eventual model was inaccurate. Understanding the function of genes is the key to the rational development of new treatments, but though some cancers are the result of an altered function of a single dominant gene, many arise from a more complex interaction between genes. New mathematics is being developed to help understand the complexity of these biologic systems. In spite of the complexity, important information has been provided using molecular techniques, allowing substantial improvement in management of patients with cancer. Improvements have included the identification of predisposition to some forms of cancer, more accurate diagnostic and prognostic information, new markers for analyzing tumor progression, a quantified assessment of minimal residual disease, and the rational development of new treatments and methods of prevention. Information on all these aspects of cancer care has been updated in this new edition. It is gratifying to see that a collaborative approach between scientists in many fields is being rewarded by so much progress in the field of human cancer care. As an undergraduate at Cambridge in the1950s, I had the advantage of contact with Crick, Brenner, vii
viii
Foreword to the Second Edition
Sanger, and Perutz, each of whom provided some insight into what was to come. Although since this time progress has been logarithmic, there is a great deal that remains a challenge for future editions of this book. Principles of Molecular Oncology provides valuable information for the continuing education of all oncologists. Derek Crowther, PhD, MB BChir, FRCP, FRCR Emeritus Professor of Medical Oncology University of Manchester and Christie Cancer Centre
References Charles Darwin “Recapitulation and Conclusion,” from The Origin of Species (1859): Appleton-Century-Crofts Inc. John Dewey “The Influence of Darwinism on Philosophy,” from The Influence of Darwinism on Philosophy and Other Essays (1910), reprinted from the Popular Science Monthly (July 1909), Henry Holt & Co.
Foreword to the First Edition
At the midpoint of the 20th century, our knowledge of cancer was based on epidemiology and pathology, and treatment consisted of surgery and radiation therapy. At mid-century, Medawar and colleagues initiated the understanding of transplantation immunology, Farber described the first use of an antifolic drug to treat leukemia, and Jacobson and coworkers described the irradiation-protection effect of spleen cells. These observations opened the door to the development of chemotherapy and transplantation in the treatment of cancer. Despite the rapid development of these new disciplines, progress was usually based on empiric observations and clinical trials. The rapid advances in molecular biology at the end of the 20th century mark a new era in our knowledge of cancer. Molecular immunology, molecular genetics, molecular pharmacology, and the Human Genome Project are in the process of providing a level of understanding of cancer undreamed of
in the past. Optimism is based on the firm belief that understanding at the molecular level will lead to better and earlier diagnosis, to new forms of treatment, and, most importantly, eventually to prevention ofmany types of cancer. Principles of Molecular Oncology provides a bold new look at the evolution of our knowledge of cancer. Authors from many disciplines are bringing together the facets that provide a comprehensive view of the whole. In a field progressing as rapidly as the understanding of cancer at the molecular level, any book must be regarded as a report of work in progress. The reader will enjoy the opportunity to pause and look at the whole field as it stands today. This book will prove both informative and intellectually satisfying. E. Donnall Thomas, MD Fred Hutchinson Cancer Research Center Nobel Laureate in Medicine/Physiology, 1990
ix
Foreword to the First Edition
A famous London surgeon is quoted as saying that a cure for cancer would not bediscovered by people in white coats working in laboratories, but rather by somebody leaning over a fence watching workmen digging a hole in the ground. Indeed, the ideathat malignant disease might have a single cause was rife until quite recently. But untilthe era of molecular biology, and the remarkable insights into cell biology that followed,the cancer field was in the doldrums. Viruses as the cause of human cancer had come and gone, chemical carcinogens and exposure to ionizing radiation seemed to be unlikelycauses of the bulk of human cancers, and it was not at all clear where to turn in cancer research. However, in the 1960s, two fields of investigation started to yield results that at least held some promise. Epidemiological studies showed quite unequivocally that there is a relationship between the development of certain cancers and cigaret smoking. And at least some forms of leukemia appeared to be associated with specificchromosomal changes. However, until the advent of recombinant DNA technology, there was no indication as to how these observations might be connected or about the cellularmechanisms of malignant transformation. When historians of science look back on the close of the 20th century and try toevaluate the fruits of the application of molecular and cell biology to the study of human disease, it is likely that they will pinpoint the better understanding of the biology of cancer as one of the highlights of this period. The discovery of oncogenes, together with improvements in cytogenetics, resulted in an amalgamation of these two fields of research and led to the dawning of an understanding of how cancers might result from the breakdown of normal cellular homeostatic mechanisms. Subsequently, the elucidation of the genetic control of the cell cycle, and how certain oncogenes monitor different aspects of cellular activity, allowing cells to go into cycle or directing them toward apoptosis, has started to provide some insights into the cellular mechanisms of malignant disease. Almost overnight, cancer has become less mysterious. It is clear that in many cases it results from the acquisi-
tion of mutations in one or more oncogenes that we acquire during our lifetime. Since at least some of these may result from specific chromosomal changes, or from the action of environmental carcinogens, these observations provide an elegant synthesis of several different fields of research. So although the final details of how a cell becomes cancerous still remain to be worked out, at last we have a blueprint of where to go in the future. Although it is true to say that the clinical impact of the remarkable advances in molecular medicine of the last few years may still be some time in the future, and that their immediate benefits have been oversold to the public, there seems little doubt that these new discoveries will play a major role in the cancer field in the future. The molecular approach is likely to provide a wide range of extremely valuable diagnostic agents for both the early recognition and assessment of the prognosis of different forms of cancer. It also seems likely that gene therapy, something that has been “just around the corner” for far too long, will find some of its early applications in cancer treatment. Thus, although molecular biology has shown us that cancer is an extremely complex disease, and that there are multiple routes to the neoplastic phenotype, there is little doubt that much of this work will find application in the clinic in the not too distant future. All these aspects of this complex and rapidly moving field are covered in this excellent book, Principles of Molecular Oncology. Clinical oncologists will find a series of balanced reviews of the current state-of-the-art of the diagnosis and treatment of cancer based on molecular technology, and, since cancer touches almost every field of clinical practice, specialists in other disciplines will find a very lucid and readable account of what is happening in one of the genuine success stories of today’s molecular medicine. Writing a foreword for a book for one of one’s former students, while a constant reminder of the closeness of personal dissolution, is still an enormous pleasure. If nothing else, it is reassuring to see that at least a few resistant xi
xii
human lines can survive all the potential damage of medical education and emerge relatively unscathed. I wish the editors and the excellent team of authors that they have brought together all the success with this book that it deserves. In a field that is moving so rapidly it is vital to have a bird’s eye view of the state of the art: I am sure that readers will
Foreword to the First Edition
obtain a balanced view of the potential and limitations of this exciting field. Professor Sir David J. Weatherall, MD, FRS Regius Professor of Medicine University of Oxford
Preface
The last 30 years or so has seen rapid growth in our understanding of the molecular basis of cancer. Many oncogenes and tumor suppressor genes have been discovered. The function of their protein products has been defined and they have been placed on signaling pathways and networks that are hijacked in cancer in ways that we can now comprehend. The three editions of Principles of Molecular Oncology have appeared during a period of unprecedented definition of the nature of molecular causation of cancer and the most rapid rational exploitation of this knowledge for the design of molecularly targeted cancer therapeutics. Although still incomplete, we have assembled a considerable “parts list” for normal and malignant cells. The current and future challenge is to complete this parts list and to assemble the components into a model of the whole that is intellectually satisfying and also allows robust and accurate predications of how biological systems respond to perturbation, including pinpointing the best therapeutic approaches. Of course, the sequencing of the human genome has made a major impact on the completion of the parts list. Technologies for gene resequencing and gene- and protein-expression profiling provide opportunities for genome-wide and proteome-wide searching. At the time of this writing, a debate rages, particularly in the United States, concerning the value for money of “big science,” “cancer genome anatomy” projects—which contribute further to the parts list and provide the tools for hypothesis generation—as distinct from individual investigator-led, hypothesis-driven “small science” that has been the traditional mechanism for basic research. This debate is healthy and is understandable in what is inevitably a cash-limited setting. However, in my view both approaches are important and are mutually beneficial. It is already almost impossible to imagine doing biomedical science without the human genome sequence. Similarly, accumulating the corresponding cancer genome sequences and other related information such as gene-expression patterns in cancer cells will make the ultimate understanding of the molecular basis of cancer much less difficult. At the same time, creative ideas generated by individual researchers remain crucial. A great
example of the mutual benefit of the two approaches is provided by the discovery of mutant B-RAF as an oncogene by high-throughput kinase mutation analysis and the subsequent functional and structural characterization, leading rapidly to drug discovery initiatives. The progression from gene to drug, along with the identification of the necessary biomarkers for diagnosis and prognosis and also pharmacodynamic endpoints for proof of concept, can now be accelerated by an array of powerful technologies [1]. These include RNA interference, high-throughput compound screening, chemical biology, and structural biology to name but a few. Over the last 5–10 years, translational cancer research has accelerated tremendously, particularly in area of targeted molecular therapeutics. The successes with trastuzumab, imatinib, gefitinib, erlotinib, bevacizumab, and others have clearly exemplified the ability to exploit our knowledge of the molecular biology of cancer to produce drugs that have a real impact on patients’ lives. This 3rd edition of the Principles of Molecular Oncology illustrates how far we have come in a short space of time. On the other hand, this edition also highlights the things that we need to do to move forward towards the goal of personalized medicine. Some have criticized the inevitable hype around the publication of the human genome sequence because of the somewhat inappropriate prediction that personalized medicines would simply fall into our hands. However, it is very clear that cancer is the therapeutic area in which individualized therapies based on genomic information on the particular patient concerned will be forthcoming over the next 5–10 years. To achieve this we need to complete the parts list and to understand the systems biology of cancer. Characterization of the multiple genes and proteins contributing to each individual cancer will lead to the potential for mathematical modeling of the responses of normal and pathologic systems when perturbed by cancer genes and therapeutic agents. Improved biomarkers will need to be developed. Ideally these will be minimally invasive markers, and the prospects for the use of molecular imaging are clearly very bright. The multiple drivers of malignant progression, together with the plasticity of cancer genomes that predispose to the development of therapeutic xiii
xiv
resistance will necessitate the development of combinatorial treatments. We can now clearly envisage the scenario in which, at some finite time in the future, a cancer patient will undergo a set of analyses—perhaps involving a whole genome scan—and the individualized therapy will be selected on that basis. The cancer treatment will no longer be based on anatomical location and the appearance of the tumor under the light microscope, but will be directly linked to molecular causation. We will look forward to the rapid progress towards this ambitious scenario and reading about this in future editions of Principles of Molecular Oncology.
Preface
I would like to thank my co-editors, Miguel Bronchud, MaryAnn Foote, Giuseppe Giaccone, and Olufunmilayo Olopade. Particular thanks go Miguel for his tireless leadership of the project. Paul Workman, PhD
Reference 1. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nature Chem Biol 2006;12:689–700
Contents
Foreword . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Karen Antman Foreword to the Second Edition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Derek Crowther Foreword to the First Edition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E. Donall Thomas Foreword to the First Edition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sir David J. Weatherall Preface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
xiii
Contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
xvii
Color Plates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
xix
Chapter 1
Selecting the Right Targets for Cancer Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Miguel H. Bronchud
Chapter 2
Clinical Importance of Prognostic Factors: Moving from Scientifically Interesting to Clinically Useful . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N. Lynn Henry and Daniel F. Hayes
v vii ix xi
1
27
Chapter 3
Genetic Markers in Sporadic Tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Elena Tamborini, Federica Perrone, Milo Frattini, Tiziana Negri, Antonella Aiello, Annunziata Gloghini, Antonino Carbone, Silvana Pilotti, and Marco A. Pierotti
43
Chapter 4
Genetic Markers in Breast Tumors with Hereditary Predisposition. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Tatyana A. Grushko and Olufunmilayo I. Olopade
85
Chapter 5
Circulating Tumor Markers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Alan Horwich and Gill Ross
107
Chapter 6
Antibody-Based Proteomics Analysis of Tumor Cell Signaling Pathways . . . . . . . . . . . . . . . . . . . . . . . . . . . Steven Pelech and Hong Zhang
117
Chapter 7
Gene Expression Arrays for Pathway Analysis in Cancer Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Xiang Sean Yu, Raymond K. Blanchard, Yexun Wang, and Min You
135
Chapter 8
Signaling Pathways in Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Daniel Kalderon
153
Chapter 9
Estrogen Receptor Pathways and Breast Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Jing Peng and V. Craig Jordan
189
xv
xvi
Contents
Chapter 10 Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Marcos Malumbres
207
Chapter 11 Angiogenesis Switch Pathways . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Jaume Piulats and Francesc Mitjans
239
Chapter 12 Apoptosis Pathways and New Anticancer Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Frank A.E. Kruyt, Jose A. Rodriguez, and Giuseppe Giaccone
257
Chapter 13 Genomic Instability, DNA Repair Pathways and Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gabriel Capellá, Josep Balart, and Miguel Angel Peinado
269
Chapter 14 Epigenomics and Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Isabel López de Silanes and Manel Esteller
281
Chapter 15 Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All’s Well That Ends Well? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Angelo A. Cardoso
293
Chapter 16 Aurora Kinases: A New Target for Anticancer Drug Development. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Teresa Macarulla, Francisco Javier Ramos, and Josep Tabernero
307
Chapter 17 Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways . . . . . . . . . . . . . . . Alison H.M. Reid, Richard Baird, and Paul Workman
317
Chapter 18 Suicide Gene Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Silke Schepelmann, Ion Niculescu-Duvaz, and Caroline J. Springer
367
Chapter 19 Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs . . . . . . . . . . . Rosario García-Campelo, Miquel Tarón, Itziar De Aguirre, Pedro Méndez, and Rafael Rosell
383
Chapter 20 A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible? . . . . . . . . . . . . . V. Craig Jordan
391
Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
399
Trade Names/Generic Names . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
403
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
405
Contributors
Karen Antman, MD, Clinical Dean and Provost, Boston University School of Medicine, Boston MA. Past President of ASCO (American Society of Clinical Oncology). Past President of AACR (American Association of Cancer Research) Antonella Aiello, PhD; Molecular Pathology, National Tumor Institute, Milan, Italy Richard Baird, PhD; Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK Josep Balart, MD, PhD; Translational Research Laboratory, IDIBELL-Catalan Institute of Oncology; Llobregat Hospital, Barcelona, Spain Raymond K. Blanchard, PhD; SuperArray Bioscience Corporation, Frederick, Maryland, USA Miguel H. Bronchud, MD, PhD; Division of Medical Oncology, Hospital General of Granollers, Barcelona, Spain Rosario Garcia-Campelo, MD, PhD; Juan Canalejo Hospital, A Coruña, Spain Gabriel Capellá, MD, PhD; Translational Research Laboratory, IDIBELL-Catalan Institute of Oncology; Llobregat Hospital, Barcelona, Spain Antonino Carbone, MD; Molecular Pathology, National Tumor Institute, Milan, Italy Angelo A. Cardoso, MD; Indiana University School of Medicine, Division of Hematology/Oncology, and Walther Oncology Center, Cancer Research Institute, Indianapolis, Indiana, USA Derek Crowther, MD, MB BChir, FRCP, FRCR; Emeritus Professor of Medical Oncology, University of Manchester and Christie Cancer Centre, Manchester, UK Itziar De Aguirre, MD; Catalan Institute of Oncology, Badalona, Spain Manel Estellar, PhD; Cancer Epigenetics Laboratory, Spanish National Cancer Centre (CNIO), Madrid, Spain MaryAnn Foote, PhD; MA Foote Associates, Westlake Village, California, USA Milo Frattini, PhD; Laboratory of Molecular Diagnostic Clinical Pathology; Cantonale Institute of Pathology, Locarno, Switzerland Giuseppe Giaccone, MD, PhD; National Cancer Institute, Bethesda, Maryland Annunziata Gloghini, PhD; Diagnostic Immunohistochemistry and Molecular Pathology Unit, Aviano, Italy Tatyana A. Grushko, PhD; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
Daniel F. Hayes, MD; Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA N. Lynn Henry, MD, PhD; Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA Alan Horwich, MD, PhD, FRCR, FRCP; The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK V. Craig Jordan, OBE, PhD, DSc; Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA Daniel Kalderon, PhD; Department of Biological Sciences, Columbia University, New York, NY, USA Frank A. E. Kruyt, MD; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands Isabel López de Silanes, PhD; Cancer Epigenetics Laboratory, Spanish National Cancer Centre (CNIO), Madrid, Spain Teresa Macarulla, MD; Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain Marcos Malumbres, PhD; Cell Division and Cancer Group, Centro Nacional de Investigaciones Oncológicas Madrid, Spain Pedro Mendez, MD; Catalan Institute of Oncology, Badalona, Spain Francesc Mitjans, Tiziana Negri, PhD; Molecular Pathology, National Tumor Institute, Milan, Italy Ion Niculescu-Duvaz, PhD; Institute of Cancer Research, CRC Centre for Cancer Therapeutics, Surrey, UK Olufunmilayo I. Olopade, MD; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Illinois, USA Miguel Angel Peinado, PhD; Molecular Oncology Center, IDIBELL; Llobregat Hospital, Barcelona, Spain Steven Pelech, PhD; Canadian Institute for Health Research, Kinexus Inc, Canada Marco A. Pierotti, PhD; Deparment of Experimental Oncology; National Tumor Institute, Milan, Italy Silvana Pilotti, MD; Molecular Pathology, National Tumor Institute, Milan, Italy Jing Ping, PhD; Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA Jaume Piulats, PhD; Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain Francisco Javier Ramos, PhD; Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain Alison H. M. Reid, PhD; Bob Champion Stem Cell Laboratory, The Institute of Cancer Research, Sutton, Surrey, UK xvii
xviii Jose A. Rodriquez, MD; Department of Medical Oncology, MD; VU University Medical Center, Amsterdam, The Netherlands Rafael Rosell, MD; Juan Canalejo Hospital, A Coruña, Spain Gill Ross, MD, PhD, FRCR; The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK Silke Schepelmann, PhD; Institute of Cancer Research, CRC Centre for Cancer Therapeutics, Surrey, UK Caroline J. Springer, PhD; Institute of Cancer Research, CRC Centre for Caner Therapeutics, Surrey, UK Josep Tabernero, MD; Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain Elena Tamborini, PhD; Molecular Pathology, National Tumor Institute, Milan, Italy Miguel Tarón, PhD; Catalan Institute of Oncology, Barcelona, Spain
Contributors E. Donnall Thomas, MD; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Yexun Wang, PhD; SuperArray Bioscience Corporation, Frederick, Maryland, USA David J. Weatherall, MD, FRS; Department of Medicine, University of Oxford, Oxford, UK Paul Workman, PhD, FMedSci; Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK Min You, PhD; SuperArray Bioscience Corporation, Frederick, Maryland, USA Xiang Sean Yu, PhD; SuperArray Bioscience Corporation, Frederick, Maryland, USA Hong Zhang, PhD; Canadian Institute for Health Research, Kinexus Inc, Canada
Color Plates
Color Plates follow p. 316 Color Plate 1
Fig. 3-1. The p53 pathway. (See discussion on p. 46)
Color Plate 2
Fig. 3-5. PTEN. The PI3K/PTEN/AKT pathway. (See discussion on p. 58)
Color Plate 3
Fig. 7-3. Gene-expression analysis by real time PCR array. The typical gene-expression analysis by PCR array starts with total RNA extraction, then reverse transcription to generate cDNA. The PCR reaction mixture and cDNA are dispensed onto PCR plates containing an array of prevalidated and optimized primer pairs. Using a real time PCR instrument, the amplification plots for all genes are generated and Ct values are compared between different samples. The relative gene expression change can be inferred by the ∆∆Ct methods. (See discussion on p. 139)
Color Plate 4
Fig. 7-4. Array microarray images from different pathway models used to analyze cancer genotype-specific and chemotherapeutic treatment responses. CDDO-Im induced upregulation of genes in both iMycEµ-1 and-2 cells. Shown are images of the cDNA arrays involved in cell cycling (top row), apoptosis (2nd row), stress and toxicity responses (3rd row), and NFκB signaling (bottom row). CDDO-Im treated and untreated samples are presented as array pairs by genotype. Squares indicate the CDDO-Im–induced genes and they are listed in the text box to the right of each array. Underlined gene names indicate genes that changed and are present on multiple arrays. Note that although the induction of some genes is visible by eye, others are not visible at these photographic settings but still detected by image analysis software. Reprinted with permission from S-S Han et al. Molecular Cancer, 2006, 5:22 [53]. (See discussion on p. 149)
Color Plate 5
Fig. 10-6. Structural representation of CDK-cyclin interaction. Structural coordenates of CDK2 bound to cyclin A [84] or cyclin E [305] were obtained from the NCBI database and represented using Cn3d. (See discussion on p. 213)
Color Plate 6
Fig. 13-1. Main types of DNA repair. Schematic representation of the main types of DNA repair pathways depicting origin of the damage, type of damage produced, and repair pathway involved. (See discussion on p. 270)
Color Plate 7
Fig. 14-1. Schematic of the altered epigenetic pattern of cancer cells versus normal cells. An array of nucleosomes is shown where DNA (red line) is wrapped around histone octamers (grey circles). In the normal cell (top), CpG islands at the promoter of tumor-suppressor genes (TSG) are unmethylated (lack of red circles) and histone tails (protruding gray lines) show acetylated histone H3 (AcH3) and H4 (AcH4) and trimethyl-K4 of histone H3 (3mK4 H3), which represents a transcriptionally active environment and the gene will be expressed. In cancer cells (bottom panel), many TSG undergo aberrant hypermethylation (red circles) at their CpG islands and many different elements are recruited: DNA methylation is carried out by DNA methyltransferase proteins (DNMT) that participate in a multiprotein complex that contain histone deacetylases (HDAC) or histone methyltransferases (HMT) or both, and methyl-binding proteins (MBD) can be loaded onto methylated DNA through their interaction with both HDAC and HMT. Histone marks displayed by normal cells are lost and new marks as dimethyl-K9 at histone H3 (2mK9 H3) are gained. All these cooperative interactions are responsible for gene silencing of TSG in cancer cells. (See discussion on p. 283)
Color Plate 8
Fig. 17-1. Subway map of cancer pathways. Reprinted by permission from Nature Reviews Cancer, copyright (2002) Macmillan Magazines Ltd. Available online at http://www.nature.com/nrc/journal/v2/n5/weinberg_poster/, with links to seminal papers and NCBI LocusLink entries for each gene product (Hahn WC, Weinberg RA. A subway map for cancer pathways. Nature Rev Cancer 2002;2(5):331–341). (See discussion on p. 317)
xix
Chapter 1 Selecting the Right Targets for Cancer Therapy Miguel H. Bronchud
1.1
Introduction
Molecular Oncology can be defined as that branch of medical science that looks at cancer from a molecular point of view. For several reasons, outlined in all of the chapters of this book, and globally reviewed in this first and initial chapter, “molecular oncology” represents the “heart of the matter” of cancer, and our best hope for developing more rational and safer new therapies for cancer throughout the multiple stages of cancer development, including its “pre-clinical” natural history, also known as “carcinogenesis.” These new anticancer drugs based on molecular oncology are also called “targeted therapies,” for it is precisely the “molecular targets” relevant to the cancer phenotype that are aimed at. But the impact of molecular oncology is not restricted to the development of new therapies. As I shall briefly review, and as is explained also in other chapters of this book, molecular oncology is helping us to define new methods for primary cancer prevention (for example, effective vaccines against carcinogenic viruses, like Hepatitis B virus and human papilloma viruses), or for secondary cancer prevention (like inhibitors of cyclo-oxygenase 2 (COX-2), to prevent colonic adenomas or carcinomas, or new antiestrogen molecules for breast cancer prevention, or antiandrogens for prostate cancer prevention). It is also allowing powerful new “molecular imaging” methods, that promise to detect and measure some of the key properties of malignant cells “in vivo,” as well as their response to therapy. In this first chapter, we shall try to see “the wood, rather than the individual trees,” even if, in light of present knowledge, it remains difficult to bridge the vast gulfs that open up on closer examination, and that cannot yet be spanned by the most audacious hypothesis. The evolution of most human cancers can be viewed as the operation of Darwinian selection, the processes among competing populations of dividing cells and the sequential accumulation of relevant genetic and epigenetic events. There are different types of tumor markers: (1) genetic markers in both hereditary tumors and nonhereditary tumors;
From: Principles of Molecular Oncology, Third Edition Edited by: Miguel H. Bronchud et al. © Humana Press Inc., Totowa, NJ
(2) cellular and tissue markers; (3) epigenetic markers, usually in nonhereditary tumors; and (4) circulating cancer markers. Some of these markers are already used routinely in clinical practice (e.g., several circulating cancer markers are useful for the diagnosis, prognosis, and follow-up of some cancer types), others are being investigated as a source of important prognostic information or even as predictors of response to chemotherapy or radiotherapy (e.g., several cellular and tissue markers), and others still are being explored, in the context of genetic counselling, as potentially useful in screening for hereditary cancer predisposition. Some epigenetic markers (see chapter on Epigenomics and Cancer by Manel Esteller and colleagues) promise to be useful in detecting premalignant changes, for example in the bronchial epithelium of heavy smokers. Regulatory pathways involved in the complex regulation of cell growth, differentiation, senescence, and cell death are being gradually understood. Although we are still largely unable to draw schematically precise cell-type-specific regulatory pathways, current knowledge and research efforts will be updated. In contrast, the classical metabolic regulatory pathways have been known for many years. Pathways such as, for example, the “citric acid cycle” (postulated by Krebs in 1937), the central role of ATP in the energy-transfer cycles (postulated mainly by Lipmann in 1939–1941), or the intriguing Mitchell’s hypothesis (1961) to explain the mechanism of oxidative and photosynthetic phosphorylation, to name but a few examples, have been part of biochemistry textbooks for decades. Some 29 years ago, the structure of DNA had already been known for over 2 decades and yet eminent scientists were pessimistic about real therapeutic progress in oncology. This book is a good demonstration that things have changed. Although there is still no treatment for any of the major lethal cancers that is as effective as the antibiotics are for infections, the knowledge that has accumulated on the fine regulatory mechanisms that are deranged in cancer cells is vast and undoubtedly promises new therapeutic insights. The introduction into routine clinical use of selective (though not entirely specific) tyrosine kinase inhibitors, for example for chronic myeloid leukemia or some solid tumors, like gastrointestinal stromal tumors (GIST), nonsmall cell 1
2
lung cancer, renal cell carcinomas, and others, and the development of specific monoclonal antibodies for breast cancer or some lymphomas, are good examples. In contrast to the situation some 20 years ago, not only do we know many molecular targets to design new drugs for the chemoprevention or treatment of cancer, but, paradoxically, we have an apparent excess of targets for our current resources of drug development worldwide. The Human Genome Project has completed its first basic human genome map well ahead of schedule, and it is likely to give us further insights and more potential targets. It is now estimated that the human genome contains some 30,000 genes, less than originally thought by most researchers. Because of alternative splicing and other mechanisms these genes can code for up to 300,000 different proteins in human cells. Many of these genes and proteins are well characterized and their functions in various pathways are known. But the real function of the majority of these human genes and proteins remains speculative. In other words, the rate-limiting step in true progress against cancer is the amount of resources we can spend and the optimization and coordination of this huge research process, rather than a shortage or lack of therapeutic targets. Selecting the right targets for cancer therapy can make a big difference. If, for example, we were clever or lucky enough to correctly guess the right targets for the main human cancers, and if large multinational pharmaceutical companies agreed to focus their efforts and enormous resources on these targets, then revolutionary new cancer treatments might become available for clinical testing within 5 to 10 years. But, if we were wrong, or not enough importance was given to this war against cancer, then it might take another 20 or 30 years, or even more. The object of all cancer research is simply to stop cancer from being a major cause of death and human suffering, and it is in this light that all new research must ultimately be judged. In spite of progress there is still ample room for improvement, and many practicing oncologists still believe that new cancer drugs often deliver less than they promise. The problem may not only lie in the drugs themselves, but also in the way they are tested and used. The methodology of clinical development of new targeted drugs, coupled with new molecular imaging tools and a more precise understanding of what these drugs are actually doing in different cancers, will also need to improve if we want to reduce total costs for each new drug, still estimated to be between 600 and 800 million US dollars, and the overall time “from bench to regulatory approval” for clinical use, still around the 10 years mark. For example, it is commonly accepted that targeted drugs are generally very much less harmful and toxic than conventional cytotoxic agents, which probably means less need for phaseI studies (many trials are now directly coupling the phase I to a single phase-I/II study), but also more in-depth phase-II studies, with pharmacodynamics in well-defined populations of cancers, and ideally combination studies with two or more agents to hit the cancer-specific targets in the most efficient
M.H. Bronchud
and intelligent way. These methodological changes will need the support and adaptation of regulatory bodies, as well as new mathematical, imaging, and biochemical tools to assess response. In this initial chapter we review some new prospects in the prevention, early detection, and treatment of cancer, based on four basic truths of oncology: 1. cancer can be prevented; 2. cancer can be diagnosed, and the earlier the diagnosis the higher the chances of curative treatment; 3. cancer can be cured (by local or systemic therapies, or a combination of both), but the impact on mortality of present therapies is often limited; 4. cancer cannot always be cured, and it seems reasonable to predict that even in the year 2040 there will still be many cancers incurable at the time of clinical presentation.
1.2
The Evolution of a Cancer
All cells in an organism are, of course, derived from a single cell, the fertilized egg. At an early stage in development, the embryo consists of three types of cells: ectoderm, mesoderm, and endoderm. Mesoderm, at a very early stage, shows a further development, part of it becoming mesenchyme. Ectoderm gives rise to all the epithelia covering the outer surfaces of the body and extending into the mouth and nasal passages. Practically all the nervous system is also ectodermal. From the same source come the smooth muscle cells of the iris and a number of other structures, such as the anterior lobe of the pituitary gland. The endoderm gives rise to all epithelia lining the alimentary tract, the respiratory passages, and the lower part of the genitourinary passages, in all cases to the point where it meets with cells of ectodermal origin. It also gives rise to the parenchymal epithelial cells of the liver and pancreas. An organ may consist of many different tissues that intermingle with each other more or less intimately. Thus, for example, even a relatively simple tissue such as the liver may contain the following cell types: hepatocytes, fibrous tissue cells, blood cells of various types, blood vessels, bile ducts, nerve fibres, reticuloendothelial cells (Kupffer cells) etc. Modern gene expression profiling methods (e.g., DNA microarrays) are good molecular witnesses of such diversity and complexity of tissues. One can even dare to say that we shall never know exactly what is cancer, until the complexity of embryonic development and the precise mechanisms that regulate gene expression and DNA replication are finally understood. For cancer is, putting it in simple terms, the end-result of what happens when these mechanisms go progressively wrong in the adult. Cancers in the embryo are extremely rare, if they exist at all, although some neoplasms of children (e.g., some acute leukemias) may well originate in utero. In the adult, solid tumors can behave as a “parasitic organism” within an organism. A cancer is alive, obeys its own rules, but ignores most of the rules of the host, continues to grow and spread locally
1. Selecting the Right Targets for Cancer Therapy
or to distant sites, and eventually destroys its host organism, paradoxically destroying itself too.
1.2.1
Relatively Old Views on Carcinogenesis
For a long time the concept of “lineage” has been central to all our ideas about cancer. According to this concept, cancer starts as a local disease, in a given cell clone that, for reasons that remained unclear until some 20 years ago, could multiply faster than normal and displace its neighbors: families of cells can emerge that increase in numbers at the expense of their neighbors. Described in these terms, the evolution of a cancer can be viewed as the result of Darwinian selection among competing populations of dividing cells. The tissues of the body normally preserve their initial fine mosaicism even in old age, indicating that under normal circumstances there is “harmony” in tissues, equilibrium between cell death and cell proliferation, balanced regulatory exchanges between stroma and epithelial cells, and little or no competition between adjacent cells. However, according to this old view that remains widely accepted today, one of the earliest steps in the sequence leading to cancer is the emergence of families that are able to displace their neighbors [1–3]. No doubt this is partly the result of some “intrinsic change” in the cells (and mutations were suspected long before oncogenes and tumor suppressor genes were discovered), that enable them to compete for territory, but the whole process can presumably be accelerated by anything that causes cell death creating an opportunity for competition to occur. As a result, the normal equilibrium is lost and a “tumor” gradually develops. These “intrinsic changes” in the cells could induce cells to multiply without the usual restraints, e.g., they divide more frequently or are subject to less cell loss, but nevertheless keep within their normal territory and do not invade the surrounding tissues, thereby forming benign tumors. Alternatively, if these “intrinsic changes” somehow damage the normal regulatory networks that maintain “territoriality” and the normal cells acquire the ability to spread to alien sites, locally or to distant regions, then the tumors formed are called “cancers” because of their malignant behavior. Therefore, monoclonality is generally considered the hallmark of tumors, but situations exist in which clonality is not unequivocally associated to malignancy. Clonal markers are useful for the diagnosis or follow-up of disease progression for both solid and hematologic tumors. Modern methods of clonality determination include X-chromosome inactivation (in females), immunoglobulin and T-cell receptor gene rearrangement analysis, and specific chromosomal translocations or deletions. Benign conditions (e.g., benign monoclonal gammopathy), and some premalignant conditions (e.g., lymphomatoid granulomatosis, lymphomatoid papulosis, Langerhans cell histiocytosis, lymphoepithelial proliferations associated with Sjögren disease, etc.) may show monoclonal rearrangement without necessarily developing malignancy after prolonged follow-up [4, 5].
3
Regarding the nature of these “intrinsic changes” that lead to cancer, several decades ago there was much debate as to whether their nature was “genetic,” secondary to mutations or chromosomal alterations, or “epigenetic,” because of abnormalities in gene expression without an underlying genetic lesion. Thus, although most known human carcinogens were proven to be mutagens, it was postulated that some cancers for which no cause had been discovered could be partly because of agents that were not mutagens, but acted instead by provoking cell division and errors in gene expression.
1.2.2
More Modern Views on Carcinogenesis
However, most of the evidence was clearly in favor of a “genetic” cause. Cancer incidence rises sharply with age and various models had been proposed to account for this [6, 7]. These models shared the view that a cancer cell arises as the end result of a series of steps that have occurred at some time in the life of the patient. They often postulated that each cell has several genes that independently restrain it from forming an ever-expanding family of cells, and that a cancer arises when a cell is created in which each of those genes has been inactivated by a separate, independent mutation. Logically, the probability of any particular one of our cells having a mutation in a particular gene will increase in direct proportion to our age. In 1958, Armitage and Doll [8] had calculated that for some of the common solid tumors the logarithm of cancer incidence should be linearly related to the logarithm of our age, and that, if such an interpretation were literally true, then we could deduce from the slope of the death rate from cancer of the large intestine in relation to age plotted logarithmically, that about six mutations are needed to produce a cancer of the large intestine. This guess is extraordinary if one thinks that more or less the same conclusion was reached, based on molecular genetic knowledge, by Fearon and Vogelstein in their classic work on colorectal tumorigenesis [9]. The “multi-step mutation” theory of cancer was also supported by other lines of epidemiological evidence [10, 11], and by the “initiation and promotion models of carcinogenesis.” A characteristic feature of most forms of carcinogenesis is the long period that elapses between initial application of the carcinogen and the time the first cancers appear. It is necessary to apply coal tar repeteadly to the skin of a mouse for several months before any tumors are detectable. Similarly, most common human cancers can take 3–30 years or more to develop. The chemical carcinogenesis models also helped to identify at least two classes of carcinogenic compounds: the initiators and the promoters. For example, if a group of mice are fed a small amount of the carcinogen dimethylbenzanthracene (DMBA) this produces widespread irreversible alterations (presumably mutations) in the cells of each mouse. Subsequent irritation of the skin by painting it twice a week with croton oil (the “promoter”) eventually results in the local appearance of tumors. These tumors will appear even if croton oil is not
4
started until 16 weeks after the DMBA feeding, but no tumors arise if either DMBA or croton oil is given alone or if the order of the treatments is reversed. In several aspects, estrogens (for breast cancer) and testosterone (for prostate cancer) have also been regarded as potential tumor promoters. Other insights into the “genetic” nature of tumorigenesis came from studies on viral carcinogenesis [12–14] and from seminal observations in the uncommon retinal cancers in children [15]. The discovery of tumor oncogenes and tumor suppressor genes almost 20 years ago opened the way to the molecular epidemiology of cancer [16–20]. Thus, it soon became apparent that in general more than one somatic mutational event was needed for malignant transformation. The possible exception being the uncommon hereditary retinoblastomas, already described by the “two-hit model” proposed by Knudson [15]. Then it was also found that certain carcinogens are linked to selective (though not entirely “specific”) mutational events. For example, molecular linkage between exposure to carcinogens and cancer types have been described for p53 mutational spectra of hepatocellular carcinoma, skin cancers, and lung cancer [19]. Fearon and Vogelstein proposed a molecular model for colorectal carcinogenesis in 1990 [9] based on the sequential accumulation of genetic events in key regulatory genes along the sequence adenoma to carcinoma. More recently, in 1997, Kinzler and Vogelstein [21] proposed the concept of two different types of carcinogenic genetic events: those involving “gatekeeper” or “caretaker” genes characterized by their control of net cellular proliferation or maintenance of genomic integrity, respectively. Examples of gatekeeper genes include APC and beta-catenin in colon epithelium, Rb in retinal epithelial cells, NF1 in Schwann cells, and VHL in kidney cells. Thus, it is proposed that an alteration in APC leads to a derangement of the cellular proliferation pathway that is important for maintaining a constant cell population, at least in colonic cells. The identification of other gatekeeper genes is expected, and some may be genes crucial to morphogenetic events of specific tissues. Unlike gatekeeper genes, caretaker genes generally maintain genomic stability and are not involved directly in the initiation of the neoplastic process, but their mutations enhance the probability of mutations in other genes, including those in the gatekeeper class. Because multiple mutations are found in cancer cells, the existence of a “mutator phenotype” was suggested by Loeb in 1991 [22, 23] as an important step in tumor development, and candidate mutator genes are involved in multiple cellular functions needed for maintaining genetic stability, such as DNA repair, DNA replication, chromosomal segregation, cell cycle control, and apoptosis. Finally, some individuals may be predisposed to cancer because of inherited mutations of some key genes that may confer a familial predisposition to cancer. This has attracted considerable attention in recent times, particularly in relationship to breast cancer and colon cancer susceptibility genes [24, 25].
M.H. Bronchud
The genetic alterations in oncogenes generally lead to an increased function of the protein, whereas, in general, tumor suppressor genes are inactivated during carcinogenesis with apparent loss of function of the protein. However, the mechanisms of activation or inactivation are multiple, and the precise consequences on gain or loss of function are incompletely understood. K-ras and H-ras genes are examples of oncogenes preferentially altered by point mutation (codons 12, 13, and 61), generating a protein with constant GTPase activity. The c-myc gene can be activated by chromosomal translocation (in some leukemias) or by gene amplification (in some solid tumors). The p53 and Rb tumor suppressor genes are often knocked out by point mutation in one allele and by deletion (loss of heterozygosity) at the other. Others, like p16, have high rates of homozygous deletions or promoter hypermethylation. Some genetic defects are fairly characteristic for a given tissue type (most colorectal cancers have APC or beta-catenin mutations). But the “same players” are frequently involved in different tumors. Each human cancer can be regarded as a different molecular entity, with a different matrix of molecular targets, and it evolves with time (even as a result of systemic or local therapies) [26].
1.2.3 Cancers are Monoclonal, but the Carcinogenesis Process is Probably Polyclonal The recent progress in the physical mapping of the Human Genome, has already reached the “Postgenome Era.” Automated or semi-automated devices capable of reading thousands of genes are already available (see chapter by Sean Yu), and immuhistochemistry is also able to map regulatory pathways (see chapter by Steven Pelech). Genomics and proteomics are here to stay [27], but their routine use in the clinic obviously require proof of efficacy and judicious use. Cancer is a state, but carcinogenesis is a process. Key to the multistep genetic nature of cancer is that carcinogenesis is “progressive.” In most epithelial tissues, progression means the sequential accumulation of somatic mutations. In some cases of familial predisposition to cancer some of these mutations are inherited. Gradually, a given target tissue experiences a transition from normal histology, to proliferative and/or dysplastic changes, to so-called “intraepithelial neoplasia” (IEN), which can be early or severe, to superficial cancers (in situ), and finally to invasive disease. In some instances, the process may be aggressive and relatively rapid (e.g., in the presence of a DNA repair-deficient genotype or an aggressive human papilloma virus), but in general these changes occur over a long period of time. In the breast, for example, it is estimated that progression from atypical hyperplasia through ductal carcinoma in situ (DCIS) to adenocarcinoma may require 30 years or more [28, 29]. Similar observations have been made in other tissues, such as lung, head and neck, prostate, bladder, and colorectal tissue [30–34]. However it would be a mistake to believe that all common epithelial human cancers follow these clear-cut histological
1. Selecting the Right Targets for Cancer Therapy
sequential patterns from adenoma to carcinoma. In fact, only a minority of the commonest type of breast cancers (infiltrating ductal carcinomas, or IDC) arise from ductal carcinoma in situ. Thus, the molecular changes leading to IDC, that account for almost 70% of all breast cancers, can happen before the histological features associated with DCIS become evident. DCIS is characterized by a proliferation of malignant epithelial cells confined to the mammary ducts without light microscopic evidence of invasion through the basement membrane into the surrounding stroma; but IDC, by definition, show signs of invasion of stromal tissue, often with vascular and/or lymphatic vessel involvement. In other words, conventional histological and radiological techniques (e.g., bilateral mammograms) are not enough to detect with precision on-going carcinogenic risk in many cases of women at risk. Patients with a head and neck squamous cell carcinoma (HNSCC) often develop multiple (pre)malignant lesions, ranging from leucoplakia to other cancers, which led Slaughter et al. [35] back in 1953 to postulate the concept of “field cancerization.” The incidence rate of second primary tumors following a first diagnosis of HNSCC is 10–35%, depending on both the location of the first primary tumor and the age of the patient. The carcinogens associated with HNSCC (alcohol and tobacco smoking) are thought to induce mucosal changes in the entire upper aerodigestive tract (UADT), causing multiple genetic abnormalities in the whole tissue region. Similar arguments apply also to other tobacco-related cancers, like transitional cell carcinomas of the urogenital tract or bronchogenic carcinomas [36, 37]. An alternative theory for these observations is based on the premise that any transforming event is rare and that the multiple lesions arise because of the widespread migration of transformed cells through the whole UADT [38, 39]. However, most field changes appear to be induced by smoking, supporting the theory of carcinogen-induced field cancerization rather than field cancerization because of migrated transformed cells [40]. Other possible causes of “field carcinogenic events” can involve hormonal factors (e.g., changes in the ovaries, breasts, or prostate), inflammation and hyperemia (increased proliferative and angiogenic activity in chronic cystitis, gastritis, esophagitis, or colitis), chronic viral infections (e.g., Hepatitis B virus for hepatocarcinomas, Epstein-Barr virus for nasopharyngeal carcinomas, or some lymphomas), aberrant methylation linked to ageing, free-radical induced DNA damage (e.g., for cancers of the gastrointestinal tract), skin exposed to ultraviolet irradiation (e.g., actinic keratosis and squamous cell carcinomas), ionizing radiation-induced damage, or aberrant morphogenetic pathways. It is also possible that different carcinogenic pathways operate in different tissue fields belonging to the same organ. For example, adenocarcinomas of the right side of the colon are often associated with different clinical and molecular characteristics than adenocarcinomas of the colorectal region. Even in breast cancer, the reported incidence of multicentric or multifocal lesions in areas away from the primary tumor in
5
mastectomy specimens ranges from 9 to 75%, depending on the definition of multicentricity, the extent of tissue sampling and different histological techniques of examination [41–43]. So that multifocality or multicentricity of breast cancers may in fact be a lot more common than currently acknowledged. In this context, the old “field cancerization” theory by Slaughter [35] and the more recent “multi-step carcinogenesis” model by Fearon and Vogelstein [9] can now come together in a single model: sequential field cancerization [44]. If it does require some seven sequential carcinogenic “genetic hits” in a single cellular clone for a malignant tumor to develop, it is mathematically more likely to occur in a tissue with a high background of genetic alterations in neighboring cellular clones, than in a tissue with a low background of such alterations, or with no detectable carcinogenic mutations at all (Figs. 1-1 and 1-2). The probability of a single clone accumulating seven independent but sequential genetic alterations leading to a malignant phenotype, without any similar events occurring in neighboring cells would seem to be rather low. This simple conclusion, and our ability to measure “background carcinogenesis” in different parts of the body, might lead to several unexpected implications. Technology is just beginning to be sufficiently sensitive to start testing the hypothesis. One potential technical problem is that in premalignant tissue, the “signal” (e.g., relevant oncogenetic lesions) might be diluted by the “noise” (normal genome of most of the cells in the tissue), until the premalignant clones have expanded enough to become more numerous locally than normal cells. However, it is only a matter of time before this goal is technically achievable. A possible future objective is the development of a combined histological and molecular staging system (Fig. 2). For example, after a follow-up of 5–10 years, one would expect more new cancers to developn in group IIIc of Fig. 1-2 (dysplastic changes and three or more than three significant mutations identified), than in group Ia (normal histology and no mutations identified). The clinical application of this concept and technology should then help to classify patients into various relative risk groups early on in the development of a malignant disease, allowing a tailor-made program for follow-up and screening, as well as more appropriate therapeutic and chemopreventive interventions [45–47]. For example [48, 49], a suitable combination of relevant biomarkers might help clinicians to identify smokers at high risk of developing lung cancers (approximately 10–15% of frequent smokers). Confrontation with personal cancer risk rather than general statistical risk, is a potent motivation to quit smoking and to undergo more frequent health checks (like high-resolution CT-scans to detect isolated pulmonary nodules). Some smokers might be protected because of genetic polymorphisms of enzymes involved in the molecular activation of precarcinogens present in tobacco, whereas others may be more vulnerable to the carcinogenic effects because of genetic defects in DNA repair enzymes. Some molecular changes associated with ageing and carcinogenesis might be epigenetic (e.g.,
6
M.H. Bronchud Multiclonality of Pre-Malignant Changes
FIELD CARCINOGENESIS
MULTISTEP CARCINOGENESIS
• transitional cell cancers of the urogenital tract • aerodigestive cancers (head and neck, lung, others) • multicentric, multifocal, synchronic, metachronic carcinomas (breast, prostate, colon, skin, others) Atleast 7 sequential oncogenetic “hits”
Multiclonality of premalignant changes
?
Fig. 1-1. Carcinogenesis is a “process” that is likely to be polyclonal and age-dependent. Cancer is a “state.” The word “cancer” has been for decades synonymous with “pernicious evil” in the figurative sense of the word. Partly because, unlike, for example, the infectious diseases, cancer is the “enemy within,” produced by our own body, not only because of environmental agents (external to us like tobacco, asbestos fibers, ionizing radiation, some viruses, or chemical carcinogens), but also because our own cells and our own genes can produce it. See text for explanation.
Fig. 1-2. Breast Ia is considerably less likely to develop a malignant tumor than breast IIIc. See text for explanation.
promoter hypermethylation) rather than genetic [50]. Even some pediatric malignancies might be secondary to abnormal morphogenetic events in utero [51]. It has been estimated that in the USA alone some 30% of people above the age of 60 can be found to have adenomas of the colon by colonoscopy, 70% or more of men above the age of 80 will have IEN of the prostate, 30% of people aged 60 or more have actinic keratosis on their skin, 20% of sexually active women above the age of 40 may have some degree of cervical IEN, at least 40% of heavy smokers can show metaplastic or dysplastic changes in their bronchial mucosa, and some 20% of women with dense mammograms and aged more than 50 may show atypical cells on ductal washings from the
nipple or ultrasound-guided fine-needle aspirates. The use of a battery of genetic or protein biomarkers relevant to each of the main cancer types may soon help us to better define individual cancer risks, and to measure background carcinogenesis in individual tissue samples. Perhaps, not too long from now, oncology units will be devoted to the treatment of carcinogenesis just as much as to the treatment of cancer. For example, DNA microarray-based sequence analysis uses comparative hybridization to obtain information ranging from mutational detection to polymorphism genotyping. Although further technical progress is needed to enable better detection of repeated sequences where changes may not always be distinguishable from wild-type sequences, some
1. Selecting the Right Targets for Cancer Therapy
initial experiments have found microarrays to be more sensitive, more accurate and faster than classical sequencing approaches [52, 53]. To increase the ability to detect genomic imbalance, including gains or losses of nuclei acid material, often associated with the carcinogenic process, like the occurrence of deletions in tumor suppressor genes or amplifications of oncogenes, new techniques are being developed. For example, several groups have adapted array technology to comparative genomic hybridization (CGH), leading to so-called array-CGH techniques. In CGH fluorescent signals along each chromosome are examined and analyzed to provide a cytogenetic pattern of gains and losses. In array-CGH experiments the mapping resolution can reach the kilobase level [54, 55]. Although technical limitations remain a problem, new developments proceed at a reasonably fast pace, for example to detect copy number changes in cancer cells isolated from routine paraffin-embedded tissues suitable for laser-capture micro-dissection samples [56, 57]. Single nucleotide polymorphisms (SNPs) are the most frequent form of DNA polymorphisms in the human genome, with over 1% differences among individuals, allowing the detection of specific genetic fingerprints, and have already been used to detect loss of heterozygosity (LOH) in several human tumor samples [58–60]. Finally, microarray-based gene expression profiling comparisons indicate a panel of up- or downregulated genes that can reveal candidate molecular markers for the disease in question, and help to classify tumors into novel tumor types, not previously known by conventional histological techniques, as well as help to predict clinical outcome and response to therapies [53]. Up- or downregulation of a gene can have dramatic genetic and epigenetic consequences, like the gain or loss of expression of other genes or alterations in the function of several gene-products; which, in turn, can relate to individual properties of cancer cells such as increased mutagenesis, loss of contact inhibition, independence from serum or exogenous growth factors, changes in the adhesion properties of the cell, resistance to conventional chemotherapy and radiotherapy, the capacity to induce angiogenesis and to invade surrounding tissues, and eventually to form metastasis. Gene expression profiling is already allowing the identification of specific molecular fingerprints for any given cancer [61], the identification of organ-related expression of peculiar classes of genes (often with still unknown function) [62], and cluster analysis of gene expression profiles for breast cancers [63–65], ovarian cancers [66], different types of lung cancers [67], soft tissue sarcomas [68], non-Hodgkin lymphomas [69], and prostate cancers [70], among others. Recently, Sabrina Spencer, from the Computational and Systems Biology laboratory at MIT (Massachusetts Institute of Technology in Cambridge, Boston) and other colleagues have published [71] an interesting computational model of carcinogenesis, based on the “hallmarks of cancer,” as defined by Hanahan and Weinberg (2000) [72].
7
In the mathematical model proposed by Sabrina Spencer et al. [71], cancer progression is a form of somatic evolution in which certain mutations give a cell a selective proliferation advantage. Evidence strongly supports mutation as one of the dominant factors in setting rate-limiting steps in tumor progression, resulting in variation in the timing of progression between tumors. Tumorigenesis is thought to require four to six stochastic rate-limiting mutation events to occur in the lineage of one cell. Hanahan and Weinberg [72] suggest that six cellular alterations, or hallmarks, collectively drive a population of normal cells to become a cancer. The six hallmarks are: (i) self-sufficiency in growth signals, (ii) insensitivity to antigrowth signals, (iii) evasion of apoptosis, (iv) limitless replicative potential, (v) sustained angiogenesis, (vi) tissue invasion and metastasis. (vii) Genetic instability, that is defined as an “enabling characteristic” that facilitates the acquisition of other mutations because of defects in DNA repair. These hallmarks form a candidate set of rules that underlie the transformation of a normal tissue to a cancerous one. The quantitative ramifications of these rules are explored in this paper, and lead to a number of interesting phenomena and hypotheses. The author’s model [71] describes a simplified view of cancer progression using a stochastic model of tumorigenesis based on all these hallmarks. The complexity of cancer cannot be understood by considering individual mutations independent of their interactions. The effect of a mutation often depends on other mutations within the same cell, on other mutant cells within the tumor, and on the tumor microenvironment. The evolutionary dynamics of early mutations, which generally go undetected in clinical settings, act as the initial forces that drive neoplastic evolution. The key findings from this paper are the following four: (i) “Early-onset” cancers proceed through a different sequence of mutation acquisition than “late-onset” cancers. Specifically, genetic instability is the most common first mutation in early-onset cancers, whereas limitless replicative potential is the most common first mutation in later-onset cancers. (ii) Heterogeneity varies with early acquisition of genetic instability, mutation pathway, and selective pressures during tumorigenesis. (iii) There exists a range of optimal initial telomere lengths that lowers cancer incidence and raises the time of cancer onset. (iv) The ability to initiate angiogenesis is an important stagesetting mutation, which is often exploited by other cells and is therefore infrequently present in final tumors. This model presents a first step toward predicting the fate of early precancerous mutations computationally. Early events
8
M.H. Bronchud
responsible for neoplastic progression are difficult to investigate experimentally for the very reason that they have not yet been detected. The main limitation of the model is obviously the difficulty of experimental validation. A thorough testing of the model would require periodically examining single cells for the presence of mutations in the hallmark categories, beginning before an animal has developed a clinically detectable cancer. Initiating testing for mutations once the animal has a palpable tumor ignores early mutation dynamics that, according to the model, are important for determining the timing and cellular makeup of the tumor that develops. A more feasible experimental alternative, for example in the case of colon cancers, would be to look at normal tissue around malignant and nonmalignat polyps, or apparently healthy colonic epithelia in patients undergoing prophylactive colonoscopies at various ages (say 50, 60, and 70 years of age), and measure in this tissue the frequency of genetic and epigenetic events in individual cells, or cell clusters, for example by laser-capture dissection with the help of genomic (e.g., microarrays) and proteomic (immunohistochemistry or tissue microarrays) tools. The mathematical computational model by Spencer et al. [71] relies on a number of simplifying assumptions, the most important relating to tissue architecture and molecular intracellular processes. For instance, they assume that all mutations fit into one and only one of the six hallmarks, whereas p53, for example, is known to be involved in cell cycle inhibition, apoptosis, genetic stability, and inhibition of blood vessel formation. If the precise biological behavior of a cell depends at any given time on the precise functional status of all the main cellular regulatory pathways combined, then it must necessarily follow that an obvious objective of cancer research is to use
all present and future molecular techniques to define a useful composite picture of all of these regulatory pathways in any given tumor at any given time. This overall picture should then provide us with the necessary information to determine prognosis and suitable treatment targets, as well as facilitate both target selection and in vivo target validation of new anticancer drugs (see also Table 1-1, or Matrix of Targets).
1.2.4 Towards a Definition of “Matrix of Targets” One can define a “Matrix of Targets” [26], as that graphic representation (two-dimensional, or three-dimensional) that gives an accurate picture of the functional implications of the molecular changes in all key regulatory pathways, for any given cancer (Table 1-1). The genetic alterations in oncogenes generally lead to a gain of function (GF) of the protein, whereas, in general, tumor suppressor genes are inactivated during carcinogenesis with apparent loss of function (LF) of the protein. However, the mechanisms of activation or inactivation are multiple, and the precise consequences on gain or loss of function are incompletely understood. K-ras and H-ras genes are examples of oncogenes preferentially altered by point mutation (codons 12, 13, and 61), generating a protein with constant GTPase activity. The c-myc gene can be activated by chromosomal translocation (in some leukemias) or by gene amplification (in some solid tumors). The p53 and Rb tumor suppressor genes are often knocked out by point mutation in one allele and by deletion (loss of heterozygosity) at the other. Others, like p16, have high rates of homozygous deletions or promoter hypermethylation. Some genetic defects are fairly characteristic
Table 1-1. Matrix of targets. A B C D E F
RP1
RP2
RP3
RP4
RP5
RP6
RP7
RP8
RP9
GF N N N GF N
N N N N GF N
N GF N GF N N
N N N LF N N
LF N N N N GF
N N N N LF LF
N N N LF N N
LF N N N N N
N GF N N N N
The precise aberrations of regulatory pathways involved in the control of growth, differentiation, cell death, developmental history, and invasive properties can provide a “matrix of targets” for any given cancer. This matrix represents a two-dimensional “molecular fingerprint,” but also a global functional map, of any individual cancer at a given time-point, and can eventually be used to select appropriate drugs and therapeutic strategies. Abbreviations: RP regulatory pathway; N normal gene; LF loss of function (mainly because of point mutation, methylation of the promoter, or deletion); GF gain of function (mainly because of point mutation or translocation); A to F regulatory elements in any given pathway (from upstream to downstream in each regulatory cascade), because of “cross-talk” between different pathways A-F do not necessarily imply different regulatory molecules, for the same molecule can play different roles in more than one pathway: a relatively small group of key regulatory molecules are responsible for the meaning and interpretation of multiple environmental signals; RP1-RP3 growth-factor dependent pathways operating in that specific tissue; RP4 hormone-dependent pathway; RP5 invasion and metastasis pathway; RP6 DNA repair pathway; RP7 cell-cycle regulatory pathway; RP8 apoptosis pathway; RP9 angiogenesis switch pathway. In some pathways, e.g., RP7, only one key molecular alteration is enough to contribute to the cancer phenotype, because of an “exclusivity principle.” See text for full explanation.
1. Selecting the Right Targets for Cancer Therapy
for a given tissue type (most colorectal cancers have APC or beta-catenin mutations). But the “same players” are frequently involved in different tumors. Each human cancer can be regarded as a different molecular entity, with a different matrix of molecular targets, and it evolves with time (even as a result of systemic or local therapies) (see Table 1-1). In this regard, it could be argued that each individual cancer is a “rare cancer,” because of its peculiar and perhaps unique “molecular signature” both at genomic and proteomic levels, and because of its individual clonal origins and development, and its own tumor-related stroma. In other words, when testing new targeted therapies it is important to know not only which “molecular target(s)” is hit, but also its precise molecular conformation (like the most vulnerable mutant variants of the target, e.g., EGFRs) and the full matrix of targets of any given tumor. Hence, patient selection in phase-II studies should be based not only on conventional inclusion/exclusion criteria (tumor type, histological grade, TNM stage, performance status, age, and sex of the patients), but also on a reasonably specific “matrix of targets” for one or preferably more than one regulatory pathways. This means that to achieve this very high and specific degree of “patient” and “cancer” selection, phase-II studies will probably require to be multicentric to allow for a larger patient candidate population. It can also follow from this that most of these new targeted agents will only be active in subgroups of patients (e.g., only some 25% of breast cancer cases are HER-2 positive and likely to respond to trastuzumab, Herceptin®), though suitable combinations of targeted agents hitting at different matrix-specific vulnerable sites can prove more effective and increase the chemosensitive population of patients. Table 1-1 represents the simplest graphic version of a “Matrix of Targets,” as it represents in a single twodimensional, strictly Cartesian, fashion the various regulatory pathways (RPs), in the x-axis, the various cellular levels of regulation (A to F: upstream to downstream), in the y-axis, and the functional status of each regulatory protein involved (N: normal; GF: gain of function; LF: loss of function). Regulatory pathways include: growth factor-dependent pathways (GF), hormone-dependent pathways, DNA-repair dependent pathways (DR), apoptosis (Ap) and cell-cycle control pathways (CCC), angiogenesis-switch pathways, etc. Up-stream elements are usually on the cellular membrane (receptors for growth factors, for example, but also cellular adhesion molecules), and are followed by cytosolic elements (second and third or fourth messengers, “cascading” in complex intracellular signalling pathways), and/or by regulatory proteins bound (or binding) to cytoplasmic organelles (like mitochondria, in the case of pro- or antiapoptotic regulatory proteins; or like proteasomes in the case of ubiquitin-degradation pathways). Downstream elements (e.g., transcription factors, tumor suppressor proteins like pRb and p53, specific DNA or RNA sequences) are mainly nuclear, and likely to convert on a limited number of regulatory events: the expression or repression of specific sets of genes, the coordinated production of
9
DNA-replicating proteins, or specific three-dimensional conformational changes in chromatin. The latter are often the consequence of histone modification by regulatory enzymes. For example, steady-state levels of histone acetylation in the cell are maintained by a delicate balance between the action of histone acetyltransferases (HATs), and histone deacetylases (HDACs), which have become prime targets for cancer therapy in their own merit. The software of a cancer cell has gone badly and progressively wrong. Cancer cells do not have exactly the same underlying chemistry as the normal cells of the body. This makes them vulnerable to more specific and selective drugs. Most of these second, third, fourth etc. intracellular messengers are binary: they are either switched on or off (by phosphorylationdephosphorylation, for example). At any one time a number of + and - signals travel from the cell membrane to the nucleus (and, perhaps, also backwards). These signals are irreversibly altered in cancer cells. The normal balance between the on and off signals is altered in cancer cells. At present, the matrix of targets is a theoretical concept, rather than a practical reality. But, besides its conceptual value, it should eventually become possible to translate knowledge from genomic and proteomic tools into a two-dimensional matrix as shown on Table 1-1. Regarding genomics, there are three commonly used high-throughput methods to measure simultaneously the expression of thousand of genes in clinical specimens (see also the chapter by Sean Yu in this book). These include cDNA and oligonucleotide arrays, and multiplex quantitative real-time PCR. The latter, less publicized than cDNA microarrays, is based on the quantification of a fluorescent reporter generated during the PCR process. This signal increases in proportion to the amount of PCR product, that in turn reflects the abundance of the mRNA detected. Real-time PCR (RT-PCR) offers a wider dynamic range of detection compared with DNA microarrays, and also can be optimized to detect mRNA fragments recovered from formaldehyde fixed, paraffin-embedded tissues. A possible limitation of this technique is that it can measure only several dozen to a few hundred genes simultaneously, rather than several thousand genes like cDNA or oligonucleotide microarrays. Hence the need, for RT-PCR, to focuse on one or two regulatory pathways at a time. The emerging discipline of Proteomics will probably also be key to the definition of this matrix of targets. Kodadek and others have described two main practical applications of proteome arrays: protein function arrays and protein-detecting arrays [73–78]. The protein-detecting array consists of an arrayed set of protein ligands used to profile gene expression and draw proteosignatures of the cellular state. In protein-function arrays, a large amount of protein is spotted on a solid support and tested to characterize either a biochemical activity or a molecular interaction (protein binding, DNA binding, etc.). Further advances are expected to come also from so-called tissue microarrays. Gene microarray analysis generally relies on the availability of fresh frozen tumor samples. These
10
M.H. Bronchud
specimens are often collected prospectively and rarely have significant follow-up data associated with them. In contrast, tissue microarrays, developed by Kallioniemi, Sauter, and Kononen [79] allow for the combination of several hundred tumor specimens in a single paraffin block and tumors with significant clinical follow-up can be obtained and analyzed by immunohistochemistry for specific gene products. Although they do not produce overwhelming amounts of data sets, like mRNA expression profiling arrays, they still generate a huge amount of immunohistochemistry data that again requires sophisticated bio-mathematical approaches for their interpretation. Several laboratories are pioneering these proteomic and tissue array techniques [73–81], and again the subject is thoroughly reviewed in a separate chapter of this book written by Steven Pelech. An exciting new development is the combination of Proteomics with conventional magnetic resonance imaging (MRI). For example, glioblastoma multiforme (GBM) has a classic appearance on MRI as an expansile mass with central necrosis, ring enhancement, and a large region with edema. By using MRI-guided proteomics, Hobbs et al. [82] were able to show spatial differences in protein expression patterns correlating with MRI contrast differences. In summary, Although we should not forget that relatively simple clinical and biochemical variables still remain the best prognostic indicators for most tumors (for example, age and sex of the patient, performance status, TNM stage, circulating marker levels), or that even the psychosocial circumstances of the patient and the choice of surgeon can be relevant prognostic factors [83], it is obvious that the introduction of these new molecular techniques will revolutionize clinical oncology. It seems also evident that, in general, it is still a little too early to say which of these techniques, or which combinations of techniques, will be most appropriate to allow for the identification of carcinogenic status of any given tissue, or for
therapeutic target selection and validation, and clinical follow up of cancer therapies. But progress is faster than anticipated by many. Let us take as an example two of the crucial pathways involved in the majority of carcinogenic processes of epithelial tissues: the retinoblastoma (Rb) pathway, and the p53 pathway (Table 1-2). Oncogene inhibitors (OIs) are targeted therapies (like several tyrosine kinase inhibitors, e.g., imatinib) that lock the conformational state of the oncogenic protein into its “inactive form” (either by binding to the active site, usually an ATP pocket, or by binding to an allosteric regulatory site) and can be active therapeutic agents, in general “cytostatic” rather than “cytotoxic,” against a tumor with a mutation of the targeted gene, or any gene “upstream” of the target. Tumor suppressor activators (TSAs) are potential targeted therapies that can lock the tumor suppressor activity in its “active form” (e.g., by inhibiting specific-site phosphorylation of the Rb protein and thereby preventing activations of the E2F family of growth stimulatory proteins), or can activate/reactivate latent tumor suppressor functions of wild-type tumor suppressor alleles (if there are any left in the cancer cell genome), or of mutated but still potentially functional tumor suppressor proteins (e.g., truncated mutant forms, or point mutations that do not destroy all of the tumor suppressor regulatory sites in the p53 protein). TSAs can , at least in theory, act on the normal tumor suppressor protein, or a mutant form that can be “reactivated,” or any gene “down-stream” of the target. The Rb pathway is mainly involved in the control of the transition from a resting stage of the cell cycle (Go or G1) to a replicating phase (S-phase). The main products of these genes include CDK4 (cyclin-dependent kinase 4), cyclin D1 (which interacts with and and activates CDK4, and is permanently activated, usually because of a chromosomal translocation, in some malignancies like the so-called “mantle non-Hodgkin
Table 1-2. Conceptual example of a matrix of targets in the Rb and p53 pathways. Rb pathway (p16INK4A): LF (CDK): N (Cyclin D1): N, or GF if p16 is N (Rb): N, or LF if above three are N (E2F): N, or GF if above 3 are N
P53 pathway (p53): LF (or GF if “negative-dominant”) (WT1 :familial Wilms tumor gene) : N (or LF) (HPV E6): N or GF (e.g., in cervical cancers) MDM2 : N or GF P21: N or LF
In parentheses, the identity of the regulatory protein. N normal function; GF gain of function; LF loss of function. In black: Tumor suppressor proteins. The p53 protein is a complex transcription factor that normally inhibits cell growth and stimulates cell death when induced by “cellular stress” and/or DNA damage. The most common way to disrupt the p53 pathway is through a point mutation that inactivates its capacity to bind specifically to its cognate recognition sequence in DNA, but there are many other ways to achieve the same effect, like the amplification of the MDM2 (mouse double minute 2 gene) or infection with human papilloma virus (HPV) whose E6 protein can bind to p53 to functionally inactivate it. Among many other functions, p53 can induce the expression of CKI (cyclin kinase inhibitors) like p21, that normally lead to cell cycle arrest. Some of the “cross-talk” points in the pathway are not graphically illustrated, but could be represented as loops that connect the pathways (e.g., p14ARF), and some mutant forms of tumor suppressors, as for example in the case of p53, can act in a “dominant-negative” fashion, resulting in a paradoxical “oncogene-like” effect. (See explanation in the text.)
1. Selecting the Right Targets for Cancer Therapy
lymphomas), Rb (essentially a transcription factor), and p16, which interacts with and inhibits CDK4 acting as a tumor suppressor, and often absent either because of promoter hypermethylation, or other epigenetic events, or because of point mutations, insertions or deletions in the so-called exon 1α of the CDKN2A locus (Table 1-2). This CDKN2A locus on chromosome 9 is unusual in that it codes for two different proteins, both of which appear to predispose, for example, to malignant melanomas. The Melanoma Genetics Consortium (www.genomel.org) has found, in rare families with four or more cases of individuals with malignant melanomas, mutations at this CDKN2A locus on chromosome 9 [84], impacting on the two alternative splice gene products, and hence on both the Rb and the p53 pathways (p16 and p14ARF). As discussed previously, p16 is a “cell cycle regulatory protein,” though recent evidence suggests that it might also play a role in human melanocyte senescence [85]. The additional product p14ARF is part of the p53 pathway where it acts by blocking MDM2 binding of p53 [86]. This can lead to an intranuclear accumulation of p53, that if mutated can lose its tumor suppressor functions, failing to prevent S-phase or to induce apoptosis. Curiously, at least in humans, germ-line mutations in this key CDKN2A locus all seem to predispose family members to malignant melanoma alone or at least preferentially to malignant melanoma, rather than to other cancers, with the exception perhaps of pancreatic cancers. The carcinogenic mutations within each major regulatory pathway very often but not always obey an “exclusivity principle,” in that, one and “only one” of the genes involved in each pathway (e.g., the Rb pathway) is generally mutated in a single tumor, exactly as predicted if the functional effect of each mutation was similar [87–89]. This “exclusivity principle” is likely to be the result of the strong selective pressures that determine the clonal expansion of premalignant and malignant cell clones, as two “contradictory” mutations in any pathway would mutually interfere with each other and add no obvious selective advantage to transformed cells. It is also of great interest that virtually all DNA tumor viruses that cause tumors in experimental animals or humans encode proteins that inactivate both the Rb and p53 tumor suppressor proteins or their pathways, suggesting that it might prove impossible for a tumor, at least of epithelial origin, to develop unless both the p53 and the Rb pathways have been altered and their tumor suppressor functions inactivated. In other words, therapeutic agents (small molecules, peptides, or nucleic acids) capable of restoring or at least partially reactivating these pathways could result in powerful anticancer effects, and perhaps even cures. The net result of any given altered regulatory protein (either because of loss of function, as seems to be the case for most tumor suppressors, or because of gain of function, as for most oncogenes) is always dependent on the context of other regulatory pathways. This can also help to explain why different effects of the same mutation are found in distinct cell
11
types, because different cell types are likely to depend for their survival and proliferation on different combinations of growth factors, hormones and stromal-epithelial interactions. But differences in the net effects of a given oncoprotein can even be observed in the same cell type, depending on when the mutation occurred during the temporal sequence and spatial cellular clonal expansion of the carcinogenic process. An often quoted example of this property is K-RAS2 gene mutations. In normal mammalian pancreatic duct cells K-RAS2 gene mutations appear to initiate the neoplastic process, but when the same mutations occur in normal ovarian or colonic epithelial cells, they lead to self-limiting hyperplastic or borderline, rather than truly malignant or premalignat lesions. Unless, in the case of colonic cells, the cellular clone that acquires a K-RAS2 mutation already has an APC mutation, in which case the clonal expansion can progress to malignancy. APC is an important tumor suppressor protein inactivated (LF) in familial adenomatous poliposis coli (APC). In addition to the Rb and p53 pathways, as illustrated in Table 1-2, the “Matrix of Targets” concept could be applied to other important regulatory pathways, including: 1. Those involving SMADS (downstream effectors of the interesting family of transforming growth factor-beta or TGF-β), 2. Several receptor tyrosine kinases (RTKs) related to the activation of several growth factor receptors (the EGFR family, VEGFs, PDGFs, etc). 3. The adenomatous polyposis coli (APC) gene (part of the complex β-Catenin and ubiquitin-proteasome pathways that tag and degrade important regulatory proteins), 4. The glioma-associated oncogene (GLI) pathway, that can be activated if the tumor suppressor SUFU (a medulloblastoma cancer predisposition gene) is inactive, or if another tumor suppressor EXT1,2 (related to the rare syndrome of “hereditary multiple exostosis) is also inactivated. 5. The E-cadherin (CDH1) pathway, a tumor suppressor gene that codes for a cell membrane adhesion protein inactivated in several families with hereditary predisposition to familial diffuse gastric adenocarcinomas, and also and also linked to the APC pathway. 6. The phosphoinositide3-kinase (PI3K) pathway, inhibited by rapamycin-like drugs and some tyrosine kinase inhibitors (TKIs), a rather complex pathway, with several biofeedback loops that involve important regulatory molecules like the oncogene AKT (e.g., AKT2 often amplified in breast and ovarian cancers) and the tumor suppressor gene PTEN (a phosphatase rather than a kinase). 7. The Hypoxia Inducible Factor (HIF) pathway. In the latter, inactivation of the gene VHL (a classic tumor suppressor gene that when inactivated in the germ-line predisposes to the Von Hippel-Lindau syndrome) stimulates the growth of renal carcinoma cells through the control of angiogenesis. This is because the protein encoded by VHL is part of a
12
M.H. Bronchud
ubiquitin ligase complex that degrades HIF-1α in the presence of oxygen. In the absence of oxygen, under normal circumstances or when VHL is mutated in tumors, the HIF1α transcription factor is stabilized (not degraded), leading to increased expression of cytokines like vascular endothelium growth factor (VEGF) and tumor angiogenesis. The complexity of the process leading to a clinical cancer cannot be underestimated. There are at least 16 ways to reduce or abolish the function of a gene product: delete the entire gene, loss of the relevant chromosome, delete part of the gene, disrupt the gene structure (by a translocation or an inversion), insert a sequence into the gene, inhibit or prevent transcription, promoter mutation reducing mRNA levels, decrease mRNA stability, inactivate donor splice sites (causing read-through into intron), inactivate donor or acceptor splice sites (causing exon to be skipped), activate cryptic splice sites, introduce a frameshift in translation, convert a codon into a stop codon, replace an essential aminoacid, prevent posttranscriptional processing, prevent correct cellular localization of product. Mutation of a gene is not the only way to abolish its function (e.g., long-range chromatin alterations, abnormal methylation and/or imprinting). For example, in human neoplasms p16 is silenced in at least three ways: homozygous deletion, methylation of the promoter, and point mutation. The first two represent the majority of inactivation events in most primary cancers. p16 is a very common early event in cancer progression and is frequently seen in premalignant lesions. The impòrtance of p16 is probably similar to that of p53. Mutations in the p53 gene have been found in some 30% of human tumors, and wild-type p53 has been reported to suppress tumorigenesis and promote apoptosis. The p53 protein is a potent transcription factor, and may promote transcription of genes also involved in carcinogenesis and angiogenesis. Loss-of-function mutations usually produce recessive phenotypes, so that as long as one allele remains normal there are no significant phenotypic changes. But, for a limited number of genes, a 50% reduction in the dosage of the gene can lead to phenotypic changes (dosage-effect). Certain regulatory functions are inherently dosage-sensitive: e.g., gene products that compete with each other to determine a developmental or metabolic switch or that cooperate with each other in interactions with fixed stoichiometry, or gene products whose function depends on partial or variable occupancy of a receptor or DNA-binding site. Less frequently, mutations can lead to gain of function, rather than loss of function. For example, they can result in the ability to acquire a new substrate, overexpression of the gene product, receptor turned permanently “on,” ion channel inappropriately open, structurally abnormal multimers, chimeric gene, ability to bind to new DNA sequences, or to trap and inactivate important regulatory molecules. If a protein has several catalytic and allosteric domains (e.g., at a regulatory network bottle neck) destruction or loss of function of only one of these domains can allow others to be inappropriately activated.
It is, at least theoretically, possible that some carcinogenic events may include both loss of the natural function of the gene product, and gain of a function not normally associated with that particular gene product. For example, a truncated protein might be unable to perform the original function of the native protein, but could still interact functionally with other regulatory proteins by exposing the remaining protein domains. An important issue in new drug development is whether to concentrate on abnormal oncoproteins (e.g., mutated forms of the regulatory proteins involved in carcinogenesis) or on the normal counterparts. Although some oncoproteins (e.g., Ras in pancreatic cancer) are frequently mutated at the same codon for a particular tumor type, many more derive from very large genes (e.g., BRCA1 and BRCA2) or relatively large genes (p53) with multiple different possible mutations along the gene, which may differ according to tumor type and epidemiological reasons (e.g., different ethnic group, contact with specific carcinogens, etc.). Thus, it could prove globally more rewarding to concentrate on normal regulatory proteins (e.g., at downstream “bottlenecks,” or points of “cross-talk”) than on mutated oncoproteins. The problem in this case, however, is that inhibition of normal downstream regulatory oncoproteins might prove more toxic than selective inhibition of mutated oncoproteins. In general, once the relevant oncoprotein is identified and purified, gene cloning allows the production of sufficient quantities to allow the determination of its main molecular mechanisms (catalytic or regulatory) and its three-dimensional structure. Appropriate molecules (e.g., developed by empirical methods like high-throughput screening, or by rational drug design) can then be tested in vitro and in preclinical models to find out activity and toxicity, and pharmacokinetics and pharmacodynamics. More and more oncological units will be devoted to clinical testing of new drugs, and cancer research is likely to undergo a rapid growth, provided enough resources are made available.
1.3 Cancer can be Prevented by both Primary and Secondary Prevention In recent years, age-adjusted death-rates from cardiovascular diseases in the developed world have decreased significantly in great part because of the early detection of treatable risk factors, like high serum cholesterol levels, diabetes, hypertension, obesity, and sedentarism. Smoking rates are also declining, helping to decrease both cardiovascular problems and smoking-related cancers, like carcinomas of the lung, transitional epithelium of the urinary bladder, and head and neck squamous carcinomas. But apart from smoking, another good example of the potential preventability of cancer comes from virus-related carcinogenesis. It is intriguing to find that virtually all known oncogenic retroviruses, key to the experimental identification of many oncogenes, affect species other than
1. Selecting the Right Targets for Cancer Therapy
humans, like, for example, rodents, cats, dogs, and poultry. Nevertheless, there are several clear cut examples of human viruses known to be carcinogenic. The hepatitis B virus (HBV) has been linked to human hepatocarcinomas, and an effective vaccine has already been available for many years. Some of the genital human papilloma viruses (HPV) are known to cause the majority of uterine cancers, both squamous and adenocarcinomas. Cancer used to be more frequent in women than in men in nearly all countries about a century ago, because of the great frequency of carcinoma of the cervix uteri and the rarity of smoking-related cancers in women (like lung, bladder, or head and neck cancers), and it is still more common in populations like several Latin American countries where these conditions still hold. Elsewhere, in great part because of population screening in sexually active women for cervical cancer in developed countries, with Papanicolau cytological smears and more recent colposcopic and hysteroscopic techniques, cancer is now more common in men. Cervical cancer in women is still prevalent all over the world (with about half a million cases per year) and it is the leading cause of cancer mortality and morbidity in countries like Mexico, Colombia, and Ecuador. The evidence, both epeidemiological and molecular, is now very strong that human papilloma viruses (HPV) are etiological agents associated with the majority of cervical cancer types (both squamous and adenocarcinomas) [90–93]. Several large cohort studies have consistently shown that HPV infections precede by some 10–15 years the development of cervical cancer. Besides HPV DNA detection, additional markers of carcinogenic progression include HPV type, estimates of the viral load, persistence of viral infection as determined by repeated sampling, viral integration into the DNA of the host cell, and possibly other environmental factors, like smoking and other sexually acquired infections. HPVs are small DNA viruses that usually cause warts (epidermal papillomas) in the skin, but some can also infect the genital tract. More than 30 HPVs have now been identified in the female genital tract, and four of these (HPV-16, HPV-18, HPV-31, and HPV-45) probably account for some 80–90% of cervical cancers and code for at least two oncogenes (E6 and E7) which are expressed once the viral genome integrates into the host’s DNA, disrupting some of the key pathways of cell-cycle control and apoptosis. Recent studies suggest that the ideal viral protein for therapeutic intervention in cervical pre-cancerous or malignant lesions is probably the E6 polypeptide, because a key element is the induction of host apoptotic pathways, thereby eliminating a primary viral infection as well as the virus-transformed cancer cell. E6 binds to E6AP, the prototype HECT domain protein, and forms an E3 ubiquitin-protein ligase that ubiquinates p53 resulting in rapid p53 degradation by the 26S proteasome [90–93]. The use of antisense oligonucleotides against E6AP [91] or of small peptides to block the activity of E6 [92] to degrade p53 might be valid therapeutic options for already established clinical cancers of the cervix, provided the p53 pathway
13
leading to growth arrest or apoptosis are still functional, or can be reactivated in infected cells. And this is a serious problem we shall return to, when we examine in closer detail the subject of targeted therapies. It is not only a particular molecular target that matters, but the global state of regulatory pathways in any given cancer, which we have called in the past the Matrix of Targets ( see also Table 1-1 and Table 1-2). The detection of HPV infection using molecular diagnostic methods such as the polymerase chain reaction can now be used, together with the traditional cytological Papanicolau smear analysis, in screening programs of early detection of cervical cancers. Theoretically, HPV vaccines should be able to prevent infection and protect against the malignant transformation. The path towards the development of effective HPV vaccines has been arduous. Partly because of the multiple serological sub-types, partly because the main protective immunity agent active in mucosal membranes (such as the cervix uteri) is the immunoglobulin A, which is only temporarily induced so that a putative HPV vaccine would have to be administered repeteadly to maintain an effective level of immunity. However, after many years of research an effective vaccine against the carcinogenic HPV has been finally approved in 2006 by both the American Food and Drug Administration (FDA) and the European Medical Evaluation Agency (EMEA) [94, 95]. On June 8, 2006, the FDA approved GARDASIL® to prevent cervical cancer and vaginal and vulvar precancers caused by human papillomavirus (HPV) types 16 and 18 and to prevent low-grade and pre-cancerous lesions and genital warts caused by HPV types 6, 11, 16, and 18. GARDASIL® is approved in the US for 9- to 26-year-old girls and women at high risk. GARDASIL® (quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant vaccine), has also received approval by the European Regulatory Agency (EMEA) in 2006. The EMEA recommends that this HPV-vaccine be approved for the immunization of children and adolescents aged 9–15 years and of adult females aged 16–26 years for the prevention of cervical cancer, high-grade cervical dysplasia (CIN 2/3), high-grade vulvar dysplastic lesions (VIN 2/3), and external genital warts caused by human papillomavirus types 6, 11, 16, and 18. It has been shown to be an active prophylactic vaccine, but it is not intended to be used for the treatment of active genital warts; cervical cancer; cervical intraepithelial neoplasia (CIN), or vaginal intraepithelial neoplasia (VIN). It has not been shown to protect against disease because of nonvaccine HPV types. The health-care provider should inform the patient, parent, or guardian that vaccination does not substitute for routine cervical cancer screening. Women who receive this vaccine should therefore continue to undergo cervical cancer screening per standard of care. More information on this and other HPV-vaccines in development, or already approved, can be found on the following two internet web sites: 1. http://www.cancer.gov/ cancertopics/factsheet/risk/ HPV-vaccine 2. http://www.cdc.gov/od/oc/media/pressrel/r060629.htm
14
Secondary cancer prevention, might also be possible in some cases. Cancer “chemoprevention,” can be defined as the “treatment of carcinogenesis, its prevention, inhibition or reversal.” It should be regarded as “secondary prevention,” as what it does is to stop or delay carcinogenesis, rather than to stop a disease from spreading. In other words, it is meant to delay or stop the pathogenetic process, rather than destroy the cancer-related etiological agent(s). The term “chemoprevention” is controversial. “chemo” may lead to a confusion with “chemotherapy,” and “prevention” may not be the best word to define “early detection” of cancer biomarkers. The subject is bound to grow very rapidly, both in terms of the identification, validation, and clinical relevance of cancer biomarkers, but also in terms of their impact on the quantitative estimation and prediction of individual human cancer risks. Since the publication of the Second Edition of “Principles of Molecular Oncology,” in the year 2004, the role of agents, like cyclooxygenase-2 (COX-2) inhibitors in chemoprevention of adenomas and colorectal cancers, has been tested in several important clinical trials. COX-2, a key enzyme for the production of prostaglandins from arachidonic acid, is overexpressed in colon carcinogenesis, but recent reports of serious adverse cardiovascular complications from therapy with COX-2 inhibitors, mainly because of excessive thromboxane production, has raised caution among the community of cancer physicians. Nevertheless, two reports at the 2006 American Association for Cancer Research in Washington, one from a study in the US and the other from an international study coordinated from Israel, have confirmed the definite inhibitory effect of long-term therapy with COX-2 inhibitors in patients with a history of colonic polyps or other risk factors for colorectal cancers. Again, results warned against the use of this chemopreventive strategy in patients also at risk of cardiovascular disease, and more studies need to be done to better define the population of ideal candidates for COX-2 inhibitors chemoprevention in terms of both general and specific inclusion and exclusion criteria [96]. COX-2 is a proinflammatory enzyme overexpressed in several types of cancer, and it has been approved by the FDA for cancer prevention in the rare syndrome of FAP (familial adenomatous polyposis coli), when youg patients, often in their teens, have thousands of polyps in their colonic mucosa. The Adenoma Prevention with Celecoxib (APC) Trial was a clinical trial in the US to determine if the arthritis drug celecoxib, which inhibits the enzyme COX-2, reduces the occurrence of new adenomas (precancerous polyps) in the colon and rectum of people who have already had such a polyp removed. Initial results of the APC Trial showed that those taking celecoxib had 33–45% fewer new adenomas and 57–66% fewer high-risk adenomas than those taking a placebo. For those people who took celecoxib and developed recurrent adenomas, the growths were fewer and smaller in number than those on placebo. Unfortunately, the use of celecoxib in the APC Trial was suspended in December 2004 because analysis by an independent US Data Safety and Monitoring Board showed that the risk of fatal and
M.H. Bronchud
major nonfatal cardiovascular events (cardiovascular death, heart attack, stroke, or heart failure) was 2.5 times higher for participants taking the drug compared to those on a placebo. Full analysis of the cardiovascular events, published in February 2005, showed that APC participants taking 200 mg of celecoxib twice a day had more than twice the risk of serious cardiovascular events compared to those taking the placebo. The APC participants taking 400 mg of celecoxib twice a day had more than three times the risk of serious cardiovascular events, compared to those taking the placebo. However, it must be stressed that initial results of the APC Trial showed that those participants taking celecoxib had indeed significantly fewer new adenomas and fewer new advanced adenomas than those on placebo after taking one of two doses of the drug twice a day for three years. (“advanced” adenomas are greater than 1 cm in diameter and have characteristics that make them more likely to become cancer.) For those taking the lower dose of celecoxib, they had 33% fewer new adenomas and 57% fewer advanced adenomas. For those taking the higher dose of celecoxib, they had 45% fewer new adenomas and 66% fewer advanced adenomas. When those who took celecoxib developed new adenomas, they were, on average, fewer in number and smaller in size than those on placebo. These results were presented at the American Association for Cancer Research (AACR) annual meeting on April 3, 2006 and should soon be published in full. To help identify who was at greatest risk of having a cardiac event because of celecoxib, the APC investigators compared the cardiac health history of participants upon entrance to the trial. They found that almost 9% of participants with a history of cardiovascular events (heart attack, stroke, coronary heart failure, or angina) had a second serious cardiac event while on celecoxib compared to only 3% of participants with a history of cardiovascular events who were on placebo. For those with no prior history of cardiovascular events, 2% of those on celecoxib had a serious cardiac event compared to 0.7% of those on placebo. So, although an individual’s risk of a severe cardiovascular event while taking celecoxib depends on their prior health history, the increased risk was seen in both those with a prior history and those without. More than a decade of epidemiologic research suggests that people who regularly take drugs that block COX enzymes have lower rates of certain precancers, cancers, and cancer-related deaths. The data are most consistent for colorectal cancer, but this reduction in risk is also seen for other cancers. Animal and laboratory studies using a variety of NSAIDs and COX-specific inhibitors show a decrease in cancer incidence with the use of these compounds. On a molecular level, studies have shown that the inhibition of the COX pathway changes the characteristics of cancer cells by reducing cell proliferation, increasing programmed cell death, reducing formation of blood vessels to feed cancer cells, and changing the body’s immune response. A more established, but still controversial, form of “chemoprevention” (particularly controversial in Europe) is the use of anti-estrogens in women at risk of breast cancer. Craig Jordan
1. Selecting the Right Targets for Cancer Therapy
and his colleagues will discuss this rapidly expanding subject in their chapter. As guidelines and preventive policies change constantly, it is worth consulting the “US Preventive Services Task Force” web pages for the most common cancers: 1. US Preventive Services Task Force: Screening for breast cancer. http://www.ahrq.gov/clinic/uspstf/uspsbrca.htm. 2. US Preventive Services Task Force: Screening for colorectal cancer. http://www.ahrq.gov/clinic/uspstf/uspscolo.htm. 3. USPSTF: The New US Preventive Services Task Force. http://www.ahrq.gov/clinic/uspstfab.htm. 4. US Preventive Services Task Force: Screening for lung cancer. http://www.ahrq.gov/clinic/uspstf/usplung.htm.
1.4
The Era of Targeted Therapies
The first edition of this book (Humana Press, 2000) was our first comprehensive presentation of the concept of cancer as a “disease process” involving key regulatory pathways. The second edition (Humana Press,2004) reaffirmed this dynamic concept, incorporating more recent evidence, and introducing such new topics of special interest as the combination of molecular diagnostics with developmental therapeutics, and the binary state concept “active/inactive” that seeks more relevant targets within the global molecular matrix of any given cancer. Here we take these concepts further, together with a growing body of evidence to support them. Thinking “binary” may help both target selection and target validation [97]. In Chinese ancient philosophy and medicine, the Universe we live in is clearly a model of the binary nature of things. For example, “Cold” was considered to be a “Yin” pathogenic factor, and its nature is to slow things down. On the other hand, Heat, or fire, was considered a “Yang” pathogenic factor, causing expansion and increased activity. Yin represents the negative, passive force. It is female in nature, dark, contractive, descending, and is symbolized by water. Yang symbolizes the positive, active force. It is male in nature, bright, high-flying, expansive, ascending, and is represented by fire. Of the two forces, Taoists believe yin to be superior and stronger. Citing the analogy of fire and water, they point out that fire, in spite of its brief appearance of great power, is easily extinguished by water. In a similar sort of way, all biochemical regulatory proteins can be present at any one time in an “on” or “off” molecular form, with regards to one or more of their functions. In concordance with Chinese philosophy, restoring tumor suppressor function (Yin) is probably more clinically meaningful than inhibiting oncogene function (Yang). This “Yin” or “Yang” effect will depend, for the normal wild-type forms of regulatory proteins, on the regulatory microenvironment, and the possible conformational changes (usually allosteric) produced by a number of enzyme activities, including phosphorylation/dephosphorylation, acetylation/
15
deacetylation, farnesylation/defarnesylation, methylation/ demethylation etc. Evolutionary pressures have worked against the ability of polypeptides to change randomly from one conformation to another. Instead of eliminating this ability altogether, selective pressures have limited it in a highly specific way so that many, if not most, protein molecules ara able to shift reversibly between several different but related stable conformations. Proteins with this property are known as “allosteric proteins”. Each distinct conformation of an allosteric protein has a somewhat different surface, and thereof a different ability to interact with other molecules. Usually only one of two conformations has a high affinity for a particular ligand, so that the presence or absence of the ligand determines the conformation that the protein adopts. When there are two distinct ligands, each specific to a different three-dimensional surface of the same protein, the concentration of one molecule commonly changes the affinity of the protein for the other. Such allosteric changes are fundamental to the regulation of many biological processes. For example, enzymes that act early in a pathway are almost always allosteric proteins that can exist in two different conformations; one is the active conformation that binds substrate at its “active site” and catalyzes its conversion to the next substance in the pathway. The other is the inactive conformation that tightly binds the final product of the same pathway at a different place on the protein surface known as the “regulatory site.” As the final product accumulates, the enzyme is converted to its inactivated conformation because this is stabilized by the binding of the product to the regulatory site. Alternatively, an enzyme involved in a metabolic pathway can be activated by an allosteric transition that occurs when it binds a ligand that accumulates when a cell is deficient in a product of the pathway. These simple mechanisms result in elegant feedback modes of regulation. Because the binding of a ligand to one site can affect another site by changing the protein’s conformation, any enzyme reaction or metabolic process can in principle be regulated by any other in the cell, regardless of its chemical nature. A classic example, is that of glycogen metabolism in muscle cells that is linked to the concentration of calcium ions by means of allosteric enzymes that alter their activity when the concentration of calcium ions change. Allosteric proteins often exist as aggregates of identical subunits. The conformation of one subunit can, following contact with a signal/ligand, influence that of neighboring subunits, producing an effect similar to amplification. Allosteric proteins of this kind act rather like a “switch-flipping” from one state to another, and the “cooperative binding” of substrate molecules produces a typical “sigmoidal response” curve. Conversion between one three-dimensional conformation to another may require an input of chemical energy, for example by transferring a phosphate group from ATP to a serine, threonine or tyrosine residue in the protein, forming a covalent linkage. About one tenth of all the different proteins made in
16
M.H. Bronchud
a mammalian cell contain covalently bound phosphate. Phosphate atoms are crucially involved in this complex biochemistry of cellular homeostasis. As early as 1937, Cori and Cori published their initial studies on glycogen phosphorylation, but it was not until 1988 that Tonks described the first partial sequence of a tyrosine phosphatase, and today we think that the human genome contains over 2,000 kinase genes, and over 1,000 phosphatase genes [98]. One of the key carcinogenic molecular changes, involved in about half of all human malignancies, refers to alterations in the p53 tumor suppressor (TS) protein, that is a complex protein with both DNA-binding domain and several regulatory proteins binding domains [99]. The TS p53, for example, interacts with many proteins implicated in regulation of protein function, including protein kinases and phosphatases, heat shock proteins, and DNA binding proteins, as well as with single stranded RNA or DNA. The functional p53 protein is usually a nuclear tetramer, and it is the ability to bind to specific DNA-sequences that is more tightly linked to TS function. Biochemical analysis of the regulation of wildtype p53 sequence-specific DNA binding has shown that the unphosphorylated tetramer has a cryptic sequence-specific DNA binding activity [100]. This cryptic or “latent state” of p53 depends upon a C-terminal negative regulatory domain, which locks the unphosphorylated tetramer into an inactive state. Phosphorylation of this C-terminal negative regulatory domain of latent p53 by a number of enzymes (e.g., protein kinase C or casein kinase II), or by deletion of this regulatory domain, or by binding to monoclonal antibodies can induce a conformational change in
the p53 tetramer capable of activating the sequence-specific DNA binding. About a decade ago, David Lane and colleagues [101], at the University of Dundee in Scotland, elegantly showed that the activation of p53 as a sequence-specific transcription factor following UV irradiation does not require increases in protein level and can be mimicked in vivo by the intranulcear microinjection of antibody directed to the C-terminal negative regulatory domain of p53. They proposed a model in which each C-terminal negative regulatory domain interacts with a motif in the core of the tetramer and must be displaced to permit the specific DNA binding activity of the protein. A prediction of this model, proposed long before the elucidation of the crystal structure of the phosphorylated and unphosphorylated p53 tetramer or the (still unclear) full molecular mechanisms of latency and activation, was that small peptides derived from the C-terminal negative regulatory domain might interfere with this intra- or intermolecular interaction, and activate the DNA binding function of latent p53. In very simple terms, see Fig. 1-3 (A and B) for graphic explanation, the new therapeutic drugs designed to restore the normal balance between Yin and Yang regulatory forces should, for example, either: 1. Lock or inhibit activated proto-oncogenes in their inactive state, like imatinib mesylate in the case of several tyrosine kinases, for example in the abl-bcr fusion protein of chronic myeloid leukemia, or the PDGFR tyrosine kinase in GIST (Fig. 1-3A); or:
A
B ONCOGENES
A
TUMOR SUPPRESSOR GENES
ACTIVE
INACTIVE
B
A
INACTIVE
B
AA
ACTIVE
B
A
B P
P D X
X D
AA
B
= ligand A,B = Subunits of Regulatory Molecules
A A
B
B
D = Blocker drug P = Phosphorylation
= ligand A,B = Subunits of Regulatory Molecules
A
B
D = Blocker drug P = Phosphorylation
Fig. 1-3. A Oncogenes as targets. A and B, subunits of regulatory molecules. D, drug that can lock the oncogene protein into its inactive form; P, phophorylation. Triangle, ligand. B Tumor suppressor as targets. Reproduced from Principles of Molecular Oncology (Bronchud M.H., Chapter 1), 2nd Ed., (2004), Humana Press, NJ.
1. Selecting the Right Targets for Cancer Therapy
2. Considering the binary states of most regulatory molecules (active/inactive) somehow lock or stabilize tumor suppressor proteins in their active state, which is the one normally responsible, for example, for inhibiting entry into S-phase or mitosis, or responsible for maintaining the normal differentiation and apoptotic pathways. An alternative, is a drug that deliberately activates “cryptic sites” in an inactive tumor suppressor protein (e.g., a truncated version of the wild-type protein) by inducing the suitable conformational changes (Fig. 1-3B). In other words, as regulatory proteins are usually present in normal cells in either an active form or an inactive form, and the chemical equilibrium between the two forms depends on the regulatory microenvironment of the cell, new targeted therapies should be able to correct, or al least limit, the malignant phenotype by restoring the normal balance between stimulatory and inhibitory signals within the cell.
1.4.1
Examples of Oncogene Inhibitors (OI)
Oncogenes are growth control genes present in the human genome (as “proto-oncogenes”), as well as in the genome of most if not all multicellular organisms. Incorrect expression or mutation of an oncogene usually results in “gain of function” and unregulated cell growth, as seen in malignant cells. Many of them are part of the complex cell’s signal transduction pathways, including cell membrane growth factor receptors, or intracytoplamic proteins. These signal proteins may be an intracytoplasmic piece of the receptor molecule, or another molecule activated just inside the membrane. Tyrosine kinase is an example of a signal molecule. The first signal may serve only as an intermediary, affecting a change in a second messenger. The G proteins, for example (belonging to the Ras oncogene family) are a group of intracytoplasmic secondmessenger molecules. The intracellular cascade of signals eventually reaches the nucleus, leading to changes in gene expression, and cell behavior. Of the over 100 oncogenes that have been identified so far, most are key players in these signal transduction pathways. Many examples of these new types of drugs [102–104] of “oncogene inhibitors” are already on the market; e.g., tyrosine kinase inhibitors (imatinib, erlotinib, trastuzumab), or EGFR inhibitors (cetuximab) , or VEGF inhibitors (bevacizumab). Many others are still undergoing clinical development, and will be reviewed by Paul Workman and his colleagues in this book. Indeed a “second generation” of tyrosine kinases is also already close to reaching the market, like dasatinib and lapatinib. Dasatinib (BMS-354825), for example, is a new, oral, small-molecule tyrosine kinase inhibitor (TKI) developed by Bristol Myers Squibb for the treatment of CML. Encouraging clinical trial data suggest it may have potential in the treatment of patients with CML whose cancer has become resistant to imatinib therapy. CML, one of the most common forms of leukemia, arises from the excessive production of abnormal stem cells in the bone marrow, which eventually suppress the
17
production of normal white blood cells. The disease usually has three identifiable phases: the initial chronic phase, which is typically benign and lasts for an average 3 to 5 years from diagnosis, the accelerated phase and finally the blast-crisis phase. The vast majority of patients with CML have a genetic mutation called the Philadelphia chromosome, because of reciprocal translocation between the long arms of chromosomes 9 and 22. This leads to the creation of a bcr-abl fusion gene that encodes the production of the bcr-abl protein, a tyrosine kinase that influences cell growth, differentiation, and survival. Cells containing the Philadelphia chromosome replicate rapidly producing the characteristic pattern of abnormal cells seen in the bone marrow and blood of CML patients. Because the bcr-abl fusion protein is almost never seen outside leukemia cells, it presents an attractive therapeutic target and has been successfully exploited in the development of new treatments for CML. Conventional treatment options for patients with CML include conventional cytotoxic chemotherapy, interferon-alpha, allogeneic stem cell transplant (SCT), the only potentially curative therapy, and imatinib mesylate, the current gold standard. The development of imatinib (Glivec/Gleevec), a small-molecule TKI, was the first rationally designed drug for CML. It competitively inhibits bcr-abl tyrosine kinase activity. By blocking the effects of the bcr-abl fusion protein, imatinib helps destroy leukemic cells. It is currently indicated as a first-line treatment in patients with chronic Philadelphia-positive-chromosome CML as well as those who initially present in the accelerated or blastcell crisis phase. Although most patients with CML initially respond to treatment with imatinib, cases of imatinib resistance are increasingly being reported. Unmet clinical need therefore exists for drugs that can override imatinib resistance in patients with CML, especially in those who progress to the accelerated and blast-crisis phase. Preclinical and early clinical experience with dasatinib suggests that it possesses potent antileukemic activity in imatinibresistant cell lines as well as in malignant bone marrow cells isolated from patients with imatinib-resistant CML, and in mouse xenograft models of imatinib-resistant CML. Promising antileukemic activity has now been confirmed in an early clinical study in patients with imatinib-resistant and intolerant accelerated and blast phase CML who received twicedaily dasatinib. Major hematologic response, defined as the presence of less than 5% marrow blasts, were reported at the American Association of Cancer Researcc (AACR) meeting in Washington 2006 in 80% of patients in the accelerated phase and in 69% of patients in the blast-crisis phase of the disease. Corresponding cytogenetic response rates were 40% and 56% respectively, rates that compare very favorably with responses to imatinib. Typically about 46% of patients in the accelerated phase and 24% in the blast-crisis phase experience a major hematologic response to imatinib, whereas about 24% and 16% respectively have major cytogenetic responses. Lapatinib is an oral therapy targeting intracellular components of a receptor known as ErbB2 and a second receptor,
18
ErbB1, which have been implicated in the growth of various tumor types. The phase-II trial (EGF 20009) tested lapatinib as first-line therapy for breast-cancer patients with tumors that express large amounts of ErbB2. An already marketed therapy, Herceptin® (trastuzumab), also works through its effect on ErbB2, but it is a monoclonal antibody administered by intravenous infusion. None of the patients in this lapatinib trial had been treated with Herceptin. Thirty-five percent of women (14 of 40) with locally advanced or metastatic breast cancer responded to lapatinib as first-line therapy, according to interim results of a study reported at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2006. The data are the first to be reported on the use of lapatinib as a first-line therapy, but full publication is pending. The data presented at ASCO 2006 were derived from an interim analysis planned at the start of the trial and have been confirmed through an independent review. In the 35% of patients who experienced a partial response, tumor size was reduced by at least 30%. An additional 35% (an additional 14 of the 40 patients) showed stable disease through 12 weeks of therapy. All patients will continue to be followed for disease progression as part of the planned efficacy assessment. Full publication of the trial is eagerly awaited.The most frequently reported adverse events in this trial have been mild to moderate itching, rash, diarrhea, acne, and dry skin. No adverse events deemed drug-related, including cardiotoxicity, have been serious enough to cause clinical problems. At present all of these these “oncogene inhibitors” could be classified as follows (but the list is continuously growing): 1. Tyrosine kinase inhibitors: imatinib, gefitinib, erlotinib, lapatinib, dasatinib, etc. 2. EGFR inhibitors (other than 1): cetuximab (Erbitux®); panitumumab (Vectibix®). 3. VEGF inhibitors (other than 1): bevacizumab (Avastin®) 4. HER-2 inhibitors: trastuzumab (Herceptin®) It seems that most of the new drug entities acting on cell surface growth-factor receptors, or cytosolic down-stream regulatory elements, like for example inhibitors of the EGFR (epidermal growth factor receptor), or associated with their tyrosine-kinase activities, are mainly “cytostatic” in vivo rather than “cytotoxic”; they are fairly nontoxic (though, at times, with new unpredicted toxicities, like acneiform skin rashes), and are best given on a continuous long-term protocol. These considerations can lead to some methodological problems in clinical trials design. The primary end-points in phase-III randomized clinical studies should remain those reflecting survival of patients, but secondary endpoints should include measurable quality of life, disease-related symptoms, performance status, and standardized criteria to measure objectively and reproducibly time to disease progression. On the other hand, primary end-points in phase-I and II studies should include, besides toxicity and classical pharmacokinetics, data on relative efficacy and sophisticated in vivo pharmacodynamics, ranging from changes in genomics
M.H. Bronchud
(gene expression profiling) and proteomics (protein expression, intracellular localization, and posttranslational modifications) of key targets, and down-stream effector molecules, in tumors in response to the new drug. Additional surrogate end-points to be considered in phase-II studies include relevant in vivo dynamic changes on positive emission scanning imaging (PET), new dynamic molecular imaging like dynamic enhanced magnetic resonance imaging (DCE-MRI), and other methods to quantify changes in the growth kinetics of tumors, and for the subset identification of cancers that respond (versus those that do not respond) to the new therapies. There are still rather few published studies dedicated to examining in detail the various possible mechanisms of resistance to EGFR targeting, irrespective of the anti-EGFR drug considered. There is also some confusion as to the precise cytosolic and nuclear downstream effects following EGFR targeting, particularly when combined with conventional cytotoxic drugs. Moreover, although some consensual findings tend to suggest a link between the level of the EGFR protein target (as detected by IHC) and the intrinsic efficacy of the targeting drug, more pharmacodynamic studies in vivo are needed to establish convincing conclusions regarding EGFR levels and targeting efficacy on which clinical strategies can be based with confidence. It is however clear that some mutant forms of the EGFR molecule are linked to clinical response to some of these inhibitors. The best example is that of EGFR mutations that enhance the inhibitory activity of gefitinib (Iressa®) [105]. Responses to another tyrosine kinase inhibitor, erlotinib (Tarceva®) in non small cell lung cancer have led to significant though “marginal” (few months) improvements in survival, with oral therapy and little toxicity [106, 107]. This drug is now approved in both the USA and Europe for the treatment of locally advanced or metastatic nonsamll cell lung cancer. At times clinical and radiological responses are impressive (see Fig. 1-4 of a patient with bilateral bronchoalveolar carcinoma treated at our Divisions of Oncology in Granollers, Barcelona) with the conventional dose of 150 mg/ day of Tarceva® (Fig. 1-4). Whether these perhaps nonfrequent (around 12% of cases in our experience) , but truly impressive responses are caused by special molecular variants of the EGFR is under active investigation. The functional status of downstream effectors of the EGFR, like RAS and its pathway, is also of likely relevance to the tumour response to EGFR inhibitors. Activated oncogenes can also be inhibited by agents other than small molecular weight drugs, or monoclonal antibodies [108]. Progress is being made in the use of “antisense” (AS), technologies. Single-stranded antisense DNA forms a covalent bond with a specific sequence of messenger RNA (mRNA) inhibiting translation and rendering the complex susceptible to degradation by the enzyme RNaseH. ISIS 3521 ia a 20-base phosphorothioate antisense oligonucleotide targeted to the 3 untranslated region of the human PKC-α mRNA. Promising results in in vitro experiments and early phase-I clinical studies, have now led to phase-II studies, and some encouraging responses in low-grade non-Hodgkin lymphomas [109] with thrombocytopenia as the dose-limiting toxicity. The maxi-
1. Selecting the Right Targets for Cancer Therapy
19
Fig. 1-4. A CT scans of the chest in a 56-year-old woman, nonsmoker, with bilateral bronchoalveolar carcinoma who had progressed following cisplatin-based chemotherapy. In spite of a rather poor performance status and serious respiratory insufficiency, she was treated at our center (Hospital General of Granollers, Barcelona) with oral Erlotinib (Tarceva®) at conventional doses, and her splendid radiological response is clearly visible comparing the pretreatment (A) (February 2006) and posttreatment (July 2006) CT scans. (Pictures published with written consent by the anonymous patient). B Radiological response is clearly visible following treatment with erlotinib (Tarceva®) in this patients with bilateral bronchoalveolar carcinoma.
mum tolerated dose was 2 mg/kg/day when ISIS 3521 was given as a continuous infusion. No phase-III studies have yet been reported with this antisense oligonucleotide.
1.4.2 Examples of Tumor Suppressor Activators (TSA) The case of tumor suppressor genes is more complex, because the ideal therapy in these cases, where the problem is usually a loss-of-function mutation (e.g., a deletion or a hypermethylation of the promotor), would be a genetic replacement of the wild type. But for mainly technical reasons (lack of suitable vector, inefficiency of the transformation systems, lack of stability of “transfected cells,” danger of oncogenetic transformation by retroviruses, etc.), the truth is that the original research enthusiasm of the 1990s for genetic therapy (GT) oncology programmes no longer exists, even if new GT approaches and new techniques are under constant active investigation. Thus it could well happen that if cancers are too advanced and evolved, there may not be any “latent” and “relevant” tumor suppressor function left as potential target for this new class of compounds or “tumor suppressor activators (TSAs). Hence the importance of combining earlier detection (e.g., research on preventive cancer medicine) with better and more effective drugs. The inability of molecules larger than 600 daltons to cross the plasma membrane has restricted the pharmacological use of proteins to those which function outside the cell, for example by binding to specific cell membrane receptors. Most tumor suppressors, on the other hand, are intracellular, and therefore cannot be administered to patients as recombinant proteins directly. Reversion of the malignant phenotype was
already demonstrated, over three decades ago, by the classical “cell fusion” experiments, with “Sendai virus” by Henry Harris, at Oxford. The loss of particular chromosomes in hybrid normal-malignant cells, or the gain of normal chromosomes when fusing normal cells with particular types of malignant cells in vitro, led to the first experimental data to back the hypothesis of “antioncogenes,” or tumor suppressor genes. Later experiments in the 1980s and 1990s, with the help of gene transfer methods including modified retroviruses and adenovirus, have given more support to the idea that in many cases the malignant phenotype of cancer cells can be reversed, in vitro and in vivo, by replacing a single key tumor suppressor gene. The technical difficulties, and potential dangers, of gene therapy in patients, however, have not yet led to clinically relevant forms of gene therapy in this context. Unlike oncogenes, tumor suppressor genes (formerly “antioncogenes”) display the function of suppressing cellular proliferation, and/or maintaining cellular differentiation, facilitating normal cellular adhesion mechanisms, stopping entry into the cell cycle (G1, S-phase , mitosis or G2) to allow DNA-repair mechanisms, maintaining normal cellular shape, cell contact inhibition mechanisms, etc. The tumor suppressor paradigm characteristically calls for loss of both functional copies of the gene and indeed many, but not all, tumor suppressor genes must undergo biallelic inactivation to sustain a true loss-of-function effect. However, a substantial number of cancer cells retain at least one “functional copy” (wild-type or mutant) of one or several key TS genes [110]. Tumor suppressor genes are either under-expressed in cancer cells, because of genetic deletions or promoter hypermethylation, or have sustained other forms of loss-of-function
20
M.H. Bronchud
genetic or epigenetic changes. For example, abnormal p53 function can result through the acquisition of point mutations, posttranslation inactivation through binding to other regulatory proteins, like the so-called MDM2, enhanced degradation (e.g., by the activity of the E6 protein of carcinogenic human papilloma viruses), or other mechanisms like decreased translation of wild-type p53 by the folate-dependent enzyme thymidylate synthase. In these cases, depending on the cellular context and microenvironment, cancer cells are unable to undergo cell cycle arrest and/or apoptosis in response to the DNA damage produced by cytotoxic chemotherapy or radiotherapy. As “gene replacement” methods, by gene therapy of in vivo cell fusion, have not proved effective, and seem unlikely to do so in the near future, the possibility exists, at least in theory, of developing drugs capable of inhibiting the “inactivation of tumor suppressor function”; e.g., small molecular weight inhibitors of Rb phosphorylation, or capable of “restoring cryptic tumor suppressor function,” like d-peptide activators of p53. These new types of anticancer drugs could be called tumor suppressor activators (TSAs). Recent research work on the two main TS proteins identified so far (p53 and pRb), still in the preclinical phases of study, can serve as an example of the tremendous potential of these “tumor suppressor activating” (TSA) drugs as powerful anticancer agents.
1.4.2.1
p53 as an Example
Because of the presence of either wild-type or mutant p53 protein in most human tumors, restoration of endogenous p53 function in cancer cells, by small molecular weight compounds as shown by Bykov et al. [111], or by the in vivo delivery of transducible, proteolytically stable p53C′ d-peptides (like RITATp53C′), as recently shown by Snyder et al. [112] have become promising new approaches to cancer therapy. In other words, an important example of a TS that can prove a valid target for cancer therapy is p53. Underactivity of p53, because of loss-of-function mutations, encourages the growth of cancer, whereas overactivity can accelerate the aging process and cell death. Following some elegant pioneering work by Snyder and colleagues [113], a synthetic 34-amino-acid peptide, made of d-amino acids, rather than the conventional l-amino acids, and called “RI-TATp53C”, has been shown to be a potent activator of both wild-type and mutant p53 TS and DNA-Binding functions. In preclinical models, this synthetic peptide, that cannot be degraded by proteases and is internalized into cancer cells by a lipid-raft-dependent pinocytosis mechanism, has been shown to achieve complete cures in a mouse model of terminal peritoneal lymphomas. The use of d-amino acids is a clever trick. All proteins in living systems on this planet Earth are composed of l-amino acids. Is there any reason for the selection by Nature of the l-configuration at the Cα-atom? The ribosomal protein
chain-synthesizing machinery requires a standard and identical configuration, otherwise synthesis would be too complex, and therefore would not have a competitive chance. But there is no obvious reason, in this binary universe, for preferring the l-configuration over its mirror image. Presumably this “choice” occurred by chance, but this fact can provide us with a potential pharmacological opportunity. In fact, conventional l-peptides, even if of small molecular weight, are usually rapidly degraded by proteases, phagocytosed by immune cells or neutralized by antibodies. But synthetic d-peptides are not recognized by Nature, and may prove an effective “weapon” against cancer cells, however doubts remain over their pharmacokinetic, pharmacodynamic and safety profiles, as well as on their potential to generate inactivating immunological responses as these artificial peptides could prove to be rather immunogenic. Cα–aminoacids can be linked together by covalent “mirror image” peptide bonds, and the resulting “antipeptide” can be tailor made to act as an allosteric regulator. Alternative ways to activate p53 tumor suppressor functions are also under study. Some include a careful search for downstream mediators of these functions. For example, Boiko et al. [114], have developed a systematic approach for down stream mediators of the tumor duppressor function of p53 that reveal a major role for BTG2. Research led by Vassilev and colleagues (at ROCHE R&D laboratories in Nutley, N.J. and Penzberg, near Munich in Germany) has focused on MDM2 (mouse double minute 2) antagonists that can activate p53 and have already been shown to have synergistic antitumor activities with conventional genotoxic/cytotoxic drugs in animal models. These experiments have led, directly or indirectly, to a true revamping of the p53 tumor suppressor activator (TSA) area in recent months [115–137], and it is only a matter of time before promising small molecules (perhaps “Nutlins”) can enter the clinical development phase. Vassilev and colleagues [138] have elegantly shown in animal models with human tumor xenografts that the in vivo activity of Nutlins may affect not only tumor cells, but also their microenvironment. And they may induce cytostatic as well as cytotoxic effects not only in tumors with aberrant MDM2 expression, but also in those tumors that have retained wild-type p53 function. Hence, once again, the need to stress the importance of earlier detection of cancers, before they lose all of their TS genes, as well as the need for new TSA targeted drugs.
1.4.2.2
pRb as Another Example
At first sight, the retinoblastoma (Rb) protein is the true bottleneck of most cell cycle controlling pathways [139], even if it has been suspected for a long time that there is close molecular communication between p53 and pRb [140]. At least two “regulatory loops” are highly active in this Rb-p53 “cross-talk”: the already mentioned MDM2 and p14ARF. The additional product p14ARF is part of the p53 pathway where it acts by blocking MDM2 binding of p53 (86, 140).
1. Selecting the Right Targets for Cancer Therapy
In 1986–1987 the tumor suppressor Rb gene, first identified because mutated in hereditary retinoblastomas, was cloned by three different laboratories headed by eminent molecular biologists: Robert A. Weinberg and Thaddeus Dryja, William Benedict and Yuen-Kai Fung, and Wen-Hwa Lee. It is a rather large gene, over 200 kb and with 27 exons. It codifies for a nuclear protein of 928 amino acids, which is constitutively expressed during the cell cycle, but with characteristic cell cycle-dependent different degrees of phosphorylation. Phosphorylation of pRb is carried out initially by D-type cyclins (in protein complexes with CDK4 or CDK6) followed later by cyclin E/CDK2 . Virtually all human tumors tested so far show mutations that directly, or indirectly, alter the normal function of Rb. Nearly all tumor derived pRb mutants have lost the ability to repress E2F-responsive genes, and reintroduction by gene transfer of wild-type pRb into Rb −/− tumor cells leads to restoration of E2F control and cell cycle arrest. There are at least six human E2F genes (E2F1 to E2F6) and their protein products bind to specific DNA sequences as heterodimers with either DP1 or DP2 proteins. It is now clear that binding to pRb converts the E2F family from transcriptional activators to potent transcriptional repressors. E2F6, unlike the other E2F family members, is an intrinsic transcriptional repressor and does not apparently interact with pRb family members. Hyperphosphorylated pRb is unable to maintain the binding and inactivation of E2F, and free E2F molecules lead to transcription of multiple genes involved in the initiation of DNA synthesis and cellular proliferation. Using gene expression profiling methods (Affymetrix GeneChips) it has been possible to demonstrate changes in the expression of over 200 genes, most of them involved in cell cycle control, by CDK phosphorylation of wild-type pRb. Some of these genes are also involved with DNA repair, or changes in chromatin structure. As expected, a significant fraction of Rb-repressed genes have promoters that are bound/ regulated by E2F family members. However, targets were also identified that are distinct from genes known to be stimulated by overexpression of specific E2F proteins, suggesting that some of the multiple pRb effects are not directly related to E2F proteins. The conformation and activity of pRb is rather complex, and not fully understood. It is widely accepted that the activity of this large tumor suppressor protein is largely dependent upon the phosphorylation status of at least 16 potential CDK phosphorylation sites. But how exactly does phosphorylation of any of these sites change the full range of activities of pRb remains a matter of intense studies. Low molecular weight drugs designed to block “site-specific phosphorylation” of these sites is also under research, as they may ultimately lead to the growth arrest of populations of tumor cells [141]. Yuen Kai Fung’s laboratory, at the University of Southern California, has identified all the CDK sites (Thr-356, Ser-807/Ser-811, and Thr-821) the phosphorylation of which drastically modify the conformation of pRb. The so called
21
m89 strutural motif (identified in the m89 mutant of pRb) has greatly enhanced growth suppressing activity, similar to a mutant with alanine substitutions at Ser-807/Ser-811. Moreover, this m89 region is part of a structural domain, p5, conserved antigenically and functionally between pRb and p53. Rationally designed drugs capable of interacting with these key molecular sites [142–144] may exploit the coordinated regulation of the activity of these two tumor suppressors, or at least block the conformation of the tumor suppressor pRb into its active growth inhibitory hypophosphorylated structure (see also Fig. 1-3). One of the seemingly tragic, and yet unexplained, features of our human genome is that the key sensors that control many of the functional interactions between Rb and p53 are actually linked in the same gene, making them dually vulnerable to the same genetic attack. In general, mutational events that disable the Rb pathway and facilitate cell proliferation are counterbalanced by a p53-dependent response that eliminates, or at least inhibits, incipient cancer cells. Conversely, loss of p53 function enables cells sustaining oncogenic damage to survive and proliferate. Unfortunately for us, and as already pointed out, the INK4A-ARF locus encodes in the same genetic locus two distinct tumor suppressor proteins that regulate both the Rb and the p53 pathways. ARF (p19) is a sensor of inappropriate proliferation brought about by loss of Rb .The product of the p53 gene is part of the intrinsic mechanisms that monitor the cell cycle, for example inducing the expression of p21, and mutations, deletions, or underexpression of p19ARF facilitate Mdm2’s degradation of p53, leaving the cell unaware of the need to initiate cell death. It can be speculated (Table 1-1 and 1-2) that if effective and safe drugs were available to reactivate p53 (via MDM2 antagonists, or otherwise), in cancer cells with an intact pRb pathway or , in combination with effective inhibitors of pRb phopshorylation, if the upstream elements of this pRb pathway are also altered in the same cancer cells, then we could witness dramatic responses and perhaps even cures in up to 30–50% of the common solid cancers. Another potential mechanism to reactivate tumor suppressors is by epigenetic mechanisms. In this context, The US Food and Drug Administration (FDA) has approved Zolinza® (vorinostat) capsules for the treatment of advanced cutaneous T-cell lymphoma (CTCL), to be used when the disease persists in spite of conventional therapy, gets worse, or comes back during or after treatment (www.fda.gov/bbs/ topics/NEWS/2006). ZOLINZA®’s generic name is vorinostat, also known as suberoylanilide hydroxamic acid, or SAHA, is the first in a new class of anticancer therapies called histone deacetylase (HDAC) inhibitors. Histone deacetylation is thought to be a mechanism for silencing some tumor suppressor genes and other genes responsible for cell cycle progression, cell proliferation, programmed cell death (apoptosis), and differentiation (transformation of young cells into specialized cells), by altering the gene expression patterns secondary to chromatin three-dimensional structure. Vorinostat
22
was approved as part of FDA’s Orphan Drug program, which offers companies financial incentives to develop medications for diseases affecting fewer than 200,000 American patients a year. Evidence of Zolinza’s safety and effectiveness was developed in two clinical trials with 107 CTCL patients who received Zolinza after their disease had recurred following other treatments. A response, defined by improvements on a scale that scores skin lesions, occurred in 30% of patients who received Zolinza and lasted an average of 168 days. In summary, relevant molecular targets offer us a tremendous opportunity for both cancer prevention and cancer therapy. They are also of increasing use as predictive or prognostic markers of malignant disease, as reviewed “on balance” by Daniel Hayes in his chapter, and they have also entered the field of “molecular imaging” [145–150].With the aid of a cyclotron, for example, it is possible to develop positronemitting isotopes of elements that are easily incorporated into biological molecules such as fluorine-18, carbon-11, nitrogen-13, and oxygen-15, thereby allowing the direct in vivo detection and visualization of parts of the body with activated metabolic pathways (the classic is basic glucose metabolism with fluorine-18 linked to deoxyglucose. The disadvantage of PET radiopharmaceuticals is that they tend to have relatively short half-lives (from approximately 2 hours to some 20 minutes), and require for the generation an on-site cyclotron to produce them. An exciting development will be the production of efficient methods of generating and detecting fluorine-18 labeled nucleotides (like thymadine) that could be used to study cell tumor kinetics in vivo. In my opinion, this is crucial to the understanding of both human tumor biology and the assessment of clinical response to new cytostatic drugs, like many of the new “targeted therapies.” Thus when clinicians talk about “stable diease” or “stabilization” following some new drug trial, the doubt remains as to what was the natural cell kinetics in vivo of the tumor. To know beforehand the expected “doubling time,” “growth fraction” or even “mitotic index” would provide very valuable data, because there is great variability in the cell kinetics of tumors. In any case, the introduction of these more precise imaging techniques [145–150], and of these new targeted therapies have led to important changes in both response criteria and clinical trial design [151–154]. For example, new imaging techniques outdated most of the WHO criteria of response to therapy, first adopted in the late 1970s, and prompted the introduction of the so-called RECIST criteria for oncological clinical trials (Response Evaluation Criteria in Solid Tumors) from the year 2000. Neither these new diagnostic imaging tests [145–150] nor the new targeted drugs are “cheap”, and the relevance of financial considerations is of increasing importance to all health-care providers, including experimental oncologists, practicing oncologists, hematologists, radiotherapists, and cancer surgeons [153–154].
M.H. Bronchud
1.4.3 New Approaches to Targeting Loss-Of-Function Mutations in Tumor Suppressor Genes Loss-of function mutations in tumor-suppressor genes have been unfairly neglected so far for target-based drug discovery in cancer [97], mostly perhaps because it is easier to design small molecules to inhibit the gain of function in oncogenes than to restore or reactivate the function of tumor-suppressor genes. The case of Tumor Suppressor Genes is certainly more complex than the case of Oncogenes, because the ideal therapy in the former, where the problem is usually a loss-offunction mutation (e.g., a deletion in a gene or a hypermethylation of the promotor), would be a genetic replacement of the wild type. But gene therapy might not be the only answer to this problem. Drugs designed to target epigenomic changes [155] and, for example, re-activate the transcription of suitable tumor suppressor genes, or drugs that can reactivate cryptic proteins domains in tumor suppressor proteins or decrease the rate of degradation of tumor suppressors, thereby increasing their functional half-lives, are certainly possible, and already under study. Unfortunately, it could well happen that in cancers that are too advanced or evolved, there may not be any more “latent” or “relevant” tumor suppressor functions left as potential target for this new class of compounds that can be known as “Tumor Suppressor Activators (TSAs). Hence the importance of combining earlier detection of cancers (hence the need for more research on preventive cancer medicine), with the discovery and development of better and more effective drugs [97]. Unlike oncogenes, tumor suppressor (TS) genes (formerly “anti-oncogenes”) display the function of suppressing cellular proliferation, and/or maintaining cellular differentiation, facilitating normal cellular adhesion mechanisms, stopping entry into the cell cycle (G1, S-phase, mitosis or G2) to allow DNA-repair mechanisms, maintaining normal cellular shape, cell contact inhibition mechanisms, and senescence. The tumor suppressor paradigm characteristically calls for loss of both functional copies of the gene and indeed many, but not all, tumor suppressor genes must undergo biallelic inactivation to sustain a true loss-of-function effect. However, a substantial number of cancer cells retain at least one “functional copy” (wild-type or mutant) of one or several key TS genes. Wang et al. [156], at the Translational Genomics Research Institute in Phoenyx, AZ, directed by Daniel D. Von Hoff, have recently reviewed the targeting of loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents. So called “synthetic lethal screening” has been a genetic technique used to identify mutations that are lethal in combination. Von Hoff’s recent research efforts are directed towards the discovery and development of what they have named “pharmacologic synthetic lethal screening” (PSLS), by cleverly using molecular techniques such as siRNA, RNAi or antisense molecules to identify genotypeselective anti-tumor agents.
1. Selecting the Right Targets for Cancer Therapy
References 1. Leblond C.P. Classification of cell populations on the basis of their proliferative behavior. Natn. Cancer Institute Monogr. 14, 1964: 119–150. 2. Fialkow P.J. Clonal origin of human tumors. Biochim Biophys Acta 458, 1976: 283–321. 3. Cairns J. Cancer: Science and society. W.H. Freeman , San Francisco 1978; Chapter 4: 35–61. 4. Collins R.D. Is clonality equivalent to malignancy: Specifically, is immunoglobulin gene rearrangement diagnostic of malignant lymphoma? Hum Pathol 28, 1997: 757–759. 5. Birindelli S, Aiello A., Lavarino C. et al. Genetic markers in sporadic tumors. In: Principles of molecular oncology, M.H. Bronchud et al. (eds), Humana Press N.J. 2000, 45–93. 6. Fisher J.C., Hollomon J.H. A hypothesis for the origin of cancer foci. Cancer 4, 1951: 916–918. 7. Nordling C.O. A new theory on the cancer-inducing mechanism. Brit J Cancer 7, 1953: 68–72. 8. Armitage P., Doll R. The age-distribution of cancer and a multistage theory of carcinogenesis. Br J Cancer 8, 1954: 1–12. 9. Fearon E.R. and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61, 1990: 759–767 10. Fisher J.C. Multiple-mutation theory of carcinogenesis. Nature 181, 1958: 651–652. 11. Armitage P., Doll R. A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Brit J Cancer 11, 1957: 161–169. 12. Friedewald W.F., Rous P. The initiating and promoting elements in tumor production. J Exp Med 80, 1944: 101–126. 13. Baltimore D. Viruses, polymerases and cancer. Science 192, 1976: 632–636. 14. Temin H.M. The protovirus hypothesis: speculations on the significance of RNA-directed DNA synthesis for normal development and for carcinogenesis. J Natn Cancer Inst 46, 1971: iii–viii. 15. Knudson A.G. Mutation and human cancer. Adv Cancer Res 17, 1973: 317–352. 16. Doll R. Nature and nurture: Possibilities for cancer control. Carcinogenesis (Lond.) 17, 1996: 177–184. 17. Couch D.B. Carcinogenesis: Basic principles. Drug Chem. Toxicol. 19, 1996: 133–148. 18. Shields P.G. and Harris C.C. Molecular epidemiology and the genetics of environmental cancer. J. Am. Med. Assoc. 266, 1991: 681–687. 19. Harris C.C. The Walter Hubert Lecture. Molecular epidemiology of human cancer: Insights from the mutational analysis of the p53 tumor suppressor gene. Br J Cancer 73, 1996: 261–269. 20. Perera F.P. Molecular epidemiology: Insights into cancer susceptibility, risk assessment, and prevention. J. Natl.Cancer Inst. 88, 1996: 496–509. 21. Kinzler K.W., Vogelstein B. Gatekeepers and caretakers. Nature (Lond.) 386, 1997: 761–763. 22. Loeb L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51, 1991: 3075–3080. 23. Loeb L.A. Cancer cells exhibit a mutator phenotype. Adv Cancer Res 72, 1998: 25–56. 24. Ponder B. Genetic testing for cancer risk. Science (Washington DC) 278, 1997: 1050–1054.
23 25. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87, 1996: 159–170. 26. Bronchud M.H., Peters W.P. Selecting the right targets for cancer therapy. In: Principles of molecular oncology, M.H. Bronchud et al. (eds), Humana Press N.J. 2000: 3–27. 27. Banks R.E., Dunn M.J., Hochstrasser D.F., et al. Proteomics: New perspectives, new biomedical opportunities. The Lancet 356, 2000: 1749–1756. 28. Frykberg E.R., Bland K.I. “In situ” breast carcinoma. Adv Surg 26, 1993: 29–72. 29. Page D.L., Dupont W.D., Rogers L.W., Rados M.S. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer (Phla.) 55, 1985: 2698–2708. 30. Day D.W., Morson B.C. The adenoma-carcinoma sequence. In: The pathogenesis of colorectal cancer, 1978, Bennington J.L. (ed.) vol 10, Chapter 6: 58–71; Saunders, Philadelphia. 31. Bostwick D.G. Prostatic intraepithelial neoplasia (PIN): Current concepts. J Cell Biochem 16H, 1992: 10–19. 32. Califano J., van der Riet P. Westra W. et al. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 56, 1996: 2488–2492. 33. Sidransky D, Mikkelsen T, Schwechheimer T et al. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature (London) 355, 1992: 846–847. 34. Sidransky D., Messing E. Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes and growth factors. Urol Clin North Amer 19, 1992: 629–639. 35. Slaughter D.P., Southwick H.W., Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Cancer (Phila.) 6, 1953: 963–968. 36. Knowles M.A. The genetics of transitional cell carcinoma: progress and potential clinical applications. Br J Urol International 84, 1999: 412–427. 37. Ahrendt S.A., Chow J.T., Xu L.H. et al. Molecular detection of tumor cells in bronchioalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 91, 1999: 332–339. 38. Bedi G.C., Westra W.H., Gabrielson E. et al. Multiple head and neck tumors: Evidence for a common clonal origin. Cancer Res 56, 1996: 2484–2487. 39. Partridge M., Emilion G., Pateromichelakis S. et al. Field cancerisation of the oral cavity: Comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions. Oral Oncol 33, 1997: 332–337. 40. Lagios M.D., Westdahl P.R., Rose M.R. The concept and implications of multicentricity in breast carcinoma. Pathol Annu 1981; 16: 83–102. 41. Lagios M.D., Richards V.E., Rose M.R., Yee E. Segmental mastectomy without radiotherapy: Short term follow-up. Cancer 1983, 52: 2173–2179. 42. Holland R., Solke H.J.V., Mravunac M. Multifocality of Tis, T 1-2 breast carcinomas. Cancer 1985; 56: 979–990. 43. Van Oijen M.G.C., Slootweg P.J. Oral field cancerization: carcinogen-induced independent events or micrometastatic deposits? Cancer Epid Biomark and Prevent 9, 2000: 249–256. 44. Bronchud M.H. Is cancer really a “local” cellular clonal disease? Medical Hypotheses 2002; 59: 560–565. 45. Kelloff G.J., Sigman C.C., Johnson K.M. et al. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epid. Biomark. and Prevention 9, 2000: 127–137.
24 46. Miller A.B., Bartsch H., Boffetta P., Dragsted L., Vainio H. Biomarkers in cancer chemoprevention. IARC Scientific Publications 154, 2001. 47. Moolgavkar S., Krewski D., Zeise L., Cardis E., Moller H. Quantitative estimation and prediction of human cancer risks. IARC Scientific Publications 131, 1999. 48. Kersting M., Friedl C., Kraus A. et al. Differential frequencies of p16 (INK4a) hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 18, 2000: 3221–3229. 49. Man Y.G., Martinez A., Avis I.M. et al. Phenotypically different cells with heterogeneous nuclear ribonucleoprotein A2/B1 overexpression show similar genetic alterations. Am J Respir Cell Mol Biol 2000; 23: 636–645. 50. Issa J.P. The epigenetics of colorectal cancer. Ann N Y Acad Sci 2000; 910: 140–153. 51. Konrad M., Ge Y., Naber J. et al. Leukemic clones are frequently present in neonatal blood samples of children with acute lymphoblastic leukemia. Amer Assoc Canc Res 2001: a 2196: 408. 52. Wen W.H., Bernstein L., Lescallett J. et al. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res 2000; 60: 2716–2722. 53. Mohr S., Leikauf G.D., Keith G., Rihn B.H. Microarrays as cancer keys: An array of possibilities. J Clin Oncol 2002; 20: 3165–3175. 54. Pollack J.R., Perou C.M., Alizadeh A.A. et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 1999; 23: 41–46. 55. Bruder C.E., Hirvela C., Tapia-Paez I. et al. High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF”) patients using microarray-CGH. Hum Mol Genet 2001; 10: 271–282. 56. Forozan F., Mahlamaki E.H., Monni O. et al. Comparative genomic hybridization analysis of 38 breast cancer cell lines: A basis for interpreting complementary DNA microarray data. Cancer Res 2000; 60: 4519–4525. 57. Daigo Y., Chin S.F., Gorringe K.L. et al. Degenerate oligonucleotide primed polymerase chain reaction-based array comparative genomic hybridization for extensive amplicon profiling of breast cancers: A new approach for the molecular analysis of paraffin-embedded cancer tissue. Am J Pathol 2001; 158: 1623–1631. 58. Sapolsky R.J., Hsie L., Berno A. et al. High-throughput polymorphism screening and genotyping with high-density oligonucleotide arrays. Genet Anal 1999; 14: 187–192. 59. Mei R., Galipeau P.C., Prass C. et al. Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. Genome Res 2000; 10: 1126–1137. 60. Lindblad-Toh K., Tanenbaum D.M., Daly M.J. et al. Loss of heterozygosity analysis of small cell lung carcinomas using single nucleotide polymorphisms arrays. Nat Biotechnol 2000; 18: 1001–1005. 61. Golub T.R., Slonim D.K., Tamayo P. et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531–537. 62. Ross D.T., Scherf U., Eisen M.B. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24: 227–235.
M.H. Bronchud 63. Perou C.M., Sorlie T., Eisen M.B. et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747–752. 64. Hedenfalk I., Duggan D., Chen Y. et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344: 539–548. 65. Ahr A., Holtrich U., Solbach C. et al. Molecular Classification of breast cancer patients by gene expression profiling. J Pathol 2001; 195: 312–320. 66. Ono K., Tanaka T., Tsunoda T. et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000; 60: 5007–5011. 67. Bhattacharjee A., Richards W.G., Staunton J. et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98: 13790–13795. 68. Dirix L.Y., van Oosterom A.T. Gene-expression profiling to classify soft-tissue sarcomas. Lancet 2002; 359: 1263–1264. 69. Alizadeh A.A., Eisen M.B., Davis R.E. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511. 70. Dhanasekaran S.M., Barrette T.R., Ghosh D. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822–826. 71. Spencer S.L., Gerety R.A., Pienta K.J., Forrest S. Modeling somatic evolution in tumorigenesis. PLoS Computational Biol 2006; 2(8): e108. 72. Hanahan D., Weinberg R. The hallmarks of cancer. Cell 2000; 100: 57–70. 73. Kodadek T. Protein microarrays: Prospects and problems. Chem Biol 2001; 8: 105–115. 74. Senior K. Fingerprinting disease with protein chip arrays. Mol Med Today 1999; 5: 326–327. 75. Jain K.K. Applications of proteomics in oncology. Pharmacogenomics 2000; 1: 385–393. 76. Zhu H., Snyder M. Protein arrays and microarrays. Curr Opin Chem Biol 2001; 5: 40–45. 77. Paweletz C.P., Charboneau L., Bischel V.E. et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: 1981–1989. 78. Von Eggeling F., Davies H., Lomas L. et al. Tissue-specific microdissection coupled with ProteinChip array technologies: Applications in cancer research. Biotechniques 2000; 29: 1066–1070. 79. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844–847. 80. Nocito A., Bubendorf L., Maria Tinner E., et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001; 194: 349–357. 81. Camp R.L., Charette L.A., Rimm D.L. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 1943–1949. 82. Hobbs S.K., Homer R.J., Harsh G.R. et al. Image guided proteomics in human glioblastoma multiforme: New clinical technique for molecular target discovery. Proc Amer Assoc Cancer Res 2001; abstract 532. 83. Lerut T. The surgeon as prognostic factor. Ann of Surg 2000; 232: 729–732. 84. Bishop J.L., Harland M., Bishop T. The genetics of melanoma. Brit J Hosp Medicine, 2006; 67 (6): 299–303.
1. Selecting the Right Targets for Cancer Therapy 85. Bennett D.C. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 2003; 22 (20): 3063–3069. 86. Chin L., Pomerantz J., DePinho R.A. The INK4a/ARF tumor suppressor: One gene-two products-two pathways. Trends Biochem SCI 1998; 23 (8): 291–296. 87. Sherr C.J. Cancer cell cycles revisited. Cancer Res 2000; 60: 3689–3695. 88. Ortega S., Malumbres M., Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602: 73–87. 89. Classon M., Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002; 2: 910–917. 90. Foster S.A., Demers G.W., Etscheid B.G. et al. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 1994; 68: 5698–5705. 91. Beer-Romero P., Glass S., Rolfe M. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene 1997; 14: 595–602. 92. Butz K., Denk C., Ullmann A. et al. Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 2000; 97: 6693–6697. 93. Liaw K.L., Hildesheim A., Burk R.D. et al. Prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183: 8–15. 94. Koutsky L.A., Ault K.A., Wheeler C.M. et al. A controlled trial of a human papilloma virus type 16 vaccine. New Engl J Med 2002; 347: 1645–1651. 95. HPV vaccine: GARDASIL, proprietary information and news releases from www.merck.com 96. Up-dates on Celecoxib Trial to Prevent Colonic Adenomas: http://www.cancer.gov/newscenter/pressreleases/APCtrial COX2QandA. 97. Bronchud M.H. The yin and yang of cancer therapeutics. Current Opinion in Drug Discovery & Development, 2005; 8 (2): 184–198. 98. Paul M.K., Mukhopadhyay A.K. Tyrosine kinase- role and significance in cancer. Intern. J of Med Sci 2004; 1(2): 101–115. 99. Hahn W.C., Weinberg R.A. Rules for making human tumor cells. New Engl J Med 2002; 347: 1593–1603. 100. Hupp T.R., Lane DP. Allosteric activation of latent p53 tetramers. Curr Biol 1994; 4: 865–875. 101. Hupp T.R., Sparks A., Lane D.P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995; 83: 237–245. 102. Castillo L., Etienne-Grimaldi M.C., Fischel J.L. et al. Pharmacological background of EGFR targeting. Ann of Oncol 2004; 15: 1007–1012. 103. Baird R., Workman P. Emerging molecular therapies: drugs interfering with signal transduction pathways. In: Principles of molecular oncology (2nd Ed), Bronchud M.H., Foote M.A., Giaccone G., Olopade O., Workman P. (eds); Humana Press NJ, 2004: 569–606. 104. Arnold D., Peinert S., Voigt W., Schmoll H.J. Epidermal growth factor receptor tyrosine kinase inhibitors: Present and future role in gastrointestinal cancer treatment: A review. The Oncologist 2006; 11: 602–611.
25 105. Paez J.G, Janne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–1500. 106. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T. et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353 (2): 123–132. 107. Herbst R.S. Erlotinib. Clin Adv Hematol Oncol 2005 ; 3 (2): 125–141. 108. Oved S., Yarden Y.. Signal transduction: molecular ticket to enter cells. Nature 2002; 416: 133–136. 109. Rao S., Watkins D., Cunningham D. et al. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated lowgrade non-Hodgkin’s lymphoma. Ann of Oncol 2004; 15: 1413–1418. 110. Lane D. The promise of molecular oncology. Lancet 1998; 351 (suppl II): SII 17-SII 20. 111. Bykov V.J.N., Issaeva N., Shilov A. et al. Restoration of tumor suppressor function to mutant p53 by a low molecular weight compound. Nature Med 2002; 8: 282–288. 112. Snyder E.L., Meade B.R., Saenz C.C., Dowdy S.F. Treatment of terminal peritoneal carcinomatosis by a transducible p53activating peptide. PloS Biology 2004 (2): 186–193. 113. Lane D. Curing cancer with p53. N Engl J Med 2004; 350: 2711–2712. 114. Boiko A.D., Porteous S., Razorenova O.V et al. A systematic search for downstream mediators of tumor suppressor function of p53 reveal a major role for BTG2. Genes & Development 2006; 20: 236–252. 115. Dai M.-S., Shi D., Jin Y., Sun X.-X., Zhang Y., Grossman S.R., Lu H. Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem 2006; 281: 24304–24313. 116. Kojima K., Konopleva M., McQueen T., O’Brien S., Plunkett W., Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcriptionindependent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108: 993–1000. 117. Dubbink H.J., Hersmus R., Pike A.C.W., Molier M., Brinkmann A.O., Jenster G., Trapman J. Androgen receptor ligandbinding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping. Mol Endocrinol 2006; 20: 1742–1755. 118. Wang W., Kim S.-H., El-Deiry W.S. Small-molecule modulators of p53 family signaling and antitumor effects in p53deficient human colon tumor xenografts. PNAS 2006; 103: 11003–11008. 119. Vassilev L.T., Tovar C., Chen S., Knezevic D., Zhao X., Sun H., Heimbrook D.C., Chen L. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. PNAS 2006; 103: 10660–10665. 120. Scoumanne A., Chen X. The epithelial cell transforming sequence 2, a guanine nucleotide exchange factor for Rho GTPases, is repressed by p53 via protein methyltransferases and is required for G1-S transition. Cancer Res 2006; 66: 6271–6279. 121. Cheung H.H., LaCasse E.C., and Korneluk R.G.. X-Linked inhibitor of apoptosis antagonism: Strategies in cancer treatment. Clin Cancer Res 2006; 12: 3238–3242.
26 122. Cruz C.D., Palosaari H., Parisien J.-P., Devaux P., Cattaneo R., Ouchi T., Horvath C.M.. Measles virus V protein inhibits p53 family member p73. J Virol 2006; 80: 5644–5650. 123. Secchiero P., Barbarotto E., Tiribelli M., Zerbinati C., di Iasio M.G., Gonelli A., Cavazzini F., Campioni D., Fanin R., Cuneo A., Zauli G. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107: 4122–4129. 124. Coll-Mulet L., Iglesias-Serret D., Santidrian A.F., Cosialls A.M., de Frias M., Castano E., Campas C., Barragan M., de Sevilla A.F., Domingo A., Vassilev L.T., Pons G., Gil J. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107: 4109–4114. 125. Ricci M.S., Zong W.-X. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 2006; 11: 342–357. 126. White D.E., Talbott K.E., Arva N.C., Bargonetti J. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Res 2006; 66: 3463–3470. 127. Tabakin-Fix Y., Azran I., Schavinky-Khrapunsky Y., Levy O., Aboud M. Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: Mechanisms and clinical implications. Carcinogenesis 2006; 27: 673–681. 128. Patton J.T., Mayo L.D., Singhi A.D., Gudkov A.V., Stark G.R., Jackson M.W. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006; 66: 3169–3176. 129. Dudgeon C., Kek C., Demidov O.N., Saito S.-i., Fernandes K., Diot A., Bourdon J.-C., Lane D.P., Appella E., Fornace Jr A.J., Bulavin D.V. Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene. Cancer Res 2006; 66: 2928–2936. 130. Tomko Jr R.J., Bansal P., Lazo J.S. Airing out an antioxidant role for the tumor suppressor p53. Mol Interv 2006; 6: 23–25. 131. Jung E.J., Liu G., Zhou W., Chen X. Myosin VI Is a Mediator of the p53-Dependent Cell Survival Pathway. Mol Cell Biol 2006; 26: 2175–2186. 132. Tovar C., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., Zhao X., Vu B.T., Qing W., Packman K., Myklebost O., Heimbrook D.C., Vassilev L.T. From the Cover: Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. PNAS 2006; 103: 1888–1893. 133. Harris C.C. Protein-protein interactions for cancer therapy. PNAS 2006; 103: 1659–1660. 134. Levine A.J., Feng Z., Mak T.W., You H., Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes & Dev 2006; 20: 267–275. 135. Yu G.W., Rudiger S., Veprintsev D., Freund S., FernandezFernandez M.R., Fersht A.R. The central region of HDM2 provides a second binding site for p53. PNAS 2006; 103: 1227–1232. 136. Berkson R.G., Hollick J.J., Westwood N.J. et al. Pilot screening programme for small molecule activators of p53. Int J Cancer 2005; 115: 701–710. 137. Sunder-Plassman N., Giannis A. Novel activators of the TUMOUR suppressor p53. ChemBioChem 2004; 5: 1635–1637. 138. Vassilev L.T., Vu B.T., Graves B. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844–848.
M.H. Bronchud 139. Bronchud M.H., Brizuela L., Gyuris J., Mansuri M.M. Cyclin-dependent kinases and their regulators as potential targets for anticancer therapeutics. In: Principles of molecular oncology (2nd Ed), Bronchud M.H., Foote M.A., Giaccone G., Olopade O., Workman P. (eds); Humana Press NJ, 2004: 359–410. 140. Yap D.B., Hsieh J.K., Chan F.S., Lu X. Mdm2: A bridge over the two tumour suppressors, p53 and Rb. Oncogene 1999; 18: 7681–7689. 141. Barrie E., Eno-Amooquaye E., Hardcastle A. et al. Highthroughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells. Analytical Biochem 2003; 320: 66–74. 142. Harbour J., Dean D. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes Dev 2000; 14: 2393–2409. 143. Kaelin W.G. Jr. Cancer chemotherapy based on E2F and the retinoblastoma pathway. In: Targets for cancer chemotherapy: Transcription factors and other nuclear proteins. La Thangue N.B., Bandara L.R. (eds), Humana Press 2002: 1–13. 144. Banerjee D., Bertino J.R. E2F and Cancer Chemotherapy. In: Targets for cancer chemotherapy: Transcription factors and other nuclear proteins. La Thangue N.B., Bandara L.R. (eds), Humana Press; Totowa, NJ, 2002: 289–298. 145. Hillman B.J., M. Schnall, Sullivan D.C., Kressel H.Y. Applications of medical imaging to oncology. J Clin Oncol 2006; Special Issue Monograph on Medical imaging applied to Oncology, 24 (20): 3223–3314. 146. Thrall J.H. ACR primer on molecular imaging. J Amer Coll Radiol 2004; 1:32. 147. Schnall M., Rosen M. Primer on imaging technologies for cancer. J Clin Oncol 2006; 24 (20): 3225–3232. 148. Barentsz J., Takahashi S., Oyen W. et al. Commonly used imaging techniques for diagnosis and staging. J Clin Oncol 2006; 24 (20): 3234–3244. 149. Jaffe C.C. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006; 24 (20): 3245–3251. 150. Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216. 151. Black W.C. Randomized clinical trials for cancer screening: Rationale and design considerations for imaging tests. J Clin Oncol 2006; 24 (20): 3252–3260. 152. Von Hoff D.D. There are no bad anticancer agents, only bad clinical trial designs. Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 1998; 4:1079–1086. 153. Nadler E., Eckert B., Neumann P.J. Do oncologists believe new cancer drugs offer good value? The Oncologist (Commentary) 2006; 11: 90–95. 154. Wagstaff A. Lost in translation. Cancer World (Jan-Feb) 2006: 12–17. 155. Tischer E., Mitchell R., Hartman T. et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;226: 11947–11954. 156. Wang H., Han H., Mousses S. et al. Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents. Sem in Oncol (Elsevier) 2006; 4 (13): 513–520.
Chapter 2 Clinical Importance of Prognostic Factors Moving from Scientifically Interesting to Clinically Useful N. Lynn Henry and Daniel F. Hayes
2.1
Introduction
The term prognostic factor, when used regarding patients with malignancies, has taken on several meanings. In general, a prognostic factor is considered to be useful because its results serve to separate a large heterogeneous population into smaller populations with more precisely predictable outcomes. In theory, if this separation is both reliable and disparate, one can apply therapy more efficiently to the population by exposing those most likely to need and benefit from the therapy while ensuring that the other group avoids needless toxicities. In essence, the term tumor marker has come to describe a variety of molecules or processes that differ from the norm in the malignant cells, tissues, or fluids of patients with malignancies. Assessment of these alterations from normal can be used to place patients into categories that are distinguished by different outcomes, either in the absence of specific therapy, or after various treatments are applied. Tumor markers can include changes at the genetic level (e.g., mutations, deletions, or amplifications), the transcriptional level (e.g., over- or underexpression), the translational or post-translational level (e.g., increased or decreased quantities of protein, or abnormal glycosylation of proteins), and/ or the functional level (e.g., histologic description of cellular grade or presence of neovascularization). Each of these can be assessed by one or more assays, which uses one or more methods with differing reagents. This enormous heterogeneity of approaches is the root of considerable confusion regarding the true value, in clinical terms, of a given tumor marker. The “molecular revolution” is now well into its fourth decade. Yet, in spite of impressive advances in our understanding of the biology of human malignancy, and in the technology of investigating molecular processes, the number
From: Principles of Molecular Oncology, Third Edition Edited by: Miguel H. Bronchud et al. © Humana Press Inc., Totowa, NJ
of clinically useful products from these advances is disappointing. For example, in 1995, the American Society of Clinical Oncology (ASCO) first convened a panel of experts to establish guidelines for the use of tumor markers in colon and breast carcinoma. Although the expert panel reviewed many putative markers (including both tissue-based and circulating markers), its ultimate recommendations were surprisingly sparse (Table 2-1) [1, 2]. In its first deliberations, the panel felt that none of the newer molecular markers (e.g., erbB-2, p53, cathepsin D) was established in a scientifically rigorous fashion to be reliable and definitive. The most recent update from the year 2000, however, reflect some progress in the field, with recognition of erbB-2 (HER2) as a potential marker for sensitivity or resistance to certain standard therapies against breast cancer, and, more importantly, as a target of specific therapy itself [3, 4]. Why are the ASCO guidelines so conservative? In reviewing the available literature, the panel recognized that the science of clinical tumor marker investigation has been haphazard and relatively chaotic. Too often, studies of tumor markers are more inclined to “fishing expeditions” with the hope that something interesting will be detected with statistical significance, rather than being prospective, hypothesis-driven investigations. In light of this confusion, several authors of the guidelines separately developed a proposal for a framework in which previously published tumor marker studies might be critically evaluated. The authors also suggested that this framework might be used by investigators to plan future studies in a fashion that leads to more rapid acceptance, or refutation, of a given marker in the clinical arena. Details of this system, designated the Tumor Marker Utility Grading System (TMUGS), have been published elsewhere [5]. The contents of the current review will apply the principles of TMUGS to examples of evaluations of tumor markers in solid tumors, especially breast cancer, although these systems are certainly applicable to other malignancies in general. Recently developed reporting recommendations intended to guide researchers when designing and publishing tumor marker studies will also be discussed [6]. 27
28
N.L. Henry and D.F. Hayes
Table 2-1. American Society of Clinical Oncology clinical practice guidelines for use of tumor markers in breast cancer (tissue factors only). Factor
Use
Guideline
Estrogen and progesterone receptors
Predictive factors for endocrine therapy
DNA flow cytometrically derived parameters erbB-2 (HER-2/neu)
Prognosis or prediction Prognosis Prediction for: trastuzumab CMF-like regimens doxorubicin taxanes endocrine Rx
p53 Cathepsin-D
Prognosis or prediction Prognosis
Measure on every primary breast cancer and on metastatic lesions if results influence treatment planning Data are insufficient to recommend obtaining results Data are insufficient to recommend obtaining results for this use erbB-2 should be evaluated on every primary breast cancer at time of diagnosis or at time of recurrence for use as predictive factor for trastuzumab; Committee could not make definitive recommendations regarding CMF-like regimens. erbB-2 may identify patients who particularly benefit from anthracycline-based therapy but should not be used to exclude anthracycline treatment. erbB-2 should not be used to prescribe taxane-based therapy or endocrine therapy Data are insufficient to recommend use of p53 Data are insufficient to recommend use of cathepsin-D
Modified from Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865–1878.
2.2 Importance of Tumor Markers: Adjuvant Systemic Therapy of Breast Cancer as a Case Study From the 1950s until about 1985, the annual odds of mortality because of breast cancer per 100,000 women increased steadily in the United States and other western countries (Fig. 2-1). In the mid-1980s, however, age-adjusted, breast cancer-mortality rates plateaued for women in the Western world, and, more recently, mortality from breast cancer has taken a rather dramatic decline [7]. Although screening and early application of local therapy (surgery, radiation) may have contributed to this decline, it is likely that these encouraging statistics are at least in part the result of widespread application of systemic therapy, including endocrine and chemotherapy [7, 8]. Indeed, several meta-analyses of worldwide data from prospective randomized clinical trials have confirmed that adjuvant systemic therapy reduces breast cancer recurrence rates by approximately 25% and, more importantly, mortality by approximately 15% in the population of women who participated in these trials, without further subgroup analyses [9–12]. These studies are not trials of treatment versus no treatment. Rather, they are trials of early treatment of the entire population versus later treatment of only those who have disease recurrence, if and when metastases occur. Because recurrent breast cancer is rarely if ever cured [13], these data illustrate the high stakes in making decisions about adjuvant systemic therapy. Given this dramatic and life-saving progress, should all patients with newly diagnosed breast cancer be treated with all available therapy to ensure maximum benefits? Application of systemic therapy to all patients with breast cancer would be inefficient, with the majority of patients being exposed to toxicities of therapy for little or no benefit. One might argue that the toxicities of endocrine therapies, such as
tamoxifen or aromatase inhibitors, are sufficiently tolerable that these therapies are acceptable to most if not all women. Tamoxifen is now used as a “chemopreventive” or “chemoprophylactic” to reduce risk of new breast cancers in women at high risk who have never had the disease [14]. Tamoxifen, however, causes occasional life-threatening toxicities (thromboses, second malignancies). Even the aromatase inhibitors, which may have fewer life-threatening toxicities compared with tamoxifen, at least with short follow-up, are not used indiscriminately because of side effects [15]. The side effects of chemotherapy are more dramatic, including nausea, vomiting, fatigue, and risk of infection and bleeding, and potential long-term complications such as second malignancies and congestive heart failure. Factors that might identify those patients most likely to have disease recurrence (designated prognostic factors), and factors that might identify those patients whose disease is most likely to respond to specific therapies (designated predictive factors), would be extraordinarily helpful; however, these factors need to be accurate. If they are not, women who are likely to benefit will be excluded from therapy, blunting the decline in mortality discussed previously.
2.3
Prognosis versus Prediction
Estimating a patient’s prognosis requires a complicated set of evaluations, which includes the propensity of a malignancy to expand in volume (proliferative capacity), its ability to escape its natural site of origin and establish growth in a foreign tissue (metastatic potential), and its relative sensitivity or resistance to therapy. Therapies for most solid tumors include surgery, radiation, systemic therapies, hormone therapies, or chemotherapies. In this regard, the terms prognostic and predictive have taken on separate meanings [16, 17]. The prognostic factor designation is usually reserved for those markers
2. Clinical Importance of Prognostic Factors: Moving from Scientifically Interesting to Clinically Useful Fig. 2-1. Age-standardized breast cancer death rate of women aged 35 to 69 years in the United States from 1950 to 2001. (From Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. With permission.)
29
80
70
Lung
60
50
Breast
40
30
20
Colon and rectum Uberus
10
Stomach 0 1950
that specifically provide an estimate of the odds of a given cancer’s recurrence after local therapy alone. It is usually a measure of both proliferation and metastatic potential, and it usually implies the odds of systemic recurrence or death in a patient who does not receive systemic therapy. A schematic illustration of a pure prognostic factor is provided in Fig. 2-2A. In this case, in the absence of therapy, patients who are positive for the prognostic factor have a worse outcome than those who are negative. Therapy may be effective, but it is equally so (in relative terms) for both factorpositive and factor-negative patients, and therefore the curves from no treatment to treatment for factor-positive and factornegative patients are parallel. The prognosis for factor-negative patients is so favorable that only a few patients, at most, will benefit, even from very effective therapy. Therefore, a prognostic factor is most helpful in determining if a patient is likely to be cured by the prior therapy, such as local therapy alone (surgery or radiation therapy or both), or whether he or she is more likely to have a subsequent recurrence. If so, and if therapy is available that has demonstrated efficacy in that setting, knowledge of an individual’s prognosis permits reasonable decision-making regarding whether or not appli-
1960
1970 1980 Years
1990
2000
2010
cation of further therapy is indicated, especially if the therapy is associated with modest-to-severe toxicities. The best examples of prognostic factors for most solid tumors are the tumor-node-metastasis (TNM) staging systems [18]. A predictive factor is a tumor marker that helps select therapies most likely to work against a patient’s tumor. A predictive factor may be the precise target of the therapy, an associated molecule or pathway that modifies the effectiveness of the therapy, or simply an alteration that is an epiphenomenon linked to the target or pathway of the therapy (such as high levels of proliferation or coamplification of a neighboring gene). A factor that purely predicts benefit from therapy (a positive predictive factor) is illustrated in Fig. 2-2B. In this case, the prognosis in the absence of therapy is the same for factor-negative and factor-positive patients (i.e., the factor has no prognostic effects). Factor-positive patients, however, have a much better prognosis than factor-negative patients in the presence of the therapy for which the factor is predictive, and therefore the curves are not parallel. For example, it is clearly established that estrogen receptor (ER) content in breast cancer tissue is positively related to the odds of response and benefit from antiestrogen hormonal therapy, such as ovarian ablation,
30
N.L. Henry and D.F. Hayes
A
PURE PROGNOSTIC FACTOR (Unfavorable)
Factor Neg
Good P r o g n o s i s
Factor Neg Factor Pos
Factor Pos
Poor
Factor Pos
Good P r o g n o s i s
Factor Neg Factor Pos Factor Neg
Poor
No Therapy
MIXED FACTOR (Favorable Prognostic/ Favorable Predictive)
Factor Pos
Good
Factor Pos
Factor Neg
Poor No Therapy
No Therapy
Therapy
C
P r o g n o s i s
PURE PREDICTIVE FACTOR (Favorable for response)
B
Factor Neg
Therapy
Therapy
MIXED FACTOR (Unfavorable Prognostic/ Favorable Predictive)
D
Good P r o g n o s i s
Factor Pos Factor Neg Factor Neg Factor Pos
Poor No Therapy
Therapy
Fig. 2-2. Schematic representation of prognostic and predictive factors. A Illustration of pure prognostic factor that is associated with unfavorable prognosis. B Illustration of pure predictive factor that is associated with response to specific therapy. C Illustration of mixed factor that is associated with favorable prognosis and favorable response to therapy. D Illustration of factor that is associated with unfavorable prognosis but favorable response to therapy. (Modified from Hayes DF, Trock B, Harris A. Assessing the clinical impact of prognostic factors: When is “statistically significant” clinically useful? Breast Cancer Res Treat. 1998;52:305–319. With permission.)
tamoxifen, or aromatase inhibitors, because ER plays a fundamental role in estrogen-dependent tumor growth and biology [19]. By contrast, p-glycoprotein content is a negative predictive factor for resistance to certain drugs, because this protein modulates multidrug resistance by increasing efflux of the antineoplastic agent from the cancer cell [20]. In real life, many if not most factors may be both prognostic and predictive (Fig. 2-2C). For example, in addition to serving as a strong predictive factor, ER is also a weakly favorable prognostic factor. Breast cancers with high ER content have generally slower growth potentials, and patients
with ER-positive tumors have a better prognosis, even if they receive no treatment [21, 22]. To further complicate this discussion, some markers may be associated with a poor prognosis independent of therapy, but they may predict for an improved outcome related to specific treatment modalities (Fig. 2-2D). One such marker in breast cancer is the erbB-2 (HER-2, c-neu) proto-oncogene. Since 1987, conflicting results from several studies have been reported regarding whether erbB-2 amplification or overexpression or both is a marker of poor prognosis [23–26]. erbB-2 is also a predictive factor. To add to the confusion, however,
2. Clinical Importance of Prognostic Factors: Moving from Scientifically Interesting to Clinically Useful
it may be a predictive factor for response to some therapies and resistance to others. For example, erbB-2 appears to predict relative resistance to hormone therapy and to alkylating agents, but sensitivity to anthracyclines [27–31]. More strikingly, erbB-2 serves as the target for a humanized monoclonal antibody, trastuzumab. Response to and benefit from trastuzumab is closely linked to erbB-2 amplification or overexpression or both, which was initially demonstrated in the metastatic setting [32, 33], and recently was shown to result in significantly improved outcomes in the adjuvant setting as well [34–36]. These considerations are often ignored in many prognostic factor studies. Rather, a population of patients is studied with a new, putative prognostic factor simply because the samples to be assayed are available and the outcome for the patients is known. Indeed, a prognostic factor can only be evaluated in the absence of systemic therapy, or at least in the absence of any therapy with which it interacts. A predictive factor can only be evaluated in the context of an untreated control group, preferably one that is prospectively identified and followed, as in prospective randomized trials. It is not surprising that studies of a marker that might have both prognostic and predictive capabilities, especially if these effects are in opposition (as may be the case with erbB-2), will provide relatively random and conflicting results if not carefully planned with both appropriate consideration of treatment effects and selection of satisfactory control groups.
2.4 How should Tumor Markers be Selected for Clinical Use? Ideally, a specific therapy will benefit all those to whom it is administered, and no patient will be exposed to toxicity needlessly. In an imperfect world, however, only a fraction of patients who receive a given treatment will benefit, whereas all are at risk for the side effects. Although identification of favorable and poor-prognosis subgroups is important, simply having a poor prognosis is not justification for treatment. Indeed, many patients will have tumors that are already resistant to specific treatments. In this case, predictive factors will permit selection of those patients who will benefit from the specific therapy. Unfortunately, treatment for the other patients may not be available or as effective. Therefore, even though their prognosis may be relatively poor, it is unreasonable to expose them to toxicity with no benefit. Do prognostic and predictive factors exist that permit such elegant selection of patients for treatment? Sadly, in most solid tumors, the answer is no. For patients with newly diagnosed solid malignancies, no prognostic factors predict subsequent recurrence and death with absolute certainty. Therefore, when they are applied in the clinic, both physician and patient must accept some margin of error. These decisions involve a careful assessment of several issues: the degree of separation
31
in outcomes between groups of patients defined by the marker results (marker strength), the reliability of the estimate of this degree of separation (assay methodology and statistical analysis), the magnitude of effectiveness of therapy for the patient’s condition (proportional reduction in risk of events), the degree of toxicity of that therapy, and the patient’s willingness (as well as the caregiver’s and society’s) to either forego potential benefit to avoid toxicity or to accept toxicity and cost to gain benefit. Part of the art and science of medicine is to determine which markers are most reliable in separating groups of patients who will do well from those who will not, and who will benefit from therapy from those who will not. If done appropriately, tumor-marker analysis should permit delivery of therapy as efficiently as possible, providing benefit to the greatest number of patients while avoiding exposure to toxicities as much as possible.
2.5 Recommending Therapy: How Much Benefit is needed to Justify Treatment? With an estimate of the odds of an event in the absence of therapy (the patient’s prognosis), and an understanding of the proportional reduction in the odds of an event (such as recurrence or death) because of application of therapy (prediction that a specific therapy will work for a given patient), one can calculate an approximate absolute chance of that patient benefiting from the therapy. Again, adjuvant therapy for breast cancer provides a useful example. One might estimate, using standard prognostic factors, that in the absence of systemic therapy a patient has a relatively high (e.g., 60%) chance of recurrence and death over the succeeding 10–15 years after diagnosis. Using predictive factors, one can also estimate the proportional reduction in this chance of recurrence (e.g., 30%) when adjuvant systemic therapy is applied to a population of women with similar characteristics. In this case, a 30% proportional reduction of a 60% absolute risk reduces the odds of an incurable recurrence by 20%. Put another way, 20% of women who would have had recurrent disease if untreated will not as a result of treatment. In this example, the odds of being cured increase from 40% to 60%. Consider another example: the same patient has a favorable prognosis (e.g., a 10% chance of recurrence over 10–15 years) in the absence of systemic therapy. Applying a similar predictive factor profile, the same therapy will still result in a 30% proportional reduction in events. In this case, only 3% of patients will benefit, because 90% are cured by local therapy alone. In a third example, if the same patient has a 10% chance of recurrence, but the patient’s predictive marker profile suggests a 70% proportional reduction in recurrence or death, then the absolute benefit is 7%. If you were the first patient, would you undergo 3–6 months of chemotherapy for a 20% improvement in the chances of being alive and disease free for the next 10 years? If you were
32
N.L. Henry and D.F. Hayes
the second patient, would you agree to the same therapy for only a 3% improvement in survival? What if you had a favorable prognosis, but your chance of benefit was 7%? Several investigators have tried to address this subjective decisionmaking process with questionnaires that pose these dilemmas to respondents regarding adjuvant therapy for breast cancer [37–39]. Such studies are difficult to conduct, however, because an appropriately representative population is not readily identified. Unaffected subjects who are asked to serve as surrogates may not have the same perceptions as they might have if truly afflicted with the disease. Patients who must actually decide are often anxious and unsure, and their hypothetical answers may not reflect their true actions. Survivors who are separated in time from the point of making their decision may have considerable cognitive bias, because they may be more willing to accept the therapy that they perceive has led to their current state of well-being. Nonetheless, these studies have demonstrated remarkably similar and striking conclusions. For example, in one study, previously treated survivors were asked if they would reaccept adjuvant chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil [CMF]) for 6 months, placed in the context of various prognostic scenarios [37]. As expected, most patients stated that would take therapy again when the gains were large (> 10% absolute benefit), and a decreasing fraction would be willing to do so as potential gains diminished. More than 50% said they would undergo chemotherapy for gains as small as 3–5%, and nearly 50% would be willing to accept therapy for as little as a 1% absolute improvement in outcome (Fig. 2-3) [37]. Nonetheless, given that a substantial proportion of patients would not accept therapy for an absolute benefit < 10%, accurate assessments of prognosis and prediction are essential. Similar scenarios can be generated for nearly all medical decision-making situations, assuming that the odds of event
occurrence, the proportional odds of reduction of the event, and the toxicities are well established. Computer models to help breast cancer patients estimate their absolute risks and benefits are now available on the World Wide Web [40–42].
2.6 How Can the Relative Strength of a Prognostic Factor be Determined? Prognostic and predictive factors can be placed into categories based on their relative strengths to divide a single population into two or more subgroups that have distinct outcomes (Figs. 2-4A and 2-4B) [43]. Let us consider 2 prognostic factors (Fig. 2-4A). One factor separates the population very strongly, so that factor-negative patients are very likely to be cured by A
PURE PROGNOSTIC FACTOR (Unfavorable) 100% cure
P r o g n o s i s
Factor 1 Neg
p<0.05
Factor 2 Neg 50% cure
10% cure
Factor 2 Pos
Factor 1 Pos No Therapy
Therapy
PURE PREDICTIVE FACTOR (For Sensitivity to Therapy)
B
100 100% cure P r o g n o s i s
% 50
0 1
?
2
3
5 10 ? 15 ? Scenario: % extra survival
25
Fig. 2-3. Fraction of patients with breast cancer who would accept 6 months of adjuvant chemotherapy according to added survival benefit. Previously treated breast cancer survivors were queried regarding whether they would be willing to be retreated with 6 months of adjuvant chemotherapy (cyclophosphamide, methotrexate, 5-fluorouracil) for different scenarios regarding added survival benefits. (Modified from reference 37 with permission.) Question marks represent different “cutoffs” that might be used to select therapy or not.
Factor 1 Pos p<0.05
50% cure
Factor 2 Pos Factor 2 Neg 10% cure
Factor 1 Neg No Therapy
Therapy
Fig. 2-4. Relative strengths of prognostic and predictive factors. A Relative strength of pure prognostic factor. B Relative strength of pure predictive factor. Factor 1 (—) is a strong factor while Factor 2 (— • — • —) is a relatively weak factor. Both factors reliably separate the population into 2 distinct groups not because of chance alone (p < 0.05).
2. Clinical Importance of Prognostic Factors: Moving from Scientifically Interesting to Clinically Useful
local therapy alone and factor-positive patients have a very poor prognosis. If effective therapy is available, a sufficient number of factor-positive patients will benefit so that most patients in that population will accept the therapy and its toxicities. The second factor may also reliably separate 2 groups of patients, with 1 group having a statistically significantly more favorable outcome than the other, but not by much. If effective therapy is available, a similar number of patients will benefit in both the negative and positive groups, exceeding the cutoff required for acceptance of therapy as described earlier. Thus, the clinician would likely use the first factor to help make decisions. Although recognition of the second factor might provide insight into the biology of the disease, it would not have clinical use. One can analyze predictive factors similarly (Fig. 2-4B). A strong predictive factor provides an indication that the therapy is so effective in factor-positive patients and unlikely to be very effective in factor-negative patients that, if the prognosis warrants therapy at all, the two groups of patients would be treated differently. By contrast, a weak predictive factor may provide an indication that factor-positive patients are a little more likely than factor-negative patients to benefit. The p-value suggests that the difference in efficacy between factor-positive and factor-negative patients is unlikely to be because of chance alone, but that the benefit for the factornegative patients is still likely sufficient to justify exposure to the therapy. For patients with newly diagnosed breast cancer, we have proposed 3 arbitrary categories for both prognostic and predictive factors, based on relative strengths: weak, moderate, and strong [43–45]. Let us assume that one can place a patient into 1 of 3 prognostic categories that fundamentally affects how he or she is treated. Patients with a very good prognosis might not accept any therapy, patients with a modest prognosis might accept some therapy, and those with a poor prognosis would be willing (assuming that effective therapy is available) to accept even more therapy or therapy with more toxicity (Fig. 2-5). A strong prognostic factor is one that moves a patient across 2 of these arbitrary prognostic categories, e.g., from very good to poor (Fig. 2-5). A modestly strong prognostic factor moves a patient less far. A weak factor may improve or worsen a patient’s prognosis, but by so little that it is clinically meaningless. These arbitrary categories will differ depending on the disease, the setting, and the investigator/clinician and the patient. Again, using breast cancer as an example, we have proposed that breast cancer prognostic factors that divide the population into subgroups that differ in outcomes (risk of recurrence over 6–10 years) by twofold or more are considered strong. Good examples of strong prognostic factors include clinical stage, pathologic identification of involved axillary lymph nodes, and estimation of tumor size. Prognostic factors that divide the population into subgroups that differ by 1.5- to 2-fold are considered moderately strong. These include tumor grade and perhaps levels of cellular proliferation. Weak prognostic factors divide
33
PROGNOSTIC FACTOR Strong Poor
Modest
Very Good
Modest
Weak
50-100%
10-50%
<10%
PROGNOSIS (Odds of Dying at Ten Years if No Adj Sys Rx) Fig. 2-5. Schematic model of relative strengths of strong, modest and weak prognostic factors. A strong prognostic factor moves patients across several prognostic categories. A modest prognostic factor might move a patient across 1 category whereas the weak prognostic factor does not move a patient outside of his/her original prognostic category. Prognostic categories are arbitrarily assigned. (Modified from Isaacs C, Stearns V, Hayes DF. New prognostic factors for breast cancer recurrence. Semin Oncol. 2001;28:53–67. With permission.)
the population into subgroups with outcomes that differ by 1- to 1.5-fold, and include estimates of ER expression and possibly erbB-2 overexpression or amplification or both. Likewise, one can also estimate the relative strengths of predictive factors. The strength of a predictive factor is best determined in the context of a prospective clinical trial in which patients are assigned randomly to the treatment of interest or not. The ratio of the likelihood that a factor-positive patient will benefit from treatment compared with a factornegative patient has been designated the relative predictive value (RPV) [46]. Estimations of the RPV are illustrated in Fig. 2-6 in which the risk of recurrence for treated patients is compared with the risk for untreated patients for each predictive factor category. As with prognostic factors, 3 categories of predictive factors have been proposed, based on RPV. For breast cancer, it is proposed that weak, moderate, and strong predictive factors have RPV of < 2-, 2- to 4-, and > 4-fold, respectively. The best example of a strong predictive value is ER for tamoxifen, with an RPV > 8-fold [10]. It also appears that erbB-2 amplification is a very strong predictor for benefit from trastuzumab, as has been demonstrated in both the metastatic and adjuvant settings [32, 34, 35, 47]. An additional concept in this discussion is the issue of residual risk after a selected course of therapy (Fig. 2-7). If multiple therapies are available, some patients may only need one to achieve a prognosis sufficient to avoid further or more therapy, whereas others may benefit from additional or more aggressive or more toxic approaches. The residual risk is a function of both original prognosis and the relative benefit from specific therapies. A group of patients may have an original
34
N.L. Henry and D.F. Hayes
Determining Relative Strength of Predictive Factors Therapy Better
Relative Predictive Value= RPV (pos)/RPV (neg)
Weak negative positive Moderate negative positive Strong negative positive 0.60
0.70
0.2/0.1 =
2
0.25/0.08 =
3.125
0.4/0.05 =
8
0.80 0.90 1.0
Relative Risk of Recurrence (Rx vs. No Rx)
Fig. 2-6. Schematic model for relative strengths of predictive factors. The relative benefit between groups of patients who are positive (solid bar) or negative (shaded bar) for the predictive factor are indicated. The difference in outcome, charted as proportional reduction in the odds of recurrence for treated versus untreated patients, is relatively small for groups of patients that are separated by a weak predictive factor. This difference becomes larger for those separated by a moderate predictive factor and is quite large for those treated by a strong predictive factor. The solid vertical line (unity) denotes no difference in recurrence between treated patients and untreated patients. (Modified from Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia. 2001;6:375–392. With permission.) RESIDUAL RISK 100% cure P r o g n o s i s
Factor 1 Neg
Would not give CTX even if available 10% cure
Would give CTX if available
Would not give more CTX even if available
Would give more CTX if available Factor 1 Pos
No Therapy
Therapy
Fig. 2-7. Schematic illustration of residual risk. See text and Figs. 2-2 and 2-4 for details of graphic. (—) = patients with little residual risk. (......) = patients with substantial residual risk. CTX: chemotherapy.
prognosis that is sufficiently poor to justify an initial therapeutic regimen. Some may respond so well and benefit so much that their post-treatment prognosis is so favorable that they would elect not to receive more treatment. Other patients might benefit less from the first approach. If further therapy is known to provide additional benefit sufficient to outweigh the risks, then these patients might accept it. Residual risk might
be estimated at baseline, before any therapy is given, using initial prognostic and/or predictive factors, as illustrated in the poor prognosis category in Fig. 2-5. For example, patients with node-positive breast cancer might be more willing to accept the increased toxicities of more therapy, such as addition of a taxane to treatment with doxorubicin and cyclophosphamide (AC), than patients with node-negative disease. Residual risk might better be assessed at the completion of the initial therapy, however, if markers are available that suggest residual disease burden exists. For example, recent studies of neoadjuvant therapy for breast cancer may permit clinicians to estimate the residual risk for patients after several rounds of chemotherapy (e.g., 4 cycles of preoperative AC) based on the presence or absence of residual invasive cancer in the operative specimen [48]. Because it has been established that these patients have a relatively poor prognosis, ongoing studies have been designed to determine whether these patients benefit from additional chemotherapy.
2.7 How Reliable are the Estimates of Relative Strengths of Tumor Markers? If clinicians use tumor markers to help patients avoid toxicities of therapy while still optimizing benefit, then they must be relatively confident of the estimates they have provided to patients. Clinical investigations of new cancer agents are carefully planned, using criteria and terminology that are generally agreed upon by most clinical scientists [49]. For example, new drugs are sequentially passed through phase 1, 2, and 3 studies, in which toxicity and dose, efficacy, and definitive use are determined, respectively. In these studies, scales have been developed to describe toxicities, responses, and overall outcomes. Such trials are prospectively planned, with detailed descriptions of the number and types of patients to be studied, how they will be treated, and how the statistical analysis will be performed. Indeed, these rules have been established so that the results of clinical studies approach the same veracity as those from laboratory investigations, in which variables and proper controls can be rigorously defined. Clinical studies that are not so rigorously defined, such as retrospective reviews of clinical experiences, may help generate hypotheses, but are rarely accepted as definitive. In the past, no such consensus system has existed to study tumor markers. More commonly, marker studies are performed using retrospectively available samples from patients treated in a nonuniform manner. Hypotheses are often generated after the data are analyzed, and then presented as fact. Even when multiple studies evaluating the same hypothesis are performed, the populations studied are often heterogenous and the methods often vary among investigators, which can be a source of bias, leading to invalid results, and the bias is frequently unrecognized [50]. Furthermore, negative
2. Clinical Importance of Prognostic Factors: Moving from Scientifically Interesting to Clinically Useful Table 2-2. Potential uses of tumor markers.
LIFE CYCLE OF A TUMOR MARKER
• Determination of Risk • Screening • Differential Diagnosis Benign vs Malignant Known Malignant: Tissue of Origin • Prognosis • Prediction • Monitoring Disease Course Detect Recurrence in Patient Free of Obvious Disease Patient with Established Recurrence
.
Positive Effect Benefit Neutral (RR=1)
First Paper
Second Third & Subsequent Paper Papers
35
Ultimate Estimate of RR (or Predictive Value)
Fig. 2-8. Hypothetical life cycle of a tumor marker.
results are usually not submitted for publication (unless to refute the results of a competing laboratory). It is not surprising that most tumor markers proceed through a typical life cycle before the true use is accepted or discarded (Fig. 2-8). In fact, progression through such a life cycle is common for new therapeutic ideas as well, but because the rules are better established the time required to reach consensus may be considerably shorter. We now return to the original TMUGS proposal [51]. Determination of relative strengths is only as good as the studies in which they are analyzed. In this regard, the relative quality of the studies is essential in reaching consensus about the strength of the marker. TMUGS was proposed to shorten the life cycle of tumor-marker analysis. One component of
TMUGS is the importance of a precise description of the tumor marker and the assays used to detect it. Tumor markers can be used for multiple purposes, ranging from screening for disease to monitoring progression (Table 2-2). A semiquantitative scale, which ranges from 0 to 3+, was developed to grade the clinical use of a tumor marker for any specific use (Table 2-3). For example, to assess whether a marker should be used to determine prognosis, users are urged to assign a score based on their interpretation of the available published data. A grade of 0 implies that sufficient data exist to conclude that the marker has no utility, whereas a grade of 2+ or 3+ implies that the marker should be considered or that it absolutely should be used, respectively, in routine clinical practice. More importantly, users are encouraged to support their evaluation by determining the level of evidence (LOE) on which their decision is based (Table 2-4). LOE I data are generated either from a prospective, highly powered study that specifically addresses the issue of tumor-marker use or from an overview or meta-analysis of studies, each of which
Table 2-3. Scale to evaluate use of tumor markers for favorable clinical outcomes. Use scale 0 NA +/−
+
Explanation of scale Marker has been adequately evaluated for a specific use and the data definitively demonstrate it has no use. The marker should not be ordered for that clinical use. Data are not available for the marker for that use because marker has not been studied for that clinical use. Data are suggestive that the marker may correlate with biological process and/or endpoint, and preliminary data suggest that use of the marker may contribute to favorable clinical outcome, but more definitive studies are required. Thus, the marker is still considered highly investigational and should not be used for standard clinical practice. Sufficient data are available to demonstrate that the marker correlates with the biological process and/or endpoint related to the use, and that the marker results might affect favorable clinical outcome for that use. However, the marker is still considered investigational and should not be used for standard clinical practice, for 1 of 3 reasons: 1. The marker correlates with another marker or test that has been established to have clinical use, but the new marker has not been shown to clearly provide any advantage. 2. The marker may contribute independent information, but it is unclear whether that information provides clinical use because treatment options have not been shown to change outcome. 3. Preliminary data for the marker are quite encouraging, but the level of evidence (see below) is lacking to document clinical use.
++
+++
Marker supplies information not otherwise available from other measures that is helpful to the clinician in decision making for that use, but the marker cannot be used as sole criterion for decision-making. Thus, marker has clinical utility, and it should be considered standard practice in selected situations. Marker can be used as the sole criterion for clinical decision making in that use. Thus, marker has clinical utility, and it should be considered standard practice.
From Hayes DF, Bast R, Desch CE, et al. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456–1466.
36
N.L. Henry and D.F. Hayes
Table 2.4. Levels of evidence for grading clinical use of tumor markers. Level I
II
III
IV V
Type of evidence Evidence from a single high-powered prospective study that is specifically designed to test marker or evidence from meta-analysis and/or overview of level of evidence II or III studies. In the former case, the study must be designed so that therapy and follow-up are dictated by protocol. Ideally, the study is a prospective randomized trial in which diagnostic and/or therapeutic clinical decisions in one group are determined based at least in part on marker results, and diagnostic and/or therapeutic clinical decisions in control group are made independently of marker results. However, may also include prospective but not randomized trials with marker data and clinical outcome as primary objective. Evidence from study in which marker data are determined in relationship to prospective therapeutic trial that is performed to test therapeutic hypothesis but not specifically designed to test marker use (i.e., marker study is secondary objective of protocol). However, specimen collection for marker study and statistical analysis are prospectively determined in protocol as secondary objectives. Evidence from large but retrospective studies from which variable numbers of samples are available or selected. Therapeutic aspects and follow-up of patient population may or may not have been prospectively dictated. Statistical analysis for tumor marker was not dictated prospectively at time of therapeutic trial design. Evidence from small retrospective studies which do not have prospectively dictated therapy, follow-up, specimen selection, or statistical analysis. May be matched case controls, etc. Evidence from small pilot studies designed to determine or estimate distribution of marker levels in sample population. May include “correlation” with other known or investigational markers of outcome, but not designed to determine clinical use.
From Hayes DF, Bast R, Desch CE, et al. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456–1466.
provides lower LOE. LOE II data are derived from companion studies in which specimens are collected prospectively as part of a therapeutic clinical trial, with pre-established endpoints and statistical evaluation for the marker as well as for the therapeutic intervention. Commonly, an early LOE III study will report an extraordinary difference between 2 groups delineated by a given tumor marker analysis (Fig. 2-8). Results from subsequent studies are often more inconsistent. Therefore, we have proposed that the relative strength of a marker for clinical utilities should only be determined within the context of LOE I (or at worse LOE II) studies. In these studies, the marker is the primary objective of a well-designed, highly powered, hypothesis-driven prospective clinical trial, or it is the objective of a statistically rigorous overview of LOE II or III studies or both. Furthermore, the strength of new prognostic or predictive factors can only be estimated by multivariate analytical methods, including pre-existing, accepted factors such as TNM staging and histopathology. It is possible that a marker may be quite prognostic or predictive when considered in a univariate fashion, but that it in fact is only reflecting information already achieved through other, established methods. In this case, acceptance of the new marker would only occur if it can be performed more easily, reliably, or less expensively. Unfortunately, most tumor-marker studies are LOE III, in which specimens happen to have been collected for a variety of reasons and are available for testing a given assay. In general, the authors of TMUGS suggested that results from LOE I studies are preferred to assign clinical use to a marker. Use of a system such as TMUGS to rigorously assess the reliability of assessment of the relative strengths of prognostic and predictive factors will substantially strengthen the clinicians’ confidence as they counsel their patients.
2.8 How Can the Relative Strengths of Prognostic and Predictive Factors be Applied Clinically? Outside a clinical trial, there is little value in determining that a patient has a poor prognosis unless therapy is available to change that prognosis. Moreover, if the patient or physician is unwilling to give up any benefit, regardless of how small and despite the risks, application of tumor markers is unnecessary unless the results are 100% accurate. Likewise, if the patient is unwilling to accept any therapy regardless of how large the benefit or how well tolerated the treatment, there is no point in applying tumor-marker data. In most cases, the patient and physician wish to apply therapy relatively efficiently. In this case, if the patient can judge how much benefit he or she is willing to forfeit to avoid toxicities, one can construct a model in which 1 marker might be used in some situations but not others [51]. Again, the example of application of adjuvant systemic therapy for patients with newly diagnosed breast cancer is used (Fig. 2-9). In this example, the following assumptions have been made: ●
●
●
Patients can be placed into 1 of the 3 prognostic categories based on the odds of systemic recurrence and death during the subsequent 10 years after diagnosis and local treatment in the absence of systemic therapy: very good (< 10% chance recurrence/death); moderate (10–50%); and poor (>50%); Patients would accept tamoxifen or an aromatase inhibitor for a small benefit (although not for no benefit at all), but that they would accept chemotherapy for only a 4% or higher absolute benefit; ER is a very strong predictive factor, such that tamoxifen and aromatase inhibitors proportionally decrease odds of
2. Clinical Importance of Prognostic Factors: Moving from Scientifically Interesting to Clinically Useful
Clinical Use of Prognostic and Predictive Factors
Clinical Use of Prognostic and Predictive Factors
PROGNOSIS
(Odds of Recurrence or Death at 10 Years if No Adj Sys Rx)
Poor
50-100%
PROGNOSIS 45 Year old woman with newly diagnosed breast cancer
(Odds of Recurrence or Deathat 10 Years if No Adj Sys Rx)
Very Good
40 Year old woman with newly diagnosed breast cancer
X
X
X Modest
37
X
10-50%
X
<10% ACx4 Pacl x 4
X
<10%
Very Good 4 + LN ERerbB2+
X
10-50%
Modest
Her x1y
2 +L N ER+ erbB2-
Tam
ACx4
X Pacl x4
Clinical Use of Prognostic and Predictive Factors PROGNOSIS (Odds of Recurrence or Death at 10 Years if No Adj Sys Rx)
Modest
Very Good
10-50%
65 Year old woman with newly diagnosed breast cancer
X
<10% 2cm Neg Nodes ER +
X Tam
X CTX
Fig. 2-9. Schematic illustration of use of prognostic and predictive factors to select appropriate treatments for individual patients with breast cancer (see text for details). CTX chemotherapy; Her trastuzumab; LN lymph node; Pacl paclitaxel; Tam tamoxifen.
●
●
recurrence by 40–45% in ER-positive patients and not at all in ER-negative patients [10, 15]; Different chemotherapy regimens can be applied in sequence with increasing benefits and toxicities, depending on predictive factors; and erbB-2 is strongly predictive for response to trastuzumab, resulting in approximately a 50% improvement in recurrence rate in women whose tumors overamplify erbB-2 [34, 35].
For example, 4 cycles of AC might proportionally decrease odds of recurrence by 33% in younger women (aged < 50 years), but by only 20% in older women (aged 50–69 years) [12]. We will also assume that 4 additional cycles of a taxane, such as paclitaxel, decrease the odds of recurrence proportionally by a further 20% in ER-negative patients, but perhaps not at all in ER-positive patients [52]. (Note: All of these assumptions are approximate estimates based on annual reduction of odds of recurrence calculations).
Figure 2-9 provides examples of how the combination of prognostic and predictive factors might be used. First, let us consider a 45-year-old patient with a 4-cm, poorly differentiated ER-negative, erbB-2 positive breast cancer with 4 of 10 involved axillary lymph nodes (Fig. 2-9A). This patient’s initial prognosis is poor. In the absence of systemic therapy, one might expect 60–70% of such patients to have a recurrence within the next 10 years. Endocrine therapy would not be expected to provide any benefit, and therefore would not be indicated. Four cycles of AC, with a proportional reduction of 33%, would prevent recurrence in 20–25% of patients, therefore reducing her absolute risk to approximately 50%. Four cycles of paclitaxel would be expected to further reduce her odds of recurrence proportionally by 20–30%, therefore reducing her absolute risk an additional 10–15%, to 35– 40%. Finally, 1 year of trastuzumab, started concurrently with paclitaxel therapy, would decrease her odds of recur-
38
rence proportionally by 50%, decreasing her absolute risk to approximately 20%, only one third of what her overall chance of recurrence was. In this case, most clinicians and patients would agree that the combination of chemotherapy and targeted therapy with trastuzumab is indicated. Next, consider a 40-year-old premenopausal woman with ER-positive breast cancer who has 2 positive axillary lymph nodes (Fig. 2-9B). In this case, in the absence of systemic therapy, one might estimate that her odds of recurrence over the next 10 years are approximately 50%. This patient would almost certainly find tamoxifen an acceptable adjuvant therapy, but would not be eligible for treatment with aromatase inhibitors because she is premenopausal. A proportional reduction of 40% would result in approximately 15–20 patients who would not have a recurrence, considerably exceeding the cutoff required for recommendation of the strategy. Even if the patient takes tamoxifen, however, her residual risk of recurrence over 10 years remains approximately 20–25%, still in the “moderate risk” category. Chemotherapy would result in an approximately 20–30% reduction of this 25% risk, and therefore approximately 5–7 additional patients would be alive and disease free because of the application of adjuvant AC. It would thus be reasonable to recommend 4 cycles of AC to this patient. Should this patient also receive 4 additional cycles of adjuvant paclitaxel? The answer depends on our confidence in the available data. Multiple prospective randomized clinical trials performed in the United States have addressed the use of sequential taxanes in this setting, but different dosing regimens and patient populations were evaluated. Two trials suggested that the addition of 4 cycles of paclitaxel after AC proportionally reduced the odds of recurrence and death by approximately 20% [52, 53]. An unplanned retrospective subset analysis of one of the trials suggested that this benefit was almost entirely confined to the ER-negative subgroup [54]. A third study compared AC plus 5-fluorouracil (FAC) with AC plus docetaxel (TAC), and found a 28% relative decrease in the risk of recurrence with the addition of the taxane. Other studies of taxanes have yielded contradictory or inconclusive information, however. Should the clinician wait for more mature data, probably pooled in a meta-analysis, before making decisions regarding this extra therapy? In this example, let us accept the data supporting the use of paclitaxel after AC. Furthermore, let us assume that all patients will have a further proportional reduction in recurrence of 20%, regardless of ER status. This patient’s residual risk of recurrence after tamoxifen and 4 cycles of AC is approximately 20% (Fig. 2-9B). A 20% proportional reduction of a 20% risk would result in a further absolute benefit of approximately 4% reduction of recurrence. Does this justify the therapy? This absolute benefit straddles the cut-off to treat or not, and the patient and her physician must discuss this issue carefully. Finally, consider a postmenopausal 65-year-old woman with a 2-cm, moderately differentiated ER positive breast
N.L. Henry and D.F. Hayes
cancer with no detectable axillary nodal involvement (Fig. 2-9C). In the absence of systemic therapy, her overall odds of recurrence over the next 10 years are approximately 20%. Therefore, she has an 80% chance of having been cured by local therapy alone. An aromatase inhibitor will proportionally reduce these chances by approximately 40%. Thus, for every 100 patients who are treated in this situation, 80 patients cannot benefit because they will not recur. Of the 20 patients who were destined to recur, 8 patients will not because of aromatase inhibitor therapy. Because aromatase inhibitors are relatively well tolerated, this percentage of absolute benefit exceeds our cut-off for recommending therapy, and most patients would accept it, resulting in an improvement of their expected cure rate from 80% to approximately 88%. Our assumptions suggest that chemotherapy would result in a further 20% proportional reduction in the risk of recurrence over 10 years for this group of patients. With aromatase inhibitor treatment, this patient has a residual recurrence risk of 12%. A proportional reduction by 20% of this risk represents 2–3 of 100 patients who might benefit. This number is below the cut-off that most, but not all, patients and clinicians consider worthwhile, especially given the toxicities of chemotherapy. However, some patients in this group are likely to have a difficult decision regarding whether or not to undergo chemotherapy. A promising new tool to determine prognosis has been developed for patients such as the one presented here, who have ER-positive, node-negative breast cancer. OncotypeDX is a multigene assay performed on fixed tumor tissue that is used to divide patients into 3 categories based on likelihood of disease recurrence (low, intermediate, and high) [55]. OncotypeDX is being evaluated as a predictive factor. Initial studies suggest that patients in the high-risk group are likely to benefit from chemotherapy, whereas those in the low-risk group are not [56]. It remains unclear how best to treat those in the intermediate group, however, and therefore a prospective, randomized clinical trial, designated TAILORx, has been recently opened. TAILORx will randomly assign patients in the intermediate group to chemotherapy plus endocrine therapy versus endocrine therapy alone. TAILORx and other LOE I trials may enable physicians and patients to make more informed decisions regarding the clinical use of new markers.
2.9 Are There Solid Tumor Markers that Fulfill the TMUGS Criteria for Routine Clinical Use? The previous examples regarding breast cancer illustrate how prognostic and predictive markers might be used to tailor patient care in the adjuvant setting. In all malignancies, markers might be used in one of several different situations
2. Clinical Importance of Prognostic Factors: Moving from Scientifically Interesting to Clinically Useful
(determination of risk, screening, differential diagnosis, prognosis, prediction, monitoring disease course) (Table 2-2) [5]. Different markers may perform differently in each situation for each disease (e.g., colon vs breast vs lung cancer). In general, the TNM staging system has been well accepted for prognosis for most if not all solid tumors [18]. The ASCO Guidelines Panel has made specific recommendations for breast and colon cancer based on data that they believe met criteria consistent with TMUGS (Table 2-1) [1–3]. In addition to those that have gained acceptance, newer assays such as OncotypeDX are being considered to determine if there is sufficient evidence to support routine use for prediction or prognosis or both. Few if any prognostic or predictive factors have been accepted for the other common solid malignancies, such as prostate, lung, and ovarian cancers [57–59]. For each, the TNM and grading scales are reliably prognostic. Serial circulating prostate specific antigen levels and CA125 levels are helpful in monitoring patients with prostate and ovarian cancers, respectively [58, 60]. For most solid tumors, however, better markers that have been well characterized using results from carefully designed and well performed studies are urgently needed.
2.10
Summary
In summary, the phrase “many are called, few are chosen” seems to reflect the current state of the art regarding tumor marker analysis in solid tumors. However, the field is evolving rapidly, with a convergence of molecular biology and technology and understanding of clinical trial design and analysis. Several of the large cooperative trialists groups have established separate correlative/biologic committees that are charged with designing hypothesis-driven LOE I and II studies, based on results from pilot studies. The emergence of erbB-2 in breast cancer as a predictive factor, in a manner similar to ER, may serve as a model of directed studies that lead to determination of the relative strength of the marker, and assignment of a TMUGS score that indicates whether or not it should be used clinically. In an attempt to standardize reporting of tumor-marker studies, and to guide design of the trials, the National Cancer Institute – European Organization for Research and Treatment of Cancer published REporting recommendations for tumor MARKer prognostic studies (REMARK) [6]. These guidelines outline concepts that should be considered when developing clinical studies, such as prospectively defining the question being addressed, choosing an appropriate patient population, determining endpoints, and identifying potential sources of bias. We hope that careful and thoughtful consideration of study design, such as is delineated in TMUGS and the REMARK guidelines, will considerably shorten the life cycle required to bring a tumor marker from the laboratory to the clinic.
39
References 1. ASCO Expert Panel. Clinical Practice Guidelines for the Use of Tumor Markers in Breast and Colorectal Cancer: Report of the American Society of Clinical Oncology Expert Panel. J Clin Oncol. 1996;14:2843–2877. 2. ASCO Expert Panel. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol. 1998;16:793–795. 3. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19:1865–1878. 4. Bast RC Jr., Ravdin P, Hayes DF, et al. Errata:2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:4185–4188. 5. Hayes DF, Bast R, Desch CE, et al. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456–1466. 6. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067–9072. 7. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet. 2000;355:1822. 8. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–1792. 9. Early Breast Cancer Trialists Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet. 1996;348:1189–1196. 10. Early Breast Cancer Trialist’s Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet. 1998;351:1451–1467. 11. Early Breast Cancer Trialist’s Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet. 1998;352:930–942. 12. Early Breast Cancer Trialist’s Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–1717. 13. Ellis M, Hayes DF, Lippman ME. Treatment of metastatic disease. In: Harris J, Lippman M, Morrow M, Osborne CK, eds. Diseases of the breast. 2nd ed. Philadelphia: Lippincott-Raven; 2000:749–798. 14. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–1388. 15. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol. 2005;23:619–629. 16. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med. 1992;326:1756–1761. 17. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst. 1993;85:1206–1219.
40 18. AJCC. Cancer staging manual. In: Greene FL, Page DL, Fleming I, et al., eds. American Joint Committee on Cancer, Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002. 19. Osborne CK. Receptors. In: Harris J, Hellman S, Henderson I, Kinne D, eds. Breast diseases. 2nd ed. Philadelphia: J.B. Lippincott; 1991:301–325. 20. Trock B, Leonessa F, Clarke R. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst. 1997;89:917–931. 21. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–484. 22. Fisher B, Redmond C, Dimitrov N, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med. 1989;320:473–478. 23. Ravdin PM. Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol 1999;26(4 Suppl 12):117–123. 24. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894–2904. 25. Hayes DF. Tumor markers for breast cancer. Ann Oncol. 1993;4:807–819. 26. Trock BJ, Yamauchi H, Brotzman M, Stearns V, Hayes DF. c-erbB-2 as a prognostic factor in breast cancer: A meta-analysis. Proc Am Soc Clin Oncol. 2000;372:97. 27. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808–3816. 28. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334–2356. 29. Muss HB, Thor A, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260–1266. 30. Thor A, Berry D, Budman D, et al. erbB2, p53, and adjuvant therapy interactions in node positive breast cancer. J Natl Cancer Inst. 1998;90:1346–1360. 31. Pritchard KI, Shepherd LE, O’Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med, 2006;354:2103–2111. 32. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. 33. Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol. 2000;27(6 Suppl 11):46–52; discussion 92–100. 34. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672. 35. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684.
N.L. Henry and D.F. Hayes 36. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–820. 37. Coates AS, Simes RJ. Patient assessment of adjuvant treatment in operable breast cancer. In: Williams CJ, ed. Introducing new treatments for cancer: Practical, ethical, and legal problems. New York, NY: John Wiley; 1992:447–458. 38. Ravdin P, Siminoff I, Harvey J. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol. 1998;16:515–521. 39. Lindley C, Vasa S, Sawyer T, Winer E. Quality of life and preferences for treatment following systemic adjuvant therapy for early stage breast cancer. J Clin Oncol. 1998;16:1380–1387. 40. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980–991. 41. Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol. 2001;19:972–999. 42. Whelan TJ, Loprinzi C. Physician/patient decision aids for adjuvant therapy. J Clin Oncol. 2005;23:1627–1630. 43. Hayes DF, Trock B, Harris A. Assessing the clinical impact of prognostic factors: When is “statistically significant” clinically useful? Breast Cancer Res Treat. 1998;52:305–319. 44. Isaacs C, Stearns V, Hayes DF. New prognostic factors for breast cancer recurrence. Semin Oncol. 2001;28:53–67. 45. Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: Current and new predictors of metastasis. J Mammary Gland Biol Neoplasia. 2001;6:375–392. 46. Hayes DF. Do we need prognostic factors in nodal-negative breast cancer? Arbiter. Eur J Cancer. 2000;36:302–306. 47. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6:240–246. 48. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685. 49. Simon R. Design and analysis of clinical trials. In: DeVita J, VT, Hellman S, Rosenberg S, eds. Cancer: Principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001:521–538. 50. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer, 2005;5: 142–149. 51. Hayes DF. Determination of clinical utility of tumor markers: a tumor marker utility grading system. Recent Results Cancer Res. 1998;152:71–85. 52. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer. J Clin Oncol. 2003;21:976–983. 53. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686–3696. 54. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295:1658–1667. 55. Paik S, Shak S, Tang G, et al. A multi-gene RT-PCR assay using fixed, paraffin-embedded tumor tissue to predict the
2. Clinical Importance of Prognostic Factors: Moving from Scientifically Interesting to Clinically Useful likelihood of breast cancer recurrence in node negative, estrogen receptor positive, tamoxifen-treated patients. N Engl J Med. 2004;351:2817–2826. 56. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol. 2006;24:3726–3734. 57. Strauss GM, Skarin AT. Use of tumor markers in lung cancer. In: Hayes DF, ed. Hematology/oncology clinics of North America: Tumor markers in adult solid malignancies. Philadelphia: WB Saunders; 1994:507–532.
41
58. Kantoff PW, Talcott JA. The prostate specific antigen: Its use as a tumor marker for prostate cancer. In: Hayes DF, ed. Hematology/oncology clinics of North America: Tumor markers in adult solid malignancies. Philadelphia: WB Saunders; 1994:555–572. 59. Ozols R, Schwartz P, Eifel P. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinma. In: DeVita V, Hellman S, Rosenburg S, eds. Cancer: Principles and practice of oncology. 5th ed. Philadelphia, New York: Lippincott-Raven; 1997:1502–1539. 60. Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem. 1998;44:1379–1380.
Chapter 3 Genetic Markers in Sporadic Tumors Elena Tamborini, Federica Perrone, Milo Frattini, Tiziana Negri, Antonella Aiello, Annunziata Gloghini, Antonino Carbone, Silvana Pilotti, and Marco A. Pierotti
3.1
Introduction
The rate of mortality from cancer changed very little over the past 50 years; however, during the past decade, perceptions about this situation have changed rapidly, primarily because the description of cancer in molecular terms has significantly improved the ways in which human cancers are detected (often in early stages), classified, monitored and, more importantly, treated. As a consequence, we are witnessing the start of a new exciting era in cancer research. A milestone has been the formalization of the concept that cancer is a genetic disease. This concept, however, lumps together two types of genetic diseases with the same outcome: the first linked to an entirely somatic cell–gene deregulation and the second linked to genetic susceptibility. At the somatic cell level, deregulation of cancer genes that control the careful balance between increase in cell number and withdrawal from the cell cycle promotes neoplastic growth by disrupting this balance, which occurs as a result of circumvention of the apoptotic machinery, promotion of cell division and cell proliferation, loss of cell differentiation pathways, and disruption of cell–cell communication and interaction. Thus, cancer represents the endpoint of a multistep process involving cancer genes and stimulatory and inhibitory signals provided by and controlled by products of the cancer genes. An additional feature of the cancer phenotype is the capability of cancer cells to modify their environment. This concept includes the promotion of angiogenesis, the degradation of stroma organization, and the production of factors related to inflammatory processes. In the first type of genetic disease, alterations in cancer genes can involve either dominant, gain-of-function mutations within proto-oncogenes that result in abnormal positive signals for cell proliferation or recessive, loss-of-function mutations within the tumor suppressor genes (TSG) that interfere with the negative regulation of cell growth. Mutations within TSG also may have a dominant-negative effect,
From: Principles of Molecular Oncology, Third Edition Edited by: Miguel H. Bronchud et al. © Humana Press Inc., Totowa, NJ
one in which an altered protein is produced that competes with its wild-type counterpart and prevents its activity. Mutant versions of TSG TP53 provide an example of such a mechanism. A third type of cancer gene has been identified in colorectal tumors associated with hereditary nonpolyposis colorectal cancer (HNPCC). These genes control mismatch repair (MMR), a process associated with the fidelity of DNA replication, and have been designated mutator genes. Their alterations cause microsatellite instability (MSI), characterized by random contractions or expansions in the length of simple sequence repeats (SSR) or microsatellites, and may have important prognostic implications. The second type of genetic disease is based on the recognition of a genetic susceptibility in approximately 8–10% of patients with cancer. This latter disease results from the inheritance of altered alleles of genes, which are almost always TSG. With few relevant exceptions, such as RET proto-oncogene mutated in familiar medullary thyroid carcinomas and in tumors included in multiple neoplasia type-2 syndromes. Along with different penetrance, this tumor-suppressor type determines the genetic risk of cancer, which can be almost 100% during a lifetime. In all cases, including those genes that predispose to a genetic risk of cancer [1], alterations of cancer-associated genes define molecular markers Table 3.1. These markers are useful for novel diagnostic approaches and for genetic profiling of the tumor cell, with the aim of providing better prognostic evaluation and prediction of therapeutic drug response. In particular, the introduction into clinics of novel therapeutic molecules designed to interfere with target representing the altered genetic elements of the relevant pathogenetic pathway(s) in a given tumor, has increased the number of models of the so called “personalized or targeted therapy.” To provide a more rational view of the problems, this chapter organizes the subject by discussing genetic markers from cancer-associated genes that were altered by point mutation, deletion, or inappropriate expression at somatic cell level. The classes of genetic markers derived from chromosomal instability and from nonrandom chromosomal abnormalities and generating tumor-specific fusion product are also discussed. 43
44
E. Tamborini et al.
Table 3-1. Most relevant genetic markers in sporadic tumors. Gene
Acronyms
Location
TP53
-
17p13
HRas K ras N ras BRAF
-
7 12p12.1 11p15.5 7q34
Her2/neu
Her2 Erbb2
17q21
EGFR RET BCL2
Her1 -
7p11 10q11